KOL | Roger F Butterworth∗Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada | Department of Medicine, University of Montreal, Montreal, Canada | ... |
के लिए फिर से शुरू Roger F Butterworth∗
| Year | |
|---|---|
| 2021 | Department of Medicine, University of Montreal, 45143 Cabot Trail, Englishtown, NS B0C 1H0 Canada |
| 2020 | Department of Medicine, University of Montreal, Montreal, Canada |
| 2019 | Department of Medicine, University of Montreal, 45143 Cabot Trail, B0C 1H0, Englishtown, NS, Canada University of Montreal (St-Luc Hospital), Montreal, QC |
| 2018 | CHUM St-Luc Hospital and Department of Medicine, University of Montreal, Canada. University of Montreal (St-Luc Hospital), Montreal, Québec, Canada |
| 2015 | Department of Medicine, University of Montreal, Montreal, Quebec, Canada |
| 2014 | Neuroscience Research Unit, Hopital St-Luc (CHUM) and Department of Medicine, University of Montreal, Montreal, QC H2W 3J4, Canada |
| 2013 | Neuroscience Research Unit, Hôpital St-Luc (CHUM), 1058 Rue St-Denis, H2X 3J4, Montreal, QC, Canada |
| 2012 | Neuroscience Research Unit, Saint-Luc Hospital (CHUM), University of Montreal, Montreal, Quebec, Canada |
| 2011 | Department of Medicine, University of Montreal, Neuroscience Research Unit, Montreal, Quebec, Canada |
| 2010 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), University of Montreal, 1058 St. Denis Street, Montreal, Quebec, Canada |
| 2009 | Neuroscience Research Unit, Hôpital Saint‐Luc, CHUM, Montreal, QC, Canada |
| 2008 | Neuroscience Research Unit, Université de Montréal, Montreal, QC, Canada |
| 2007 | Neuroscience Research Unit, CHUM (Campus Saint-Luc), University of Montreal, 1058, Saint-Denis Street, H2X 3J4, Montreal, Quebec, Canada |
| 2006 | Neuroscience Research Unit, University of Montreal (CHUM), Hôpital Saint-Luc, 1058 St-Denis Street, Montreal, Que., Canada H2X 3J4 |
| 2005 | Neuroscience Research Unit, Hôpital Saint-Luc (CHUM), Montréal, Quebec, Canada |
| 2004 | Neuroscience Research Unit, Montreal, Quebec, Canada |
Roger F Butterworth∗: आँकड़ों को प्रभावित करें
रिपोर्ट चलाएं
| Concept | World rank |
|---|---|
| concentrations serotonin precursor | #1 |
| portacavalshunting | #1 |
| genes astrocytic proteins | #1 |
| blood ammonia improvement | #1 |
| benzoate spf | #1 |
| progressive volume increase | #1 |
| glutamateper | #1 |
| kidney portacaval anastomosis | #1 |
| human hepatic encephalopathy | #1 |
| subjects transport defect | #1 |
| spf mice | #1 |
| distribution 3htryptamine | #1 |
| surgical probenecid rats | #1 |
| regionselective reductions | #1 |
| molecular standpoint | #1 |
| lactate medial thalamus | #1 |
| brain hepatic | #1 |
| 3865 258 nm | #1 |
| encephalopathy male | #1 |
| neuromodulatory site | #1 |
| humans gabaa steroids | #1 |
| dying hepatic | #1 |
| stages encephalopathy | #1 |
| content pallidum | #1 |
| nonvulnerable frontal cortex | #1 |
| therapy refractive tle | #1 |
| alf proinflammatory | #1 |
| blood ammonia concentrations | #1 |
| csf lactate pse | #1 |
| surgical probenecid | #1 |
| osmotic disturbance | #1 |
| acute hyperammonemia activation | #1 |
| wks spraguedawley receptors | #1 |
| 3acetyl pyridine rats | #1 |
| dansyl chloride microassay | #1 |
| brain edema rats | #1 |
| thiamine interactions | #1 |
| taurine microsomes | #1 |
| pbz binding site | #1 |
| comatose rats | #1 |
| rats metallic | #1 |
| predictive model investigator | #1 |
| modulators hepatic | #1 |
| edema encephalopathy | #1 |
| ptbr expression | #1 |
| hypothermia prevents | #1 |
| nacl calcium | #1 |
| liver failure upregulation | #1 |
| concomitantly increased | #1 |
| igg extravasation expression | #1 |
| mg2dependentatpase | #1 |
| abstract5fluoromethylornithine | #1 |
| coma pathophysiologic basis | #1 |
| autopsied frontal cortex | #1 |
| sites ptbr | #1 |
| reflex selective decreases | #1 |
| ampa sites | #1 |
| alf neuroinflammation | #1 |
| ammonia central nervous | #1 |
| glyt1 mrna | #1 |
| 001 cerebral | #1 |
| hypermmonemia | #1 |
| pyrithiaminetreated rats | #1 |
| increased synthesis cell | #1 |
| prevention brain edema | #1 |
| experimental pse | #1 |
| peripheral steroidal sources | #1 |
| ohe mhe patients | #1 |
| receptors thiamine | #1 |
| role endogenous benzodiazepines | #1 |
| encephalopathy activities | #1 |
| died hepatic | #1 |
| region‐selective alterations | #1 |
| congenital acquired hyperammonemia | #1 |
| edema glutamine | #1 |
| cerebellar concentration | #1 |
| pfco | #1 |
| encephalopathy selective loss | #1 |
| liver diseases range | #1 |
| rtpcr experiments betaactin | #1 |
| 3h8ohdpat frontal cortex | #1 |
| l‐deprenyl treatment | #1 |
| pathogenesis hyperammonemic syndromes | #1 |
| initial reports pathogenesis | #1 |
| alf mild hypothermia | #1 |
| brain gaba uptake | #1 |
| brains pcs rats | #1 |
| brain herniation alf | #1 |
| alcoholthiamine interactions | #1 |
| ammonia brain | #1 |
| astrocytic glycine | #1 |
| expression ptbr | #1 |
| histamine caudate putamen | #1 |
| ammonia glutamate uptake | #1 |
| nakatpase activity thalamus | #1 |
| loss tdpase activities | #1 |
| alterations receptor sites | #1 |
| cyclase content | #1 |
| gut ammonia | #1 |
| nacl mm nacl | #1 |
| alf alterations | #1 |
| glucose loading decreases | #1 |
| hepatic encephalopathy authors | #1 |
| thiamine deficiency humans | #1 |
| enzyme perivenous hepatocytes | #1 |
| encephalopathy thiamine | #1 |
| neuropathologic damage | #1 |
| microsomes medium | #1 |
| ptbr mrna | #1 |
| 3hcitalopram sites | #1 |
| cns wernickekorsakoff | #1 |
| neuroprotection onset | #1 |
| reduction bbb breakdown | #1 |
| dehydrogenase complex friedreichs | #1 |
| 3hpk binding | #1 |
| astrocytic proteins | #1 |
| ldeprenyl thiamine deficiency | #1 |
| early astrocytic response | #1 |
| ptbr alterations | #1 |
| thiaminedependent enzymes establishment | #1 |
| human brain ammonia | #1 |
| prior detoxification liver | #1 |
| 15–1788 | #1 |
| ldopa trace amines | #1 |
| findings reported increase | #1 |
| establishment adult activities | #1 |
| lactate brain regions | #1 |
| experimental wernicke | #1 |
| pca activities | #1 |
| cau lobe hepatic | #1 |
| dawley thiamine | #1 |
| proinflammatory mechanisms | #1 |
| capacity cerebral cortex | #1 |
| perivenous hepatocytes brain | #1 |
| alf increases | #1 |
| rats direct evidence | #1 |
| edema acute | #1 |
| “ peripheral | #1 |
| encephalopathy prevention | #1 |
| etanercept treatment reduction | #1 |
| ligand3h | #1 |
| mechanisms wemickes encephalopathy | #1 |
| progression thiamine deficiency | #1 |
| deficiency transketolase | #1 |
| selective alterations | #1 |
| alf include | #1 |
| glial filament network | #1 |
| alterations increased expression | #1 |
| thiamine deficiency appearance | #1 |
| deficiency selective | #1 |
| friedreichs ataxia thiaminedeficient | #1 |
| portacaval anastomosis | #1 |
| humans wernickes encephalopathy | #1 |
| shunted rat | #1 |
| encephalopathy pse | #1 |
| liver pca | #1 |
| decreased tdp concentrations | #1 |
| otc deficiency activities | #1 |
| evidence thiamine deprivation | #1 |
| anastomosis pca | #1 |
| opca messenger receptors | #1 |
| prevention ammoniaprecipitated coma | #1 |
| spf mouse | #1 |
| rats pca | #1 |
| pse neurotransmitter agents | #1 |
| cirrhosis nature | #1 |
| alf glucose | #1 |
| reduction mild hypothermia | #1 |
| older cirrhotic patients | #1 |
| reversal neurological symptoms | #1 |
| cirrhosis brain dysfunction | #1 |
| reversible symptoms | #1 |
| cerebral aminoacids | #1 |
| caudate putamen sum | #1 |
| serotonin precursor metabolite | #1 |
| thalamus thiaminedeficient rats | #1 |
| alterations brain dopamine | #1 |
| pss degree | #1 |
| investigator predictions | #1 |
| cerebral cortex hypokinesia | #1 |
| vicious cycle sarcopenia | #1 |
| oatreated rats alf | #1 |
| spontaneous release glutamate | #1 |
| bbb permeability alf | #1 |
| type astrocytosis | #1 |
| serum lad patients | #1 |
| cerebral hepatic levels | #1 |
| lcarnitine energy metabolites | #1 |
| alf evidence | #1 |
| 10 microm flumazenil | #1 |
| hippocampal sclerosis induction | #1 |
| seasonal ataxia | #1 |
| manganese extrapyramidal symptoms | #1 |
| protective pathogenesis | #1 |
| selective reversible decreases | #1 |
| hyperammonemic sparse | #1 |
| ammonia central | #1 |
| portacaval anastomosis tips | #1 |
| prevents brain | #1 |
| fco cau | #1 |
| brain prominent neurotoxin | #1 |
| deficiency tritium | #1 |
| 7 thiaminedeficient medium | #1 |
| cirrhotic patients densities | #1 |
| ammoniainduced inhibition | #1 |
| dehydrogenase complex transketolase | #1 |
| glutamine synthetase activities | #1 |
| patient olivopontocerebellar atrophy | #1 |
| tissues spf mice | #1 |
| αkgdh | #1 |
| alanine cerebral cortex | #1 |
| symptomatic pyrithiamine | #1 |
| surgical portacaval anastomosis | #1 |
| wernickekorsakoff syndrome disturbances | #1 |
| glast medial thalamus | #1 |
| fluid taurine | #1 |
| alf aom | #1 |
| wistar receptors pca | #1 |
| rats antisense elements | #1 |
| akgdh | #1 |
| maoa activities cerebellum | #1 |
| ammonia mrna | #1 |
| lipoamide dehydrogenase lad | #1 |
| ammoniaprecipitated coma | #1 |
| aqp4 proinflammatory mediators | #1 |
| haloperidol humans haloperiodol | #1 |
| phenols fig 1structure | #1 |
| pathophysiology cirrhosis | #1 |
| reduced thiamine intake | #1 |
| glut1 alf | #1 |
| aom treatment alf | #1 |
| pbgd rat model | #1 |
| induction epileptic patients | #1 |
| encephalopathy alcoholic | #1 |
| friedreich gilbert | #1 |
| distribution l3hnoarg | #1 |
| neurological complications alf | #1 |
| p005 5mm nh4cl | #1 |
| nh4cl glutamates hippocampus | #1 |
| mhe clinical practice | #1 |
| amines hepatic | #1 |
| doses lcarnitine | #1 |
| autopsy cirrhotic | #1 |
| increased expression ptbribp | #1 |
| therapeutic efficacy prevention | #1 |
| hippocampus cirrhotic patients | #1 |
| thiamine deficiency neurons | #1 |
| ptbr ligand 3hpk11195 | #1 |
| dehydrogenase αkgdh | #1 |
| cerebral energy deficit | #1 |
| decreased expression glt1 | #1 |
| reduction circulating neurotoxins | #1 |
| encephalopathy central | #1 |
| brain ammonia removal | #1 |
| ammonia exposure brain | #1 |
| rats surgical probenecid | #1 |
| thiamine deficiency | #1 |
| oxygenase1 hepatic | #1 |
| friedreichs ataxia dehydrogenase | #1 |
| ldopa octopamine | #1 |
| animal hepatectomy hepatitis | #1 |
| leigh disease forms | #1 |
| plasma alf rats | #1 |
| brains increased concentrations | #1 |
| alf therapeutic | #1 |
| benzodiazepine site contrast | #1 |
| encephalopathy alf rats | #1 |
| inhibitors acute hyperammonemia | #1 |
| isoquinolinebinding moiety | #1 |
| pca portacaval shunt | #1 |
| increased gabaergic tone | #1 |
| ammonia intoxication rats | #1 |
| alf rats expression | #1 |
| brain regions pyrithiamine | #1 |
| ” benzodiazepine | #1 |
| regionselective increases | #1 |
| hyperammonemic spf mice | #1 |
| clf alf | #1 |
| tdwt mice | #1 |
| cuznsod cox2 | #1 |
| deficiency wernicke | #1 |
| sodium benzoate atp | #1 |
| pca astrocytic | #1 |
| lornithine laspartate lola | #1 |
| liver failure alterations | #1 |
| monoaminergic synaptic function | #1 |
| nh4oac administration | #1 |
| atp free coenzyme | #1 |
| fastigial interpositus | #1 |
| aspartate pons | #1 |
| taurine medium | #1 |
| spf mutant | #1 |
| novo synthesis gaba | #1 |
| 3hpk11195 | #1 |
| encephalopathy neuropsychiatric | #1 |
| ptbrs binding | #1 |
| portacaval | #1 |
| activities maob | #1 |
| neuroinflammation cns complications | #1 |
| brain dysfunction pse | #1 |
| cirrhotic patients benzodiazepines | #1 |
| age time interval | #1 |
| ptbr expression pathogenesis | #1 |
| 15–1788 pharmacokinetics | #1 |
| pyrithiamine treatment | #1 |
| hereditary familial hyperbilirubinemia | #1 |
| pons thiamine treatment | #1 |
| deficiency prior | #1 |
| alf37 degrees | #1 |
| therapy ornithine transcarbamylase | #1 |
| hypothermia delay | #1 |
| cirrhosis extrapyramidal symptoms | #1 |
| portacaval shunting activities | #1 |
| lola treatment | #1 |
| agents metabolic potential | #1 |
| receptor ptbr | #1 |
| thiamine monophosphatetmp | #1 |
| caudate putamen concentrations | #1 |
| increased glutamine synthesis | #1 |
| thiaminedeficient medium | #1 |
| downregulation glutamate transporter | #1 |
| congenital otc deficiency | #1 |
| pathogenetic defect | #1 |
| 5mm nh4cl | #1 |
| alcoholic peripheral | #1 |
| brain cirrhotic patients | #1 |
| ptbr complex | #1 |
| aom animal hypothermia | #1 |
| serotonin transporter deficit | #1 |
| glur3 subunits opca | #1 |
| pdhc activities | #1 |
| spf mice activities | #1 |
| liver spf mice | #1 |
| pca ethanol | #1 |
| ptbrs portacaval anastomosis | #1 |
| pathogenesis brain edema | #1 |
| sustained hyperammonemia pca | #1 |
| inherited ataxias characteristics | #1 |
| liver failure increases | #1 |
| nacetylcysteine cerebral complications | #1 |
| hyperglycemic focal | #1 |
| pallidal binding sites | #1 |
| rats fpc | #1 |
| cell swelling major | #1 |
| improvements hepatic microcirculation | #1 |
| pca rats patients | #1 |
| nac neurological complications | #1 |
| hepatic encephalopathy | #1 |
| disproportionately levels | #1 |
| opioid encephalopathy humans | #1 |
| elucidation neurotransmitter | #1 |
| subclass sites | #1 |
| veratramines action | #1 |
| veratramines action parachlorophenylalanine | #1 |
| rat sustained hyperammonemia | #1 |
| expression ptbrs | #1 |
| increased densities | #1 |
| pyrithiamine | #1 |
| αkgdh onset | #1 |
| alf precise role | #1 |
| pse findings | #1 |
| selectively increased | #1 |
| deficiency encephalopathy | #1 |
| r071–084 | #1 |
| pglycoprotein willebrand factor | #1 |
| vulnerable medial | #1 |
| ammonia mechanisms | #1 |
| circulating neurotoxins | #1 |
| daily injections ldeprenyl | #1 |
| brain edema increases | #1 |
| coa levels brain | #1 |
| activation brain ptbr | #1 |
| alf35 | #1 |
| hypoglycaemia cerebral cortex | #1 |
| lumbar gray matter | #1 |
| alcohol‐thiamine interactions | #1 |
| acute chronic hyperammonemia | #1 |
| pathogenesis reversible symptoms | #1 |
| neuroinflammation alf | #1 |
| rate thiamine turnover | #1 |
| genes brain edema | #1 |
| transketolase tk activities | #1 |
| sgc activation brain | #1 |
| that11cpk11195 | #1 |
| focal lactic | #1 |
| transketolase enzyme activities | #1 |
| pca brainstem | #1 |
| oxotremorine particle size | #1 |
| relation energy metabolism | #1 |
| primary energy failure | #1 |
| selective increases | #1 |
| cirrhosis psychometric testing | #1 |
| ptbrs | #1 |
| normal limits findings | #1 |
| edema complications | #1 |
| propanolamines putamen | #1 |
| acute neurons mechanisms | #1 |
| ptbr mrna thalamus | #1 |
| mhe life | #1 |
| alf hypothermia | #1 |
| lola mental state | #1 |
| chronic hyperammonemia syndromes | #1 |
| cytokines mild | #1 |
| death wernicke | #1 |
| normal conditions gut | #1 |
| ligand 3hpk11195 | #1 |
| pathogenesis wernicke | #1 |
| protective findings | #1 |
| brain edema complications | #1 |
| symptoms wernicke | #1 |
| testis densities | #1 |
| thiamine deficiency bckdh | #1 |
| mbr decreased expression | #1 |
| acute male pregnenolone | #1 |
| alf animal hypothermia | #1 |
| cns pca | #1 |
| neurological symptoms normalisation | #1 |
| hyperammonaemia brain function | #1 |
| platelet taurine uptake | #1 |
| 202 55 nm | #1 |
| mild hypothermia onset | #1 |
| reversal antiparkinson drugs | #1 |
| brain pca rats | #1 |
| increased brain concentrations | #1 |
| neurological symptoms encephalopathy | #1 |
| lola reductions | #1 |
| affinity ptbr | #1 |
| weeks portacaval | #1 |
| findings ammonia | #1 |
| taurine electrolyte balance | #1 |
| appearance neurological symptoms | #1 |
| thiamine phosphatases | #1 |
| blood ammonia md | #1 |
| olivopontocerebellar atrophy expression | #1 |
| brains alf rats | #1 |
| freechoice drinking paradigm | #1 |
| integrity gabaa receptors | #1 |
| novo synthesis aspartate | #1 |
| encephalopathy histamine humans | #1 |
| ptbr brain | #1 |
| cirrhotic patients cau | #1 |
| precoma | #1 |
| monoamines hplc | #1 |
| ammonia increased production | #1 |
| betaactin housekeeping gene | #1 |
| microglial activation protective | #1 |
| ohe prevention prophylaxis | #1 |
| encephalopathy new | #1 |
| investigator neurological disorders | #1 |
| manganese etiology | #1 |
| stages igg immunohistochemistry | #1 |
| shunting hyperammonemia rats | #1 |
| mbr astrocytes | #1 |
| hepatic devascularized rats | #1 |
| peripheral‐type benzodiazepine receptors | #1 |
| 25mm nh4cl p005 | #1 |
| ammonia major roles | #1 |
| alf studies | #1 |
| pharmacological manipulation ptbr | #1 |
| brain osmolytes | #1 |
| accumulate brain | #1 |
| superoxide dismutase rat | #1 |
| rats coma | #1 |
| bbb animal hepatic | #1 |
| acute male muscle | #1 |
| neurotransmitter alterations prevention | #1 |
| liver pathology increases | #1 |
| additional thiamine | #1 |
| glast spraguedawley statistics | #1 |
| markedly impaired | #1 |
| ptbr ligand | #1 |
| metabolism ammonia | #1 |
| increased blood manganese | #1 |
| dissected brain tissue | #1 |
| encephalopathy zidovudine | #1 |
| wernickes encephalopathy aids | #1 |
| azoxymethane mouse model | #1 |
| increases glutamine | #1 |
| ucds liver failure | #1 |
| immunohistochemistry cox2 immunoreactivity | #1 |
| alf hepatic | #1 |
| ro15 10 microm | #1 |
| rats varying degrees | #1 |
| 3hmuscimol binding studies | #1 |
| thiamine daily administration | #1 |
| propanolamines putamen rats | #1 |
| exclusion brain diseases | #1 |
| ammonia removal brain | #1 |
| thiaminedeficient brain | #1 |
| stress encephalopathy | #1 |
| pathogenesis wernickekorsakoff syndrome | #1 |
| cox2 il1beta mrna | #1 |
| hypothermia ammonia | #1 |
| thalamus vulnerable region | #1 |
| pfco brain tissue | #1 |
| nh4 forms neurons | #1 |
| modulatory sites | #1 |
| alf animals expression | #1 |
| ngnitrol3harginine | #1 |
| cerebellar concentration aspartate | #1 |
| precise role glutamine | #1 |
| mild hypothermia reduction | #1 |
| selective damage pdhc | #1 |
| increased brain content | #1 |
| pca increased | #1 |
| ptbribp frontal cortex | #1 |
| thiaminedeficient mothers | #1 |
| caudate putamen 57 | #1 |
| chronic thiamine deprivation | #1 |
| tdpase tdpase activities | #1 |
| major role mechanisms | #1 |
| ptbr increased expression | #1 |
| cirrhotic brain tissue | #1 |
| ammonialowering agents | #1 |
| update hepatic encephalopathy | #1 |
| frontal cortex exp | #1 |
| reflex pdhc activities | #1 |
| loss 3hcitalopram sites | #1 |
| degree pss | #1 |
| coma stages | #1 |
| findings neuroinflammatory response | #1 |
| severe pse | #1 |
| alzheimer type astrocytosis | #1 |
| selectively decreased | #1 |
| 15–1788 kinetics | #1 |
| neuroinhibitory steroid | #1 |
| thiaminedeficient encephalopathy | #1 |
| alzheimertype astrocytosis | #1 |
| nnos expression result | #1 |
| loss nmda | #1 |
| surgical rna messenger | #1 |
| hepatic microcirculation patients | #1 |
| encephalopathy expression | #1 |
| coma stages encephalopathy | #1 |
| bioaccumulation neuropathology | #1 |
| fumazenil | #1 |
| pca cns | #1 |
| 3hpk11195 rats | #1 |
| pathogenesis hepatic encephalopathy | #1 |
| sgc activation lymphocytes | #1 |
| jadad cochrane ohe | #1 |
| restricted transfer cell | #1 |
| shunted dogs | #1 |
| glucose loading precipitates | #1 |
| excess bloodborne ammonia | #1 |
| cloned rat ptbr | #1 |
| congenital hyperammonemia lcarnitine | #1 |
| 062 009 liter | #1 |
| pathogenesis cerebral complications | #1 |
| ligand3hpk11195 | #1 |
| previous portacaval anastomoses | #1 |
| findings manganese | #1 |
| anastomosis ammonia | #1 |
| absence wernickes encephalopathy | #1 |
| alf37 alf37 degrees | #1 |
| ptbr mrna levels | #1 |
| tissue distribution neuropathology | #1 |
| hepatic microcirculation addition | #1 |
| ammonium acetate challenge | #1 |
| hypoglycaemic convulsions | #1 |
| astrocytic accumulation | #1 |
| astrocytic integrity | #1 |
| alterations brain glutamate | #1 |
| encephalopathy il1beta | #1 |
| gabaa neurosteroids | #1 |
| cerebral disorder | #1 |
| surgical rats rats | #1 |
| thiamine deficiency encephalopathy | #1 |
| thalamus thiamine | #1 |
| ouabain pyrimethamine rats | #1 |
| pathophysiology hepatic | #1 |
| encephalopathy cirrhosis | #1 |
| h1 receptor density | #1 |
| microglia evidence | #1 |
| normal cd1 | #1 |
| pfco cau | #1 |
| varying degrees pss | #1 |
| continues rely | #1 |
| brain human experimental | #1 |
| failure thiamine | #1 |
| nimesulide thiamine deficiency | #1 |
| alpha1 isoform ec50 | #1 |
| lcarnitinetreated | #1 |
| reactive gliosis contrast | #1 |
| pregnanolone brain chemistry | #1 |
| portalsystemic encephalopathy pse | #1 |
| 100 microm manganese | #1 |
| widespread alterations | #1 |
| csf concentrations bzrls | #1 |
| lornithinelaspartate prevention | #1 |
| muscarinic m1 sites | #1 |
| thiaminedeficient encephalopathy implications | #1 |
| wellestablished actions | #1 |
| 2 mm ammonia | #1 |
| pss rats | #1 |
| pathogenesis brain | #1 |
| tk activity onset | #1 |
| pse portalsystemic shunting | #1 |
| portacaval shunted | #1 |
| relation sustained hyperammonemia | #1 |
| etanercept biological plausibility | #1 |
| s‐3h5‐fluorowillardiine | #1 |
| ammoniainduced reduction | #1 |
| nonsclerotic tle patients | #1 |
| densities ptbr sites | #1 |
| pca portacaval | #1 |
| binding sites 3hpk11195 | #1 |
| alterations expression result | #1 |
| thalamus cirrhotic patients | #1 |
| pca rats phosphate | #1 |
| free coa atp | #1 |
| ohe cirrhosis | #1 |
| measured homogenates | #1 |
| selective ptbr ligand | #1 |
| ammonia cns function | #1 |
| region‐selective | #1 |
| seesection | #1 |
| brain thiamine metabolism | #1 |
| routine neurological evaluation | #1 |
| l3hnoarg binding | #1 |
| ptbr nnos | #1 |
| pse surgical probenecid | #1 |
| rats alf | #1 |
| shunting hyperammonemia | #1 |
| prevention ohe | #1 |
| shunted rats presence | #1 |
| alf brain edema | #1 |
| αkgdh activities | #1 |
| etanercept aom | #1 |
| severe liver atrophy | #1 |
| finding loss | #1 |
| experimental thiamine | #1 |
| brain ammonia measurement | #1 |
| portacaval pcs rats | #1 |
| polyclonal antibody glt1 | #1 |
| result manganese deposition | #1 |
| thiamine deficiency alcoholics | #1 |
| tdpase activities | #1 |
| increased activities tdpase | #1 |
| manganese deposition | #1 |
| 3htryptamine receptors | #1 |
| induction astrocytic cox2 | #1 |
| neurobiology hepatic encephalopathy | #1 |
| muscarinic thiamine | #1 |
| thdoc brain tissue | #1 |
| pse increased densities | #1 |
| taurines role | #1 |
| rats probenecid treatment | #1 |
| pse lornithinelaspartate | #1 |
| failure alanine | #1 |
| cns complications alf | #1 |
| hepatic abnormality characteristics | #1 |
| encephalopathy brain | #1 |
| plasma clearance halflife | #1 |
| increased levels allopregnanolone | #1 |
| central thiamine | #1 |
| psychometric testing risk | #1 |
| regional variation bckdh | #1 |
| decreased detoxification | #1 |
| rats hepatic devascularization | #1 |
| lola efficacy | #1 |
| model human disorder | #1 |
| action ro15 | #1 |
| pathogenesis hepatic | #1 |
| portocaval shunting activities | #1 |
| “peripheraltype | #1 |
| autopsied brain samples | #1 |
| hepatic encephalopathy activation | #1 |
| hepatic devascularization | #1 |
| glut1 expression alf | #1 |
| autopsy brain choline | #1 |
| pharmaceutical benzodiazepines | #1 |
| peripheral inflammation etanercept | #1 |
| 32°c–35°c | #1 |
| experimental portacaval shunt | #1 |
| thalamus wernicke encephalopathy | #1 |
| encephalopathy cau | #1 |
| neuroinflammation liver failure | #1 |
| glutaminecycle | #1 |
| brain ammonia concentrations | #1 |
| malnutrition hepatic failure | #1 |
| copper pallidum | #1 |
| pse altered expression | #1 |
| hepatocerebral disorders | #1 |
| normothermic alf rats | #1 |
| encephalopathy hypothermia | #1 |
| mechanisms brain edema | #1 |
| thiamine neurochemistry | #1 |
| protein coma stages | #1 |
| induced stereotyped behavior | #1 |
| rats acute | #1 |
| pse probenecid | #1 |
| brain consequent increases | #1 |
| thiamine deficiency implications | #1 |
| iotal6 | #1 |
| cox2 cuznsod | #1 |
| neuronastrocytic trafficking | #1 |
| postshunt myelopathy | #1 |
| endogenous opioid brain | #1 |
| pyrithiamine quinuclidinyl | #1 |
| alf mice deletion | #1 |
| increased gabaergic | #1 |
| liver pca rats | #1 |
| osmotic actions | #1 |
| sparsefur spf mouse | #1 |
| effective urea cycle | #1 |
| dha administration mnsod | #1 |
| bilirubin ataxics | #1 |
| maternal thiamine deficiency | #1 |
| activities alpha kgdh | #1 |
| ptbr | #1 |
| minocyclinetreated alf rats | #1 |
| proinflammatory cytokines strategies | #1 |
| 3hpk11195 binding | #1 |
| chronic hyperammonemic syndromes | #1 |
| material equal | #1 |
| thiamine deficiency activities | #1 |
| azoxymethane bloodbrain barrier | #1 |
| thiamine deficiency brains | #1 |
| chat loss | #1 |
| pcs rats protective | #1 |
| nh4ac rats | #1 |
| pathogenesis portalsystemic encephalopathy | #1 |
| effective approach prevention | #1 |
| animal model encephalopathy | #1 |
| nh4cl glutamate release | #1 |
| encephalopathy nitrogen | #1 |
| experimental thiamine deficiency | #1 |
| relationship blood manganese | #1 |
| experimental portal | #1 |
| fur spf | #1 |
| hyperammonemic spf | #1 |
| l‐3hnitroarginine | #1 |
| hepatic encephalopathy cirrhosis | #1 |
| failure ammonia | #1 |
| dose dependent swelling | #1 |
| 57 caudate putamen | #1 |
| brain edema encephalopathy | #1 |
| neuropsychiatric disorder evidence | #1 |
| bloodborne ammonia | #1 |
| cerebellum 22 | #1 |
| dawley ammonia | #1 |
| local brain production | #1 |
| cox2 cuznsod mrna | #1 |
| measurement aqp4 levels | #1 |
| circulating ammonia | #1 |
| pathogenesis neuronal loss | #1 |
| brain levels dheas | #1 |
| increased csf lactate | #1 |
| encephalopathy vivo | #1 |
| enos gene deletion | #1 |
| proinflammatory mechanisms pathogenesis | #1 |
| cerebellum sustained hyperammonemia | #1 |
| thalamus pyrithiamine treatment | #1 |
| portacavalshunted rats protective | #1 |
| ω3 receptor 3hpk11195 | #1 |
| ouabain doses | #1 |
| antagonist pyrithiamine | #1 |
| edema cytokines | #1 |
| enzyme activities loss | #1 |
| thiamine‐deficient | #1 |
| disorders ammonia metabolism | #1 |
| reduction cognitive dysfunction | #1 |
| acquired hyperammonemia | #1 |
| flunitrazepam modulation | #1 |
| hypothesis hepatic encephalopathy | #1 |
| pons gaba content | #1 |
| hepatic encephalopathies | #1 |
| 3htryptamine receptor | #1 |
| nmda receptor alf | #1 |
| encephalopathy animals | #1 |
| wernicke′s encephalopathy | #1 |
| ptbr densities | #1 |
| isoquinoline benzodiazepine ligands | #1 |
| abnormal pyruvate oxidation | #1 |
| inflammation thiamine deficiency | #1 |
| pca rats | #1 |
| disease outcome prevention | #1 |
| gabaaassociated receptors | #1 |
| dismutase hyperglycemic | #1 |
| etanercept hepatic | #1 |
| azoxymethane brain | #1 |
| autopsied brain tissue | #1 |
| increased activity katpase | #1 |
| restricted transfer glutamine | #1 |
| maximal binding absence | #1 |
| ouabain pyrimethamine | #1 |
| expression astrocytic | #1 |
| effects ammonia | #1 |
| thiamine deficiency 23 | #1 |
| 071−084 | #1 |
| portacavalshunted pcs rats | #1 |
| ammonialowering strategies | #1 |
| etanercept decreased plasma | #1 |
| brain major | #1 |
| brain congenital | #1 |
| taurine hepatic encephalopathy | #1 |
| exposure proinflammatory | #1 |
| removal bloodborne ammonia | #1 |
| lad platelets | #1 |
| pca encephalopathy humans | #1 |
| ligase hepatic | #1 |
| manganese phosphate mmt | #1 |
| mrnas ampa receptor | #1 |
| neuroinflammatory response alf | #1 |
| symptomatic stages encephalopathy | #1 |
| hyperammonemia aaas | #1 |
| cox2 tle | #1 |
| altered thiamine neurochemistry | #1 |
| tdpase encephalopathy humans | #1 |
| maob encephalopathy humans | #1 |
| medial thalamus day | #1 |
| brain pse | #1 |
| severity akinesia | #1 |
| preference pca | #1 |
| ethanol nutritional deficit | #1 |
| locomotor activities difference | #1 |
| alcoholic peripheral neuropathy | #1 |
| l3hnoarg | #1 |
| grc integrity | #1 |
| brain ammonia pca | #1 |
| vivo cerebral microdialysis | #1 |
| deterioration neurological status | #1 |
| loss 3hnisoxetine sites | #1 |
| fig dansyl | #1 |
| caveolin1 pathway | #1 |
| rtpcr experiments messenger | #1 |
| animal liver failure | #1 |
| nuclei fastigial interpositus | #1 |
| efficacy lola | #1 |
| onset neurological symptoms | #1 |
| binding sites cerebellum | #1 |
| encephalopathy brain edema | #1 |
| noradrenaline transporter sites | #1 |
| 6hydroxydopamine anterolateral hypothalamus | #1 |
| inhibitory ammonium ions | #1 |
| nh4 neurons | #1 |
| 15–1788 plasma levels | #1 |
| mm nacl nacl | #1 |
| perivascular endothelial cells | #1 |
| 15–1788 pharmacokinetics cirrhosis | #1 |
| glutamine astrocyte | #1 |
| severity brain edema | #1 |
| sites thiamine | #1 |
| brain glutamine severity | #1 |
| hepatic encephalopathy relationship | #1 |
| free neurological | #1 |
| brain glutamine | #1 |
| tmpase tdpase | #1 |
| pdhc step | #1 |
| hepatic glt1 | #1 |
| onset brain edema | #1 |
| methylspiperone pet | #1 |
| pca increased densities | #1 |
| alcoholrelated brain dysfunction | #1 |
| mild hypothermia prevention | #1 |
| encephalopathy adult | #1 |
| 3hpk cultured astrocytes | #1 |
| 3hcitalopram sites rats | #1 |
| flunitrazepam hepatic | #1 |
| brain ptbr | #1 |
| brain glutamate synthesis | #1 |
| acute symptomatic animals | #1 |
| ω3 receptor | #1 |
| predilection neuropathologic damage | #1 |
| dawley amino | #1 |
| portacaval shunting hyperammonemia | #1 |
| pharmaceutical benzodiazepine | #1 |
| thiamine deficiency result | #1 |
| hepatic encephalopathy integrity | #1 |
| glt1 transporter proteins | #1 |
| experimental model metabolic | #1 |
| pca beta endorphin | #1 |
| key astrocytic | #1 |
| pregnenolone brain tissue | #1 |
| aom nac | #1 |
| brain portacaval anastomosis | #1 |
| nakatpase activities striatum | #1 |
| thalamus symptomatic rats | #1 |
| bzrls cirrhotic patients | #1 |
| rendered ataxic | #1 |
| hypokinesia et495 | #1 |
| neurological syndrome nature | #1 |
| response alf | #1 |
| alf nmda receptor | #1 |
| caudate nucleus cau | #1 |
| lola effective | #1 |
| astrocytic accumulation glutamine | #1 |
| components brain glutamate | #1 |
| pca portacaval anastomosis | #1 |
| precoma coma stages | #1 |
| loss thiamine | #1 |
| liver spleen ratios | #1 |
| glt1 encephalopathy humans | #1 |
| decreased detoxification ammonia | #1 |
| brain altered expression | #1 |
| hepatic coma patients | #1 |
| regions pyrithiamine | #1 |
| rats insulin hypoglycaemia | #1 |
| diencephalic cerebellar | #1 |
| congenital hyperammonemia nakatpase | #1 |
| neurotransmitter function | #1 |
| hypothermia brain | #1 |
| betaep brain | #1 |
| acute hyperammonemic syndromes | #1 |
| catecholaminelike trace amines | #1 |
| atrophy brain glutamate | #1 |
| activation ptbr | #1 |
| alf effects | #1 |
| brain levels tmp | #1 |
| failure brain | #1 |
| overt encephalopathy alterations | #1 |
| disorder thiamine deficiency | #1 |
| densities 3hpk11195 | #1 |
| loss transporter sites | #1 |
| electroencephalogram tracings patients | #1 |
| psychometric testing falls | #1 |
| pca penicillamine | #1 |
| thiamine‐dependent enzymes | #1 |
| atp free coa | #1 |
| key astroglial proteins | #1 |
| neurological disorders selection | #1 |
| cerebellar amino acids | #1 |
| pathogenesis pse | #1 |
| lola nash | #1 |
| rats ouabain pyrimethamine | #1 |
| bzrls | #1 |
| tdpase activities loss | #1 |
| hyperammonemia accounts | #1 |
| thiaminedeficient ataxic gait | #1 |
| rat wernickes encephalopathy | #1 |
| cau cirrhotic patients | #1 |
| regionselective alterations | #1 |
| pbg pbgd | #1 |
| raphe serotonin serotonin | #1 |
| degree shunting hyperammonemia | #1 |
| homogenates cirrhotic patients | #1 |
| alterations 3h8ohdpat | #1 |
| glutamate originating | #1 |
| acquired hyperammonemic | #1 |
| pallidal signal hyperintensity | #1 |
| spectrum neuropsychiatric abnormalities | #1 |
| borne ammonia | #1 |
| alf azoxymethane | #1 |
| vulnerable medial thalamus | #1 |
| kgdh decreased | #1 |
| liver dysfunction findings | #1 |
| gabaa ammonia animals | #1 |
| direct evidence rats | #1 |
| primary astrocytopathy | #1 |
| neuronal thalamus | #1 |
| flumazenil cirrhotic patients | #1 |
| thiamine‐deficient rats | #1 |
| blood manganese etiology | #1 |
| concentrations olfactory bulb | #1 |
| hyperammonemic pathologies | #1 |
| cns relation | #1 |
| cerebral levels glutamine | #1 |
| l‐3harginine | #1 |
| nac animal hepatic | #1 |
| wernickes encephalopathy humans | #1 |
| neurosteroid modulatory | #1 |
| liver failure neuroinflammation | #1 |
| akinesia rats | #1 |
| rats thiamine deficiency | #1 |
| matkowskyj | #1 |
| prevention brain | #1 |
| encephalopathy humans pallidus | #1 |
| encephalopathy increased | #1 |
| thiamine deficiency expression | #1 |
| frontal cortex fco | #1 |
| brain pregnant rats | #1 |
| alterations neurological alterations | #1 |
| fco cirrhotic patients | #1 |
| 24 hours pca | #1 |
| familial hyperbilirubinemia | #1 |
| clinicallydefined entities | #1 |
| albumin dialysis systems | #1 |
| mild hypothermia delay | #1 |
| combined metabolic stresses | #1 |
| increased extracellular brain | #1 |
| presence brain extracts | #1 |
| interferongamma brains | #1 |
| 25mm nh4cl | #1 |
| histamine receptor sites | #1 |
| dipeptides hepatic | #1 |
| congenitally hyperammonemic | #1 |
| precipitation severe stages | #1 |
| diabetes ataxia humans | #1 |
| spraguedawley statistics immunohistochemistry | #1 |
| findings therapeutic efficacy | #1 |
| severe encephalopathy coma | #1 |
| alf rats precoma | #1 |
| specific l3hnoarg binding | #1 |
| antiparkinson drugs hypokinesia | #1 |
| encephalopathy humans opioid | #1 |
| decarboxylase hepatic | #1 |
| ligand3hpirenzepine | #1 |
| failure amino | #1 |
| loss gfap expression | #1 |
| hyperammonemic syndromes | #1 |
| selective loss | #1 |
| activities neuronal | #1 |
| fasting intravenous injection | #1 |
| 3hpk11195 human brain | #1 |
| lornithine laspartate ammonia | #1 |
| increased brain | #1 |
| portacaval anastomosis brain | #1 |
| alf37 | #1 |
| 3hkainate sites | #1 |
| sparsefur spf mice | #1 |
| ethanol preference ratio | #1 |
| daily injections thiamine | #1 |
| 70 tk | #1 |
| control alf37 | #1 |
| hepatic encephalopathy activities | #1 |
| term fluorescence phenomenon | #1 |
| reduction brain ammonia | #1 |
| edema formation mnsod | #1 |
| tnfα delayed progression | #1 |
| sgc cerebral cortex | #1 |
| pfco fco | #1 |
| daily pyrithiamine treatment | #1 |
| expression glyt1 transporter | #1 |
| thiaminedeficient animals | #1 |
| inhibitory nh4cl | #1 |
| mutant spf | #1 |
| immunohistochemistry spraguedawley statistics | #1 |
| congenital ornithine | #1 |
| novo lactate synthesis | #1 |
| indwelling cisterna | #1 |
| mitochondrial enzyme αkgdh | #1 |
| loss righting reflexes | #1 |
| ptbribp | #1 |
| aom mice nac | #1 |
| magna catheter | #1 |
| effective approach onset | #1 |
| normalisation enzyme activities | #1 |
| key astrocytic proteins | #1 |
| astrocyte undergoes | #1 |
| cerebral γ‐aminobutyric acid | #1 |
| pbgd mrna expression | #1 |
| protective portacavalshunted rats | #1 |
| cirrhosis vicious cycle | #1 |
| encephalopathy | #1 |
| ammonium acetate administration | #1 |
| region selective | #1 |
| 5mm nh4cl p0001 | #1 |
| azoxymethane toxicity | #1 |
| regional lactate levels | #1 |
| mmt manganese phosphate | #1 |
| thalamus thiamine deficiency | #1 |
| glutamate exposure ammonia | #1 |
| occludin medial thalamus | #1 |
| brain ammonia reduction | #1 |
| portacaval‐shunted rat | #1 |
| modulation nitric oxide | #1 |
| receptors pca | #1 |
| brain portacaval | #1 |
| lipopolysaccharide precipitates | #1 |
| astrocyte morphology alterations | #1 |
| encephalopathy cerebral edema | #1 |
| electroencephalogram tracings | #1 |
| muscle portacaval shunting | #1 |
| focal lactic acidosis | #1 |
| astrocyticneuronal cross | #1 |
| ammonia acute | #1 |
| 44433a | #1 |
| surgical rna | #1 |
| isomorphic model predictions | #1 |
| csf benzodiazepine | #1 |
| increased activities maoa | #1 |
| microglia neuroinflammatory response | #1 |
| ptbr sites | #1 |
| 3hpk11195 ligands | #1 |
| prophylaxis reductions | #1 |
| thiaminedeficient rats | #1 |
| region selective alterations | #1 |
| increased binding sites | #1 |
| synthesis intercellular transport | #1 |
| serum lad friedreich | #1 |
| liver failure modulation | #1 |
| nacl taurine | #1 |
| neuronal crosstalk | #1 |
| increase brain extracts | #1 |
| action acute hyperammonemia | #1 |
| encephalopathy sham | #1 |
| pss dopamine hepatic | #1 |
| nonvulnerable fpc | #1 |
| ammonia normal conditions | #1 |
| assessment locomotor activities | #1 |
| kgdh activities | #1 |
| central thiamine antagonist | #1 |
| glutamine resonance | #1 |
| pca loss | #1 |
| 3hnisoxetine sites | #1 |
| thalamus symptomatic | #1 |
| progression prevention | #1 |
| stroke forms | #1 |
| ammoniainduced decrease | #1 |
| alcoholic manganese | #1 |
| alf restricted transfer | #1 |
| experimental alf increases | #1 |
| poor nutrition vitamin | #1 |
| mental state grade | #1 |
| activities thiamine | #1 |
| hypokinesia stereotaxic microinjection | #1 |
| ammonia toxins | #1 |
| neurosteroids hepatic encephalopathy | #1 |
| nac normalization | #1 |
| cerebral cortex pca | #1 |
| previous exposure benzodiazepines | #1 |
| ammonia liver failure | #1 |
| additional bloodborne ammonia | #1 |
| brain distribution rats | #1 |
| pglycoprotein mild hypothermia | #1 |
| liver failure ucds | #1 |
| 3hpk11195 binding sites | #1 |
| brains spf mice | #1 |
| ammonia metabolism disorders | #1 |
| thiamine deficiency decreases | #1 |
| radioenzymatic assays activities | #1 |
| exposure azoxymethane | #1 |
| xlinked inherited defect | #1 |
| pugh score iii | #1 |
| lornithinelaspartate therapeutic efficacy | #1 |
| atp acetyl coa | #1 |
| metabolites term fluorescence | #1 |
| alf rats | #1 |
| treatment mild encephalopathy | #1 |
| azoxymethane mouse | #1 |
| csf lactate accumulation | #1 |
| coding key | #1 |
| 2 7fold increases | #1 |
| muscle ammonia removal | #1 |
| stress alf | #1 |
| tissue cirrhotic | #1 |
| thiaminedeficient medium 7 | #1 |
| aom mice | #1 |
| ammonia pca | #1 |
| manganese pathogenesis | #1 |
| cell damage mechanisms | #1 |
| cultured cells mrna | #1 |
| administration novo synthesis | #1 |
| in3hpk11195 binding sites | #1 |
| ammonia increased | #1 |
| disorder isomorphic model | #1 |
| astrocytic glycine transporter | #1 |
| pyrithiamine pyruvate | #1 |
| coma edema stages | #1 |
| alf relation | #1 |
| pfco frontal cortex | #1 |
| astrocytic cox2 | #1 |
| inhibition bloodbrain transfer | #1 |
| precise nature | #1 |
| direct hepatoprotective effects | #1 |
| pyrithiamine rats | #1 |
| acute male microglia | #1 |
| ” benzodiazepine receptors | #1 |
| encephalopathy alf | #1 |
| portalsystemic encephalopathy | #1 |
| manifest altered expression | #1 |
| pca operation | #1 |
| pca rat | #1 |
| capacity ammonia removal | #1 |
| omega 3 receptor | #1 |
| hepatic encephalopathy neurobiology | #1 |
| progression encephalopathy | #1 |
| oatreated rats | #1 |
| development nutritional recommendations | #1 |
| hereferences | #1 |
| receptor cirrhotic patients | #1 |
| nac aom | #1 |
| 90 fmol protein | #1 |
| viral hepatitis alf | #1 |
| densities 3hpk11195 sites | #1 |
| spine neurochemical | #1 |
| neurosteroids pregnenolone allopregnanolone | #1 |
| glutamine synthetase protein | #1 |
| 3h 11195 | #1 |
| treatment lola | #1 |
| exp assessment | #1 |
| heneuropathology | #1 |
| activities thalamus | #1 |
| lcarnitine doses | #1 |
| encephalopathy alanine | #1 |
| expression hyperglycemic | #1 |
| glast protein day | #1 |
| animal pyridinium | #1 |
| liver failure muscle | #1 |
| animals thiamine deficiency | #1 |
| maob cerebellum | #1 |
| reduced astrocytic uptake | #1 |
| deficiency densities | #1 |
| 8 cirrhotic patients | #1 |
| normal conditions kidney | #1 |
| parkinsonism cirrhosis | #1 |
| unchanged brain | #1 |
| compounds pyrithiamine | #1 |
| evidence otc deficiency | #1 |
| glutamine synthetase capacity | #1 |
| alf amino | #1 |
| transverese friedreich ataxia | #1 |
| lola prevention | #1 |
| congenital otc deficiencies | #1 |
| pbz receptor densities | #1 |
| iii flumazenil | #1 |
| medium kcl | #1 |
| pathogenesis wernicke encephalopathy | #1 |
| csf concentrations ammonia | #1 |
| pse complication | #1 |
| csf ammonia control | #1 |
| alf messenger | #1 |
| pse csf lactate | #1 |
| cerebrospinal fluid ammonia | #1 |
| liver normal cd1 | #1 |
| dopamine thiamine deficiency | #1 |
| 11 thiamine deficiency | #1 |
| edema energy | #1 |
| offspring animal pyruvate | #1 |
| maternal thiamine | #1 |
| neuroinflammationinflammation | #1 |
| manganese distribution brain | #1 |
| neuroinflammatory mechanisms pathogenesis | #1 |
| genetic xlinked deficiency | #1 |
| gaba 11 | #1 |
| etanercept il6 levels | #1 |
| specific energy metabolism | #1 |
| relation deterioration | #1 |
| male pyrithiamine | #1 |
| brain liver failure | #1 |
| 213caspartate | #1 |
| hepatic coma bbb | #1 |
| complications alf | #1 |
| hypoglycaemia onset | #1 |
| thiamine deficiency synthesis | #1 |
| acids aaas | #1 |
| alterations pse | #1 |
| encephalopathy binding | #1 |
| pathogenesis clinic | #1 |
| devascularized rat | #1 |
| onset hypoglycaemic convulsions | #1 |
| decreased pdhc | #1 |
| result toxins | #1 |
| pca rats pca | #1 |
| congenital otc | #1 |
| pfco cirrhotic patients | #1 |
| astrocytes ammonia levels | #1 |
| cox2 ca1 subfield | #1 |
| ammonia proinflammatory | #1 |
| igg extravasation reduction | #1 |
| hyperammonemic disorders | #1 |
| mild hypothermia alf | #1 |
| 1 lola | #1 |
| disorder portalsystemic encephalopathy | #1 |
| deficiency binding | #1 |
| brain astrocytes alterations | #1 |
| increased brain ammonia | #1 |
| rats portacaval | #1 |
| cirrhosis ammonia hepatic | #1 |
| failure hepatic | #1 |
| ammonia increased expression | #1 |
| metabolic scavengers | #1 |
| cell increased synthesis | #1 |
| csf portacaval anastomosis | #1 |
| etanercepttreated alf mice | #1 |
| mice encephalopathy | #1 |
| therapeutic efficacy lcarnitine | #1 |
| edematous cerebral cortex | #2 |
| ammonia central role | #2 |
| precoma stages p001 | #2 |
| chronic thiamine | #2 |
| ataxia animals | #2 |
| decreased gfap immunoreactivity | #2 |
| thiaminedeficient mice | #2 |
| model wernicke | #2 |
| 4week portacaval | #2 |
| defect membrane transport | #2 |
| wks enzyme activities | #2 |
| decreased reuptake | #2 |
| cisterna magna catheter | #2 |
| ammonia gabaergic neurotransmission | #2 |
| nmda receptor pca | #2 |
| neuronal loss alterations | #2 |
| rats portacaval anastomosis | #2 |
| nash addition | #2 |
| rats thiamine | #2 |
| treatment cns complications | #2 |
| ammonia octanoic acid | #2 |
| increase coma | #2 |
| mrna expression gfap | #2 |
| human brain contrast | #2 |
| ligand 3hpk | #2 |
| 67 coma stages | #2 |
| l‐ornithine‐l‐aspartate | #2 |
| hepatic encephalopathy controls | #2 |
| edema hepatic | #2 |
| reflex stage | #2 |
| early precoma stages | #2 |
| ornithine aminotransferase administration | #2 |
| gammagba nalphaacetylarginine nalphaaa | #2 |
| cerebellum output | #2 |
| 3acetyl pyridine | #2 |
| liver thiamine | #2 |
| brain taurine concentrations | #2 |
| hepatic encephalopathy complication | #2 |
| cholinergic neuronal loss | #2 |
| allopregnanolone fold | #2 |
| portacaval shunting | #2 |
| activities muscle | #2 |
| lornithinelaspartate | #2 |
| liver failure gfap | #2 |
| cisterna magna catheters | #2 |
| encephalopathy histamine | #2 |
| symptomatic rats | #2 |
| encephalopathy onset | #2 |
| thiamine deficiency wks | #2 |
| thiamine deprivation loss | #2 |
| pdh activity platelets | #2 |
| ammonia metabolism astrocytes | #2 |
| indomethacin locomotor deficit | #2 |
| extracellular brain | #2 |
| brain shunted rats | #2 |
| hyperammonaemia hepatic encephalopathy | #2 |
| thp metabolites fatigue | #2 |
| increase coma stages | #2 |
| thdoc fold | #2 |
| thirtytwo cirrhotic patients | #2 |
| increased manganese | #2 |
| controls 3alpha5alphathp | #2 |
| binding 3hpk11195 | #2 |
| inbred strains glutamine | #2 |
| ammonia detoxification glutamine | #2 |
| isomorphic model | #2 |
| encephalopathy major | #2 |
| increased levels pregnenolone | #2 |
| mice alf | #2 |
| brain edema concentrations | #2 |
| glutamine intracranial | #2 |
| improvement mental state | #2 |
| induced liver failure | #2 |
| animal hepatic encephalopathy | #2 |
| selective increase | #2 |
| wks decreased activities | #2 |
| impaired gaba function | #2 |
| tyrosine tyr levels | #2 |
| activities maoa | #2 |
| densities binding | #2 |
| tdp dependent enzymes | #2 |
| glutamate syndrome | #2 |
| alf drug | #2 |
| thiamine‐dependent enzyme | #2 |
| ammonia animal hepatic | #2 |
| ohe encephalopathy humans | #2 |
| mice congenital | #2 |
| neurons glutamine synthesis | #2 |
| 5ht turnover brain | #2 |
| implicated pathogenesis | #2 |
| computed wernicke encephalopathy | #2 |
| carboxamide binding | #2 |
| moderate grade iii | #2 |
| disorder loss | #2 |
| pca brain regions | #2 |
| nitric oxide brain | #2 |
| hypokinesia produced | #2 |
| liver spf | #2 |
| systemic encephalopathy | #2 |
| membranes tomography | #2 |
| protein levels glast | #2 |
| experimental alf | #2 |
| concentrations ammonium chloride | #2 |
| reduction dopamine turnover | #2 |
| alf control | #2 |
| bergmann glial pathology | #2 |
| 2 brain samples | #2 |
| neuropathic pain etanercept | #2 |
| iggimmunoreactivity | #2 |
| cerebellum cirrhotic patients | #2 |
| development ethanol preference | #2 |
| ataxic animals | #2 |
| brain organic myoinositol | #2 |
| vesicular dysfunction | #2 |
| swelling cortical astrocytes | #2 |
| neurons nmr | #2 |
| thiamine turnover | #2 |
| isomorphic models | #2 |
| precoma coma | #2 |
| pallidum cirrhotic patients | #2 |
| alanine frontal cortex | #2 |
| glt1 increased | #2 |
| sustained hyperammonemia | #2 |
| densities binding sites | #2 |
| precoma stages increase | #2 |
| bckdh bckdh activity | #2 |
| form ataxia | #2 |
| thiaminedependent enzymes | #2 |
| mouse astrocytes effects | #2 |
| plasma proinflammatory cytokines | #2 |
| brain lactate synthesis | #2 |
| encephalopathy acute | #2 |
| cirrhotic patients modulation | #2 |
| hepatic encephalopathy ohe | #2 |
| brain levels neurosteroids | #2 |
| 970±079 | #2 |
| increased activities | #2 |
| loss eaat2 expression | #2 |
| progression ohe | #2 |
| ammoniainduced alterations | #2 |
| 3alpha5betathp patients | #2 |
| reduced brain levels | #2 |
| thiamine deficiency patients | #2 |
| thiamine dependent | #2 |
| cerebral edema loss | #2 |
| cirrhotic patients pathology | #2 |
| glutamate glur2 | #2 |
| kidney ammonia | #2 |
| neuropsychiatric complication | #2 |
| deficient encephalopathy | #2 |
| body fatigue rats | #2 |
| thiamine deprivation | #2 |
| alf mrna expression | #2 |
| treatment asparagine | #2 |
| modulation sgc | #2 |
| computerized autotrack | #2 |
| hyperammonemia increased | #2 |
| 26 153 | #2 |
| cns consequences | #2 |
| lower levels arginine | #2 |
| reduced brain dheas | #2 |
| 3000 microg m3 | #2 |
| pathogenesis portal | #2 |
| loss eaat2 protein | #2 |
| neurosteroid pregnenolone fold | #2 |
| disorder mystery | #2 |
| gfap immunoreactivity degree | #2 |
| alpha kgdh | #2 |
| aged muscimol | #2 |
| pca rats allopregnanolone | #2 |
| serum lad | #2 |
| hyperammonemic brain | #2 |
| astrocytic benzodiazepine | #2 |
| millimolar concentrations brain | #2 |
| plasma levels 3alpha5alphathp | #2 |
| death thiamine | #2 |
| wernickes encephalopathy patients | #2 |
| wernickes encephalopathy | #2 |
| gaba ammonia | #2 |
| encephalopathy aids | #2 |
| mice acetaminophen toxicity | #2 |
| brain samples alcoholics | #2 |
| electrified grid | #2 |
| kinetics taurine | #2 |
| intracranial hypertension alf | #2 |
| congenital hyperammonemias | #2 |
| coma stages p001 | #2 |
| shunted pcs | #2 |
| neuroinhibitory steroids | #2 |
| sgc brain | #2 |
| novo synthesis lactate | #2 |
| mri neurological evaluation | #2 |
| spf mutant mice | #2 |
| 150 dose increase | #2 |
| failure alf | #2 |
| enzyme deficits | #2 |
| hepatic encephalopathy gabaa | #2 |
| portacaval anastomosis pca | #2 |
| fold allopregnanolone | #2 |
| responsible neurological | #2 |
| modulation brain | #2 |
| cerebral complications alf | #2 |
| hydrolases aged | #2 |
| gammagba | #2 |
| vulnerable brain structures | #2 |
| encephalopathy glutamine concentrations | #2 |
| brain lactate increase | #2 |
| osmotic effects glutamine | #2 |
| immunohistochemistry liver failure | #2 |
| pathophysiologic mechanisms | #2 |
| central neuroinflammatory | #2 |
| thiamine‐dependent | #2 |
| failure altered | #2 |
| mental state trials | #2 |
| densities bmax | #2 |
| phosphate sulfate mixture | #2 |
| brains 36 patients | #2 |
| rats cortex male | #2 |
| pyrithiamine rats rats | #2 |
| diseases manganese | #2 |
| brain portacaval shunting | #2 |
| pyrithiamine induced | #2 |
| shunted | #2 |
| ouabain upregulation | #2 |
| pathogenesis friedreichs ataxia | #2 |
| increased brain turnover | #2 |
| cuznsod mrna cuznsod | #2 |
| rat brain relation | #2 |
| dheas hepatic | #2 |
| pallidal manganese | #2 |
| taurine platelets | #2 |
| haloperiodol | #2 |
| gabaa receptor indomethacin | #2 |
| 3beta5alphathp | #2 |
| liver cirrhosis activation | #2 |
| increasing dheas currents | #2 |
| csf ammonia | #2 |
| animals hepatic | #2 |
| hyperammonemia synaptosomes | #2 |
| thiamine bloodbrain barrier | #2 |
| dheas bdl rats | #2 |
| hepatic cerebral | #2 |
| autopsy delay intervals | #2 |
| ammoniainduced neurotoxicity | #2 |
| alpha1 sites | #2 |
| concentrations dheas | #2 |
| pyrithiamine treated | #2 |
| 2 flumazenil | #2 |
| aqp4 cerebral cortex | #2 |
| deficiency include | #2 |
| methyhistamine | #2 |
| dheas body fatigue | #2 |
| fold thdoc | #2 |
| activities choline acetyltransferase | #2 |
| gabaa encephalopathy humans | #2 |
| edema alf | #2 |
| glutamine hepatic | #2 |
| brain dehydroepiandrosterone dhea | #2 |
| degree gfap immunoreactivity | #2 |
| concentrations gammaguanidinobutyric acid | #2 |
| cortical astrocytes ammonia | #2 |
| bath concentration ammonia | #2 |
| sites increased | #2 |
| symptoms thiamine | #2 |
| encephalopathy portacaval | #2 |
| reduced concentrations dheas | #2 |
| thiaminedeficiency | #2 |
| increased novo synthesis | #2 |
| encephalopathy wernicke | #2 |
| liver failure studies | #2 |
| male portacaval shunt | #2 |
| sustained deficiency arginine | #2 |
| 3alpha5alphathp 3alpha5betathp | #2 |
| dheas reduced | #2 |
| lactate coma stages | #2 |
| brain glutamine synthesis | #2 |
| alcoholics absence | #2 |
| thiamine phosphorylation | #2 |
| 3hpk11195 brain regions | #2 |
| restricted transfer | #2 |
| βendorphin akinesia | #3 |
| cellspecific pathways | #3 |
| medium 5 mm | #3 |
| 38 alcoholic patients | #3 |
| βendorphin decreased concentrations | #3 |
| operated controls | #3 |
| alcoholics wks | #3 |
| synthesis aspartate | #3 |
| reflex serotonin βendorphin | #3 |
| thiamine phosphate | #3 |
| encephalopathy hepatic | #3 |
| singlesite model | #3 |
| type ” | #3 |
| αmt βendorphin | #3 |
| signs mild personality | #3 |
| portacavalshunted rats | #3 |
| brain improvement | #3 |
| abstract mild hypothermia | #3 |
| potent neuroactive properties | #3 |
| ammoniainduced impairment | #3 |
| pdh friedreich | #3 |
| bckdh activity rats | #3 |
| cirrhosis iii | #3 |
| muscle glutamine synthetase | #3 |
| mhe lola | #3 |
| acids relation | #3 |
| male portacaval | #3 |
| repetitive removal | #3 |
| statistical significance regions | #3 |
| hyperammonemia acute | #3 |
| pbgd study | #3 |
| transketolase activities | #3 |
| late symptomatic stages | #3 |
| ganglia structures | #3 |
| testis preparations | #3 |
| astrocytic cell swelling | #3 |
| rats glutamates hippocampus | #3 |
| neuroglial proteins | #3 |
| electrically stimulated release | #3 |
| gfap mrna gfap | #3 |
| cirrhosis agents | #3 |
| hepatic devascularized rat | #3 |
| cerebral cortex pons | #3 |
| brain concentrations rats | #3 |
| drug situ nickend | #3 |
| ammonia brain edema | #3 |
| ammonia energy metabolism | #3 |
| deficiency thiamine | #3 |
| binding sites heart | #3 |
| altered glial | #3 |
| ishen guidelines | #3 |
| doubt25 ammonia | #3 |
| thiamine deficiency wernicke | #3 |
| doubt25 | #3 |
| increased uptake capacity | #3 |
| animals coma | #3 |
| peripheral‐type | #3 |
| decreased densities | #3 |
| mrna ammonia | #3 |
| vitro binding technique | #3 |
| brain edema alf | #3 |
| glutamine brain edema | #3 |
| administration ammonium | #3 |
| brain portocaval anastomosis | #3 |
| globus pallidus putamen | #3 |
| kornetsky | #3 |
| rats αmt | #3 |
| concentrations αmt | #3 |
| corneal reflex apomorphine | #3 |
| transporter snat5 | #3 |
| 3hdaspartate uptake | #3 |
| liver–brain axis | #3 |
| 5fmorn treatment | #3 |
| akinesia corneal reflex | #3 |
| ammonia swelling | #3 |
| neurobiological characterization | #3 |
| animals profiles | #3 |
| skeletal portacaval shunt | #3 |
| addition astrocyte morphology | #3 |
| regions cns | #3 |
| activities reduced | #3 |
| coma equal | #3 |
| ammonia hepatic | #3 |
| 320350 degrees | #3 |
| decreased concentrations striatum | #3 |
| increases il1beta | #3 |
| ammonia glutamate | #3 |
| deletion delays | #3 |
| cerebellum activities | #3 |
| decreased concentrations αmt | #3 |
| predictions disorder | #3 |
| acute ammonia exposure | #3 |
| il6 levels brain | #3 |
| pdhc acetyl coa | #3 |
| akinesia βendorphin | #3 |
| cholestasis‐associated fatigue | #3 |
| alf animals | #3 |
| intraneuronal release | #3 |
| hepatic encephalopathy humans | #3 |
| treatment portalsystemic encephalopathy | #3 |
| encephalopathy inflammation | #3 |
| nmda subclass | #3 |
| autotrack | #3 |
| protective glutamine | #3 |
| pca odn immunolabeling | #3 |
| protein hepatic | #3 |
| humans neurotransmitter | #3 |
| platelets 10 patients | #3 |
| activities brains | #3 |
| tetrahydrodesoxycorticosterone | #3 |
| midbrain turnover study | #3 |
| rats pse | #3 |
| major neurotransmitter systems | #3 |
| severity reviews see1–4 | #3 |
| effects ro15 | #3 |
| tissue ornithine concentrations | #3 |
| pallidus hepatic | #3 |
| central cholinergic deficit | #3 |
| turnover study rats | #3 |
| decreased aspartate | #3 |
| glutamates hippocampus rats | #3 |
| pathogenesis central | #3 |
| acids cerebrospinal | #3 |
| rats pyrithiamine | #3 |
| increase brain lactate | #3 |
| basal ganglia βendorphin | #3 |
| coma stage | #3 |
| hepatobiliary route | #3 |
| mk‐801‐sensitive nitration | #3 |
| total brain glutamine | #3 |
| acrylamide pyrithiamine | #3 |
| cogent explanation | #3 |
| brain densities | #3 |
| deficiency acidosis | #3 |
| increased ptbr | #3 |
| thiamine deficient | #3 |
| effects ldeprenyl | #3 |
| abstract hepatic encephalopathy | #3 |
| rats pathogenesis | #3 |
| αmt midbrain | #3 |
| homogenates frontal cortex | #3 |
| lcarnitine atp | #3 |
| blood transketolase | #3 |
| endogenous agonists role | #3 |
| 13 consecutive weeks | #3 |
| prevents cerebral | #3 |
| homologous models | #3 |
| cerebellar amino | #3 |
| 5fmorn | #3 |
| glutamate transporter cells | #3 |
| congenital hyperammonemia | #3 |
| portocaval anastomosis pca | #3 |
| βendorphin apomorphine basal | #3 |
| lobe hepatic | #3 |
| glial cells ammonia | #3 |
| hypothermia brain edema | #3 |
| controls emax | #3 |
| cholinergic m1 | #3 |
| αketoglutarate dehydrogenase | #3 |
| adequate substrates | #3 |
| portacaval anastomosis rats | #3 |
| astrocyte glutamine | #3 |
| precoma stages | #3 |
| edema intracranial | #3 |
| selective brain lesions | #3 |
| strains thiamine | #3 |
| pcs rat brain | #3 |
| hepatic neurological | #3 |
| pallidal signals | #3 |
| amphetamine amphetamine animals | #3 |
| neurotransmission failure | #3 |
| selective down‐regulation | #3 |
| onset neurological signs | #3 |
| ammonia‐induced brain edema | #3 |
| carnitine ammonia | #3 |
| odn immunolabeling | #3 |
| ammoniatreated cells | #3 |
| models thiamine | #3 |
| genial expression | #3 |
| encephalopathy aged | #3 |
| alf brain | #4 |
| amino acids areas | #4 |
| deoxyglucose endothelium | #4 |
| brain edema increase | #4 |
| thiamine‐deficient rat brain | #4 |
| locomotor deficit | #4 |
| brain energy failure | #4 |
| tdinduced cell death | #4 |
| brain dopamine receptor | #4 |
| carnitine energy | #4 |
| normal coupling | #4 |
| thiamine deficiency rats | #4 |
| ions synaptic | #4 |
| elevated ammonia levels | #4 |
| thiamine antagonist | #4 |
| total shunting | #4 |
| decreased activities | #4 |
| rats asparagine | #4 |
| ischemic liver failure | #4 |
| cases alcohol abuse | #4 |
| mmars increased icp | #4 |
| increased concentrations prostaglandins | #4 |
| thiamine deficient animals | #4 |
| tspo sites | #4 |
| arterial ammonia alf | #4 |
| opioid pca | #4 |
| activities brain | #4 |
| mhe mildest form | #4 |
| peripheral‐type benzodiazepine | #4 |
| pse increased | #4 |
| edema gene | #4 |
| brain thiamine | #4 |
| xlinked deficiency | #4 |
| arterial ammonia mmars | #4 |
| protein expression brain | #4 |
| ammonia levels blood | #4 |
| p001 hypothermia | #4 |
| 6 hrs alf | #4 |
| sham mmars | #4 |
| thp metabolites | #4 |
| histaminergic histamine | #4 |
| thiamine thiamine pyrophosphate | #4 |
| brain pregnenolone content | #4 |
| early microglial response | #4 |
| rat brain pca | #4 |
| brain glutamic | #4 |
| liver brain | #4 |
| benzodiazepines increase | #4 |
| albumin dialysis alf | #4 |
| thiochrome derivatives | #4 |
| astrocytic genes | #4 |
| gaba friedreich | #4 |
| treatment hepatic encephalopathy | #4 |
| newly synthesized glutamine | #4 |
| expression alf | #4 |
| inbred strains ammonia | #4 |
| transketolase wernicke | #4 |
| maoa isoform | #4 |
| vitro techniques ketoglutarate | #4 |
| subclinical seizure activity | #4 |
| taurine friedreichs ataxia | #4 |
| neurotransmitter dysfunction | #4 |
| severe neuronal dysfunction | #4 |
| brain hepatic encephalopathy | #4 |
| cbf inflammatory mediators | #4 |
| wernickekorsakoff syndrome | #4 |
| amino acids regions | #4 |
| activities prefrontal cortex | #4 |
| thiamine diphosphatase | #4 |
| encephalopathy coma | #4 |
| activities glutamine synthetase | #4 |
| acute ammonia treatment | #4 |
| izuru matsumoto | #4 |
| guanylate cyclase patients | #4 |
| 5 mm nh4cl | #4 |
| liver central | #4 |
| mmars brain water | #4 |
| acute liver failure | #4 |
| ouabainlike compounds | #4 |
| 13 moles | #4 |
| effects mild hypothermia | #4 |
| condition development | #4 |
| increased icp alf | #4 |
| shamoperated controls | #4 |
| locomotor evaluation | #4 |
| patients wernicke | #4 |
| inos mnsod | #4 |
| icp arterial ammonia | #4 |
| synaptic membrane preparations | #4 |
| increased brain glutamine | #4 |
| lornithine laspartate | #4 |
| regional amino | #4 |
| rats portacaval shunting | #4 |
| tdpase | #4 |
| administration central | #4 |
| glt1 transcript | #4 |
| brain 5ht release | #4 |
| surgical rna rats | #4 |
| brain neuroinflammation | #4 |
| time mmars | #4 |
| affinities densities | #4 |
| ornithine aspartate | #4 |
| shunted rats | #4 |
| aged pyruvate | #4 |
| otcdeficient mice | #4 |
| alf expression | #4 |
| loss glt1 | #4 |
| inflammation mediators icp | #4 |
| alf | #4 |
| extrapyramidal symptoms patients | #4 |
| alcohol thiamine deficiency | #4 |
| cerebral cortex kidney | #4 |
| calcium microsomes | #4 |
| animals liver failure | #4 |
| onset severe encephalopathy | #4 |
| anastomosis rat | #4 |
| degree alzheimer type | #4 |
| postmortem delay interval | #4 |
| plasma clearance groups | #4 |
| alcoholism thiamine | #4 |
| cerebral amino acids | #4 |
| hepatocytes ascorbate | #4 |
| rats βendorphin | #4 |
| astrocytic metabolic | #4 |
| mmars time | #4 |
| ouabain ec50 | #4 |
| postsynaptic action | #4 |
| kgdh | #5 |
| treatment malnutrition | #5 |
| allopregnanolone thdoc | #5 |
| methioninesulfoximine | #5 |
| congenital urea | #5 |
| anterolateral hypothalamus | #5 |
| brain histamine receptors | #5 |
| alterations glutamatergic | #5 |
| amino acids pathogenesis | #5 |
| laspartate lola | #5 |
| brain ammonia | #5 |
| brain glutamate concentrations | #5 |
| liver assist devices | #5 |
| neurotransmitter pool | #5 |
| patients hepatic | #5 |
| extracellular quin | #5 |
| amino acid regions | #5 |
| neurological status | #5 |
| saturation binding isotherms | #5 |
| mmars | #5 |
| glutamate symporters | #5 |
| currents concentrations | #5 |
| brain acute | #5 |
| sustained deficiency | #5 |
| prevention prophylaxis | #5 |
| latenight snack | #5 |
| hand densities | #5 |
| surgical receptors | #5 |
| alf ammonia | #5 |
| activities choline | #5 |
| mild personality | #5 |
| publication animals rats | #5 |
| astrocytic | #5 |
| spectroscopy tomography emissioncomputed | #5 |
| aspartate lola | #5 |
| pse encephalopathy humans | #5 |
| homologous model | #5 |
| acetyl pyridine | #5 |
| hyperammonemia liver | #5 |
| pregnenolone content | #5 |
| pet scan study | #5 |
| tpp cofactor | #5 |
| thiamine status | #5 |
| cytokines ammonia | #5 |
| 45 cirrhotic patients | #5 |
| age matched subjects | #5 |
| gait animals | #5 |
| intracranial hypertension rats | #5 |
| ammonia removal | #5 |
| complication acute | #5 |
| tk activities | #5 |
| ammonia lowering | #5 |
| kstimulated ca2dependent release | #5 |
| vulnerable regions | #5 |
| tissue autopsy | #5 |
| hepatic encephalopathy gaba | #5 |
| studied brain | #5 |
| kinetics pharmacology | #5 |
| increases ammonia | #5 |
| acute rats rats | #5 |
| manganese astrocytes | #5 |
| glur2 glur3 subunits | #5 |
| reserpinelike | #5 |
| chronic exposure manganese | #5 |
| sites peripheral | #5 |
| activities cerebellum | #5 |
| transporter sites | #5 |
| thiaminedeficient diet | #5 |
| liver disease rats | #5 |
| responsible brain | #5 |
| branchedchain analysis | #5 |
| medial thalamus | #5 |
| exposure cultured astrocytes | #5 |
| cns ammonia | #5 |
| glutamine hypothesis | #5 |
| activities gad | #5 |
| content modulation | #5 |
| genetics astrocytes blotting | #5 |
| reduction glutamate | #5 |
| vulnerable brain | #5 |
| ammonia muscle | #5 |
| rats portacaval shunts | #5 |
| spf mice controls | #5 |
| rats fatigue | #5 |
| encephalopathy cerebral | #5 |
| onset coma | #5 |
| topic rifaximin | #5 |
| ammonia metabolism | #5 |
| convulsions onset | #5 |
| cerebral hepatic | #5 |
| monoamines metabolites | #5 |
| acute magnetic | #5 |
| allopregnanolone gabaa | #5 |
| result altered | #5 |
| maoa activities | #5 |
| alcoholic receptors | #5 |
| hexyl1h | #5 |
| wernicke | #5 |
| adequate experimental models | #5 |
| maoa function | #5 |
| nencki | #6 |
| 14c taurine | #6 |
| expression astrocytic genes | #6 |
| increased expression aqp4 | #6 |
| hypothermia alf | #6 |
| humans hyperammonemia | #6 |
| increased glut1 expression | #6 |
| alf nac | #6 |
| arginine brain | #6 |
| tmpase | #6 |
| plasma frontal cortex | #6 |
| mice nacetylcysteine | #6 |
| fmorn | #6 |
| term fluorescence | #6 |
| perispinal etanercept | #6 |
| pca sham | #6 |
| 3htryptamine binding | #6 |
| platelets 11 patients | #6 |
| endstage liver failure | #6 |
| mars alf | #6 |
| glt1 glast protein | #6 |
| encephalopathy humans | #6 |
| unaltered distribution | #6 |
| hyperammonemic | #6 |
| receptors hepatic | #6 |
| fur mice | #6 |
| enzymes brains | #6 |
| alphaketoglutarate dehydrogenase | #6 |
| astrocyte cell volume | #6 |
| thiamine phosphate esters | #6 |
| nac alf | #6 |
| glt1 brain | #6 |
| glast transporter | #6 |
| ascorbate protects | #6 |
| 3nmol | #6 |
| concomitant 24fold increase | #6 |
| central proinflammatory | #6 |
| hepatic encephalopathy effects | #6 |
| acetyl lcarnitine | #6 |
| activities liver | #6 |
| basal ganglia structures | #6 |
| disease ammonia | #6 |
| righting reflexes | #6 |
| thiamine esters | #6 |
| controls arginine | #6 |
| direct neurotoxic | #6 |
| cerebral cortex activities | #6 |
| relationship neurological symptoms | #6 |
| gabaergic tone | #6 |
| frontal cortex rats | #6 |
| cerebral amino | #6 |
| lola improvement | #6 |
| liver failure | #6 |
| deterioration neurological | #6 |
| dehydrogenase pdhc | #6 |
| brain benzodiazepine | #6 |
| brain cirrhotic | #6 |
| induced thiamine | #6 |
| enzymes pyruvate | #6 |
| 3htryptamine binding sites | #6 |
| blood‐brain barrier integrity | #6 |
| capacity removal | #6 |
| models alf | #6 |
| cerebellum caudate nucleus | #6 |
| dha administration | #6 |
| ammonia glutamine | #6 |
| implications pathogenesis | #6 |
| dogs hepatic encephalopathy | #6 |
| inflammatory mediators groups | #6 |
| benzodiazepine intake | #6 |
| output cerebellum | #6 |
| swelling astrocytes | #7 |
| fulminant liver failure | #7 |
| tppdependent enzymes | #7 |
| alcoholic brain damage | #7 |
| hepatic encephalopathy studies | #7 |
| 3htryptamine | #7 |
| surgical rats | #7 |
| 70 mm kcl | #7 |
| pregnant rats offspring | #7 |
| glutamine increased | #7 |
| central neuroinflammation | #7 |
| vpmt | #7 |
| nutritional management patients | #7 |
| notion activation | #7 |
| transporter deficit | #7 |
| concentrations allopregnanolone | #7 |
| transketolase animals | #7 |
| hiaa increased | #7 |
| flumazenil patients | #7 |
| severe thiamine deficiency | #7 |
| typical friedreichs ataxia | #7 |
| acute minocycline | #7 |
| size portacaval | #7 |
| chemistry disease | #7 |
| increased cerebellum | #7 |
| alf arterial ammonia | #7 |
| neuropsychiatric abnormalities patients | #7 |
| loss transporter | #7 |
| columbia rating scale | #7 |
| chronic deprivation | #7 |
| kcl medium | #7 |
| glutamate acute | #7 |
| wernicke‐korsakoff syndrome | #7 |
| neurological symptoms | #7 |
| central benzodiazepine receptors | #7 |
| l3harginine uptake | #7 |
| failure acute | #7 |
| pca pss | #7 |
| thiamine absorption | #7 |
| skeletal muscle adapts | #7 |
| metallic phosphate | #7 |
| tdp ttp | #7 |
| glutamine synthesis ammonia | #7 |
| uremic coma | #7 |
| frontal cortex controls | #7 |
| edema plasma | #7 |
| ammonia kidney | #7 |
| edema extracellular | #7 |
| flumazenil 10 microm | #7 |
| thiamine dependent enzymes | #7 |
| gdh activities | #7 |
| astrocytic transporters | #7 |
| alf sham | #7 |
| neuroinhibitory | #7 |
| rats ammonium acetate | #7 |
| liver hepatic encephalopathy | #7 |
| igg immunohistochemistry | #7 |
| brain glutamate | #7 |
| icp alf | #7 |
| fatigue severity patients | #7 |
| animal hepatic | #7 |
| perineuronal astrocytes | #7 |
| mediators liver | #7 |
| inhibitor src | #7 |
| neuronal cell loss | #7 |
| cerebral alterations alf | #7 |
| ischemia hyperglycemic | #7 |
| encephalopathy findings | #7 |
| cyclase hepatic | #7 |
| gaba reverse | #8 |
| alf administration | #8 |
| measurement cell volume | #8 |
| central noradrenergic function | #8 |
| affinity glutamate uptake | #8 |
| portalsystemic shunting | #8 |
| dependent enzymes | #8 |
| study binding sites | #8 |
| regional alterations | #8 |
| neuroprotective steroids | #8 |
| expression glyt1 | #8 |
| hyperglycemic cerebral | #8 |
| nmda sites | #8 |
| thalamus cerebellum | #8 |
| intracranial pressure increase | #8 |
| alcohol thiamine | #8 |
| portocaval anastomosis | #8 |
| disease gad | #8 |
| brain increased expression | #8 |
| 3alpha5betathp | #8 |
| lactate synthesis | #8 |
| arterial ammonia concentrations | #8 |
| cirrhotic patients | #8 |
| rindi | #8 |
| active pyruvate dehydrogenase | #8 |
| probenecid 5 | #8 |
| proinflammatory mediators expression | #8 |
| taurine ca2 | #8 |
| synthesis thiamine | #8 |
| brain ammonia levels | #8 |
| neuropathologic consequences | #8 |
| ammonium ions | #8 |
| direct toxic actions | #8 |
| activities glutamine | #8 |
| voluntary ethanol consumption | #8 |
| peter dodd | #8 |
| concentrations thdoc | #8 |
| alcohol brain damage | #8 |
| ammonia metabolites | #8 |
| antisense elements genetics | #8 |
| hyperglycemic cerebral ischemia | #8 |
| strains ornithine | #8 |
| complications liver disease | #8 |
| induced akinesia | #8 |
| neurobehavioral damage | #8 |
| chronic brain dysfunction | #8 |
| tellez | #8 |
| content frontal cortex | #8 |
| normal metabolic balance | #8 |
| falls cirrhosis | #8 |
| synthesis lactate | #8 |
| cerebellum activation | #8 |
| result decreased | #8 |
| autopsied human | #8 |
| ammonia hyperammonemia | #8 |
| sourkes | #8 |
| cells ammonia | #8 |
| clive harper | #8 |
| ultraviolet uv spectrum | #8 |
| alterations modulation | #8 |
| loss congenital | #8 |
| tests ataxia | #8 |
| prefrontal nmda | #8 |
| assessment bioaccumulation | #8 |
| elfar adalsteinsson | #8 |
| spraguedawley temporal lobe | #8 |
| receptors mitochondrial | #8 |
| izuru | #8 |
| central gabaa receptor | #9 |
| brain postsynaptic | #9 |
| animals acute | #9 |
| protein glut1 | #9 |
| ammonia key role | #9 |
| manganese dust | #9 |
| taurine calcium | #9 |
| order address | #9 |
| hyperammonemia liver cirrhosis | #9 |
| glutamate glt1 | #9 |
| rats phosphate | #9 |
| observed frontal | #9 |
| pallidal signal | #9 |
| rat brain density | #9 |
| 11 cirrhotic patients | #9 |
| glyt1 transporter | #9 |
| cerebellum medulla oblongata | #9 |
| acute hyperammonemia | #9 |
| prevention complications | #9 |
| acute rats | #9 |
| edema rats | #9 |
| disease thiamine | #9 |
| male cirrhotic patients | #9 |
| portal hypertension result | #9 |
| sites frontal | #9 |
| nonneuronal elements | #9 |
| acid hepatic | #9 |
| glial tca cycle | #9 |
| ammonia neurotoxicity | #9 |
| ammonia induced | #9 |
| neuroinhibition | #9 |
| edith sullivan | #9 |
| hepatic coma | #9 |
| perispinal administration | #9 |
| mild hypothermia | #9 |
| transcarbamylase otc | #9 |
| brain herniation | #9 |
| pcs rats | #9 |
| sham alf | #9 |
| 5fluoromethylornithine | #9 |
| portacaval rat | #9 |
| hepatic encephalopathy ammonia | #9 |
| gaba reference | #9 |
| joanne lewohl | #9 |
| binding sites brain | #9 |
| acute nitric oxide | #9 |
| glutamate receptor ligands | #9 |
| activities skeletal muscle | #9 |
| gabaa tissue distribution | #9 |
| ammonia binding | #9 |
| cerebral ammonia toxicity | #9 |
| vulnerable brain regions | #9 |
| mechanisms responsible | #9 |
| arterial ammonia concentration | #9 |
| adolf pfefferbaum | #9 |
| hepatocerebral | #9 |
| autopsied brain | #9 |
| kinetics distribution | #9 |
| glucose hypothermia | #9 |
| thiamine monophosphatase | #9 |
| 37 decrease | #9 |
| taurine binding | #9 |
| binding sites nmda | #9 |
| neurotoxic substance | #9 |
| thalamic structures | #10 |
| loss reflex | #10 |
| complication chronic | #10 |
| activation pathogenesis | #10 |
| selective brain regions | #10 |
| hrqol mhe | #10 |
| rats stereotyped behavior | #10 |
| anastomosis hepatic | #10 |
| progression hepatic encephalopathy | #10 |
| 200 appearance | #10 |
| affinities binding sites | #10 |
| decreased glutamate | #10 |
| 3omethylglucose animals animals | #10 |
| labeling glutamine | #10 |
| dissected material | #10 |
| rats nimesulide | #10 |
| neurological symptomatology | #10 |
| bdl surgery | #10 |
| model alf | #10 |
| 3hketanserin binding sites | #10 |
| 10 mm concentration | #10 |
| disorders include | #10 |
| massive brain edema | #10 |
| brain edema | #10 |
| mechanisms tnfalpha | #10 |
| cerebellum pons | #10 |
| nh4ac | #10 |
| cerebral consequences | #10 |
| identification alterations | #10 |
| mechanisms free radicals | #10 |
| encephalopathy cirrhotic | #10 |
| glutamine synthesis astrocytes | #10 |
| thiamine transketolase | #10 |
| 3hpk | #10 |
| neuropsychiatric disorder | #10 |
| cord taurine | #10 |
| encephalopathy grade | #10 |
| subsequent gc analysis | #10 |
| deficiency congenital | #10 |
| expression superoxide | #10 |
| ammonia study | #10 |
| urea cycle enzymopathies | #10 |
| glutathione levels expression | #10 |
| brain pca | #10 |
| mechanisms include | #10 |
| neuroactive amino acids | #10 |
| flumazenil hepatic | #10 |
| thiamine replenishment | #10 |
| fur mouse | #10 |
| swelling ammonia | #10 |
| nh4 forms | #10 |
| rats daily injections | #10 |
| mnsod cuznsod | #10 |
| stress thiamine | #10 |
| rat leads | #10 |
| biosynthetic purposes | #11 |
| impaired oxidation | #11 |
| alterations brain | #11 |
| benzodiazepine bdz receptors | #11 |
| amino acids rats | #11 |
| pca brain | #11 |
| signal hyperintensity | #11 |
| experimental design limitations | #11 |
| brain h1 | #11 |
| portal systemic | #11 |
| cerebral vulnerability | #11 |
| rats nh4cl | #11 |
| impaired locomotor activity | #11 |
| reduced activities | #11 |
| increased expression brain | #11 |
| patients gabaa | #11 |
| 1h‐13c | #11 |
| placebo benzodiazepines | #11 |
| fluoromethylornithine | #11 |
| glutamate gammaaminobutyric acid | #11 |
| ammonia pathogenesis | #11 |
| time icp | #11 |
| deficiency brain | #11 |
| isoforms mrna | #11 |
| gabaergic tonic currents | #11 |
| brain liver | #11 |
| benzodiazepinelike compounds | #11 |
| benzodiazepines neurosteroids | #11 |
| ammonia animals rats | #11 |
| brain increased | #11 |
| cirrhotic patients relationship | #11 |
| dawley thalamus | #11 |
| dehydrogenase alpha | #11 |
| capacity ammonia | #11 |
| ammonia astrocytes | #11 |
| hypothermia liver | #11 |
| hyperammonemias | #11 |
| oxidative nitrosative stress | #11 |
| manganese blood | #11 |
| studies convincing evidence | #11 |
| halflife age | #11 |
| ammonia amino acids | #11 |
| brain alf | #11 |
| pca p005 | #11 |
| pdh alpha | #11 |
| ammonia | #12 |
| cerebellar tissue | #12 |
| brain slices synaptosomes | #12 |
| patients frontal cortex | #12 |
| contribute pathogenesis | #12 |
| prevention hepatic encephalopathy | #12 |
| humans hepatic | #12 |
| thalamus cerebral cortex | #12 |
| aqp4 brain edema | #12 |
| selective loss expression | #12 |
| p005 pca | #12 |
| total glutamine | #12 |
| improvement neurological symptoms | #12 |
| hyperammonemia liver failure | #12 |
| selective radioligands | #12 |
| anaplerotic activity | #12 |
| shunt surgical | #12 |
| mild hypothermia patients | #12 |
| rats glut1 | #12 |
| brains rats | #12 |
| diphosphate form | #12 |
| deficiency amino | #12 |
| mm nh4cl | #12 |
| microglial activation brain | #12 |
| acetyltransferase disease | #12 |
| igg extravasation | #12 |
| clinical hepatic encephalopathy | #12 |
| ammonia amino | #12 |
| thiamin triphosphate | #12 |
| loss righting | #12 |
| binding sites ligands | #12 |
| perispinal | #12 |
| ammonia animals | #12 |
| binding medium | #12 |
| subclinical encephalopathy | #12 |
| neuroactive amino | #12 |
| thiamine deficient diet | #12 |
| blood manganese concentrations | #12 |
| ammonia salts | #12 |
| increased ammonia | #12 |
| pairfed control mice | #12 |
| humans ketoglutarate | #12 |
| selective inactivator | #12 |
| brain chronic | #12 |
| veratramine | #13 |
| presence hippocampal sclerosis | #13 |
| frontal cortex administration | #13 |
| ampa receptor glur2 | #13 |
| ishen | #13 |
| ammonia manganese | #13 |
| complex ketone | #13 |
| body fatigue | #13 |
| gfap protein | #13 |
| cerebral edema icp | #13 |
| hand activities | #13 |
| neurosteroids pregnenolone | #13 |
| tissuespecific alterations | #13 |
| endogenous neuropeptide ligands | #13 |
| blood csf concentrations | #13 |
| loss gfap | #13 |
| pallidal dopamine | #13 |
| postsynaptic gaba | #13 |
| hyperglycemic ischemia | #13 |
| role selective vulnerability | #13 |
| hepatic encephalopathy patients | #13 |
| loss chat | #13 |
| transcarbamylase deficiency | #13 |
| survival liver injury | #13 |
| cytokines hepatic | #13 |
| increased brain lactate | #13 |
| hyperammonemic conditions | #13 |
| thiamine intake | #13 |
| neuroprotection pretreatment | #13 |
| sites brain | #13 |
| increased copper content | #13 |
| evidence central | #13 |
| acute ammonia | #13 |
| ammonia cytokines | #13 |
| patients flumazenil | #13 |
| development severe encephalopathy | #13 |
| increased csf concentrations | #13 |
| levels octopamine | #13 |
| regions rat brain | #13 |
| hyperammonemia ammonia | #13 |
| greatest vulnerability | #13 |
| amino acids lactate | #13 |
| treatment liver failure | #13 |
| neurosteroids gabaa | #13 |
| liver toxins | #13 |
| brain water accumulation | #13 |
| peripheral nerve conduction | #13 |
| expression ammonia | #13 |
| growing body evidence | #13 |
| butyrylglycine | #13 |
| pathogenesis | #14 |
| models hepatic | #14 |
| systemic shunting | #14 |
| clinical neurological signs | #14 |
| antibiotic minocycline | #14 |
| cerebellum cerebellar cortex | #14 |
| sparse fur | #14 |
| brain energy metabolites | #14 |
| gfap aqp4 | #14 |
| 8024 | #14 |
| αmt | #14 |
| mammillary body atrophy | #14 |
| striatum concentrations | #14 |
| glutamine concentrations | #14 |
| aged biogenic | #14 |
| portacaval rats | #14 |
| manganese distribution | #14 |
| hypothermia reduction | #14 |
| ataxia neurological signs | #14 |
| purkinje cell terminals | #15 |
| portocaval shunts | #15 |
| ataxics | #15 |
| astrocytic volume | #15 |
| hyperintensity patients | #15 |
| moderate drinkers | #15 |
| treatment measurement | #15 |
| failure encephalopathy | #15 |
| cerebral complications | #15 |
| role thiamine | #15 |
| gabaa reference values | #15 |
| vulnerable region | #15 |
| cirrhosis systematic review | #15 |
| manganese phosphate | #15 |
| thiamin metabolism | #15 |
| microglial activation neuroinflammation | #15 |
| fulminant liver | #15 |
| 3hpk 11195 | #15 |
| activity pdhc | #15 |
| acute liver | #15 |
| alcoholic brain | #15 |
| glur3 subunits | #15 |
| 3hquisqualate | #15 |
| white matter cbf | #15 |
| apaptreated mice | #15 |
| animal modelling | #16 |
| glutamine increase | #16 |
| benzodiazepine gaba | #16 |
| hypothesises | #16 |
| brain proinflammatory | #16 |
| encephalopathy loss | #16 |
| endothelial glucose | #16 |
| taurine brain | #16 |
| isoform gene | #16 |
| hypothermia 35 | #16 |
| brain modulation | #16 |
| encephalopathy chronic | #16 |
| socalled type | #16 |
| new prospects | #16 |
| nonvulnerable | #16 |
| distribution tritium | #16 |
| new mechanistic basis | #16 |
| agonal status | #16 |
| wks | #16 |
| hepatic metabolic pathways | #16 |
| cirrhosis ammonia | #16 |
| addition degree | #16 |
| pcs sham | #16 |
| gabaa receptor complex | #16 |
| pathophysiologic cascade | #16 |
| encephalopathy liver | #16 |
| benzodiazepine ligands | #16 |
| proteins implicated | #16 |
| surgical construction | #17 |
| cortical astrocyte | #17 |
| antibiotic rifaximin | #17 |
| upregulation aqp4 | #17 |
| reprint | #17 |
| liver disease mice | #17 |
| dependent enzyme | #17 |
| excess ammonia | #17 |
| cox2 expression immunohistochemistry | #17 |
| vulnerable structures | #17 |
| day heavy drinking | #17 |
| pathogenesis complications | #17 |
| pregnenolone allopregnanolone | #17 |
| absence ammonia | #17 |
| neuroinflammatory mechanisms | #17 |
| early glial | #17 |
| 4fold increases | #17 |
| glutamine phenylalanine | #17 |
| ammonia induces | #17 |
| patient malnutrition | #17 |
| glutamate enzyme | #17 |
| endogenous benzodiazepines | #17 |
| benzoate therapy | #17 |
| onset convulsions | #17 |
| early microglial | #17 |
| encephalopathy rats | #17 |
| complications malnutrition | #17 |
| isoquinoline carboxamide | #17 |
| cerebellum enzyme | #17 |
| loss liver | #17 |
| synthetase activities | #17 |
| activation sgc | #17 |
| acids ammonia | #17 |
| acid thiamine | #17 |
| platelets dopamine | #17 |
| reversible coma | #18 |
| 13c isotopomer analysis | #18 |
| result molecules | #18 |
| brain regions rat | #18 |
| generalized reduction | #18 |
| neurological psychiatric | #18 |
| patients therapeutic options | #18 |
| encephalopathy patients | #18 |
| bbb igg | #18 |
| type benzodiazepine | #18 |
| neuropathological damage | #18 |
| 11195 binding | #18 |
| active pyruvate | #18 |
| beta endorphin betaep | #18 |
| administration aom | #18 |
| prevention progression | #18 |
| doserelated reduction | #18 |
| astrocytes blotting | #18 |
| concentrations kcl | #18 |
| alcoholic cirrhotic patients | #18 |
| wernicke korsakoff | #18 |
| wernicke korsakoff syndrome | #18 |
| autopsied | #18 |
| astrocytic glutamine synthetase | #18 |
| portocaval shunting | #18 |
| compared pair | #18 |
| condition evidence | #18 |
| binding sites hippocampus | #18 |
| neuropathologic evaluation | #18 |
| activities alpha | #18 |
| coa levels | #18 |
| selective neuronal | #18 |
| severe encephalopathy | #19 |
| lola patients | #19 |
| astrocytic neuronal | #19 |
| distribution binding | #19 |
| expression result | #19 |
| energy metabolism brain | #19 |
| treatment mhe | #19 |
| cirrhotic patients controls | #19 |
| 125iiodopindolol | #19 |
| pathophysiology hepatic encephalopathy | #19 |
| errors mice | #19 |
| control groups animals | #19 |
| ornithine transcarbamylase | #19 |
| endogenous benzodiazepine | #19 |
| rats stages | #19 |
| increase brain water | #19 |
| blood manganese | #19 |
| exposure cultured | #19 |
| brain lactate | #19 |
| disease frontal | #19 |
| brain peripheral | #19 |
| free coa | #19 |
| cholinergic cell loss | #19 |
| serum ammonia levels | #19 |
| acids glutamate | #19 |
| outcome prevention | #19 |
| synthetase protein | #19 |
| equal age | #19 |
| agents hepatic | #19 |
| complications acute | #19 |
| glutamates glutamine | #19 |
| response neurodegeneration | #19 |
| csf concentrations 5hiaa | #19 |
| acute ammonia toxicity | #20 |
| syndrome wks | #20 |
| alf mars | #20 |
| coma brain | #20 |
| biochemical lesion | #20 |
| l3harginine | #20 |
| volume plasmapheresis | #20 |
| regions rat | #20 |
| lola | #20 |
| brain autopsy samples | #20 |
| brain organic osmolytes | #20 |
| benzodiazepine medication | #20 |
| diencephalic | #20 |
| glutamate increased | #20 |
| effects neurosteroids | #20 |
| glutamate nmda receptors | #20 |
| bbb alterations | #20 |
| expression oxidative stress | #20 |
| animals tests | #20 |
| adequate dietary protein | #20 |
| rats patients | #20 |
| animal frontal | #20 |
| aids patients patients | #20 |
| pallidal hyperintensity | #20 |
| symptomatic stages | #21 |
| alanine increased | #21 |
| mild hypothermia survival | #21 |
| failure skeletal | #21 |
| protective hypothermia | #21 |
| metabolic trafficking | #21 |
| 8094 | #21 |
| sgc nitric oxide | #21 |
| blood–brain barrier permeability | #21 |
| selective loss neurons | #21 |
| 3alpha5alphathp | #21 |
| deficiency synthesis | #21 |
| glast protein | #21 |
| cisterna magna csf | #21 |
| direct neurotoxic effects | #21 |
| mhe encephalopathy humans | #21 |
| transport ammonia | #21 |
| tetrahydrodeoxycorticosterone | #21 |
| hyperammonemia rats | #21 |
| endorphin induced | #21 |
| 5 p0001 | #21 |
| nakatpase activities | #21 |
| plasma ammonia concentrations | #21 |
| vivo cerebral | #21 |
| temporal cortex cerebellum | #22 |
| acute hepatic encephalopathy | #22 |
| characterized model | #22 |
| gabaa receptors humans | #22 |
| gaba regions | #22 |
| cerebral cortex brainstem | #22 |
| zieve | #22 |
| 3alpha5beta | #22 |
| alf infection | #22 |
| deficiency alterations | #22 |
| effects glutamate | #22 |
| inbred strains cns | #22 |
| sites cerebral | #22 |
| hepatic carnitine | #22 |
| 3hafdx | #22 |
| partial inverse agonists | #22 |
| stereotyped behavior rats | #22 |
| sham operation rats | #22 |
| distribution amino acids | #22 |
| exposed manganese | #22 |
| antiparkinson drugs | #22 |
| brain alanine | #22 |
| normal circumstances | #22 |
| concentrations glycine | #22 |
| brain experimental | #22 |
| sites measured | #22 |
| dewhurst | #23 |
| glutamine neurons | #23 |
| neuropathological evaluation | #23 |
| ammonia lactate | #23 |
| increased sites | #23 |
| glutamine taurine | #23 |
| amino acids model | #23 |
| cerebral gaba | #23 |
| thiamine homeostasis | #23 |
| portal systemic encephalopathy | #23 |
| glutamine accumulation | #23 |
| impaired absorption | #23 |
| cortex male rats | #23 |
| ammonia liver | #23 |
| astrocytic protein | #23 |
| brain neurosteroid | #23 |
| gabaa steroids | #23 |
| treatment sarcopenia | #23 |
| mm ammonia | #23 |
| proinflammatory cytokines mice | #23 |
| brain cell function | #23 |
| oxidative stress nac | #23 |
| hippocampus thalamus | #23 |
| diphosphate dependent | #23 |
| deficiency animals | #23 |
| marrero | #23 |
| bckdh activity | #23 |
| aspartate alanine | #23 |
| neuropathologic studies | #24 |
| external warming | #24 |
| brain coenzyme | #24 |
| serotonin 5ht metabolism | #24 |
| ” ligands | #24 |
| activites | #24 |
| p005 activities | #24 |
| encephalopathy ammonia | #24 |
| controls cirrhotic | #24 |
| sites ligands | #24 |
| pathophysiological levels | #24 |
| deficiency regulation | #25 |
| glutamine liver | #25 |
| uptake 14c | #25 |
| copper zinc concentrations | #25 |
| katpase src | #25 |
| cytotoxic brain edema | #25 |
| transketolase tk | #25 |
| chronic hepatic | #25 |
| extracellular glutamine | #25 |
| sites glutamate | #25 |
| glutamine synthesis | #25 |
| ammonia reduction | #25 |
| malnutrition chronic | #25 |
| 11195 | #25 |
| cns complication | #25 |
| human experimental | #25 |
| severe muscle damage | #25 |
| nmdareceptor | #25 |
| mousseau | #25 |
| inhalation exposure rats | #25 |
| synthase activities | #25 |
| damage dysfunction | #25 |
| synthesis amino acids | #26 |
| treatment hepatic | #26 |
| concentrations ammonia | #26 |
| aqp4 levels | #26 |
| pathogenesis cerebral | #26 |
| 60p | #26 |
| pathophysiological significance | #26 |
| alanine concentrations | #26 |
| failure increased | #26 |
| fluid amino | #26 |
| anastomosis rats | #26 |
| ketoglutarate dehydrogenase | #26 |
| arterial ammonia levels | #26 |
| adult patterns | #26 |
| flumazenil placebo | #26 |
| oxidative stress processes | #26 |
| 17 39 | #26 |
| isoquinolines ligands | #26 |
| rifaximin mhe | #27 |
| liver fasting | #27 |
| cerebellum brain | #27 |
| regional densities | #27 |
| onset encephalopathy | #27 |
| asparagine glutamine | #27 |
| manganese ammonia | #27 |
| increased concentrations | #27 |
| noradrenaline transport | #27 |
| ornithine transcarbamylase otc | #27 |
| treatment cirrhosis | #27 |
| alf induced | #27 |
| oxidative stress evidence | #27 |
| glucose loading | #27 |
| support potential | #27 |
| brain serotonin metabolism | #27 |
| binding 3hmuscimol | #27 |
| deficient brain | #27 |
| accumulation glutamine | #27 |
| binding site densities | #27 |
| fgin1 | #27 |
| beta sites | #27 |
| wernicke encephalopathy | #28 |
| activities decreased | #28 |
| experimental acute | #28 |
| astrocytes loss | #28 |
| allosteric modulatory | #28 |
| ataxic gait | #28 |
| type hepatic | #28 |
| selective neuronal loss | #28 |
| metabolism relation | #28 |
| baldessarini | #28 |
| astrocytic metabolism | #28 |
| glutamate transporter activity | #28 |
| devascularized | #28 |
| effects thiamine | #28 |
| chronic liver failure | #28 |
| eaat3 expression | #28 |
| optimal supply | #29 |
| effective adjunct therapy | #29 |
| pairfed controls | #29 |
| 3hro5 | #29 |
| travelled distance | #29 |
| cerebral cortex thalamus | #29 |
| induction mild hypothermia | #29 |
| dust rats | #29 |
| diverse etiology | #29 |
| glutamine content | #29 |
| cerebral energy failure | #29 |
| striatum contrast | #29 |
| increased glutamine | #29 |
| shamoperated control animals | #29 |
| serotonin turnover | #29 |
| dopamine metabolism striatum | #29 |
| cytoplasmic nuclear signal | #29 |
| rats probenecid | #29 |
| flumazenil flunitrazepam | #29 |
| subchronic inhalation exposure | #29 |
| superoxide scavenger | #29 |
| putamen frontal cortex | #29 |
| re‐evaluation | #29 |
| isopregnanolone | #29 |
| frontal temporal cortex | #29 |
| oxide brain | #29 |
| quantitative receptor | #30 |
| neurotransmitter amino acids | #30 |
| glycine glutamine | #30 |
| frontal cortex samples | #30 |
| gaba receptor complex | #30 |
| glutamate cgmp | #30 |
| west criteria | #30 |
| chat activities | #30 |
| nonabsorbable disaccharides | #30 |
| stroke neurological | #30 |
| flumazenil gaba | #30 |
| 3dsrt | #30 |
| encephalopathy portal | #30 |
| increased nmda | #30 |
| chronic hyperammonemia | #30 |
| progression liver injury | #30 |
| glutamate content | #30 |
| hyperglycemic stroke | #30 |
| neuronal cell counts | #30 |
| presymptomatic animals | #30 |
| studies experimental | #30 |
| inflammatory cascades | #30 |
| aspartate glutamine | #30 |
| mediated excitotoxicity | #30 |
| blood ammonia concentration | #30 |
| clinical prospects | #31 |
| dogs hepatic | #31 |
| expression tight junction | #31 |
| glutamate nmda | #31 |
| cuznsod protein | #31 |
| leading increased | #31 |
| shunted animals | #31 |
| cerebral glutamate | #31 |
| brain decreased | #31 |
| peripheral type | #31 |
| production microglial | #31 |
| brain monoamine oxidase | #31 |
| study ammonia | #31 |
| pannecrosis | #31 |
| neuroinflammation pathogenesis | #31 |
| antisense elements | #31 |
| stupor | #31 |
| acute hyperglycemic | #32 |
| minimal mhe | #32 |
| binding sites presence | #32 |
| deficiencies vitamins | #32 |
| astrocytes ammonia | #32 |
| temporal cortex patients | #32 |
| telemethylhistamine | #32 |
| cerebral ammonia | #32 |
| intracellular osmolarity | #32 |
| 2 alteration | #32 |
| binding gaba | #32 |
| friedreichs ataxia | #32 |
| uptake ammonia | #32 |
| fixed intervals | #32 |
| hepatoprotective properties | #32 |
| akinesia | #32 |
| increased nitric | #32 |
| hepatic symptoms | #32 |
| detoxification unit | #32 |
| indian national association | #32 |
| effects mild | #32 |
| gabaa receptor ligands | #32 |
| gaba aspartate | #33 |
| proinflammatory cytokines brain | #33 |
| selective decreases | #33 |
| ohe patients | #33 |
| et495 | #33 |
| rats ammonia | #33 |
| monoamines brain | #33 |
| regions brains | #33 |
| otc deficiency | #33 |
| nash treatment | #33 |
| binding microsomes | #33 |
| species rats | #33 |
| snat5 | #33 |
| failing liver | #33 |
| cns complications | #33 |
| neuronal cell survival | #33 |
| hand addition | #33 |
| reversible alterations | #33 |
| clinical laboratory findings | #33 |
| cns concentrations | #33 |
| brain gaba levels | #33 |
| glycine aspartate | #33 |
| nh4oac | #34 |
| gad activities | #34 |
| acetylcholinesterase activities | #34 |
| hepatic artery ligation | #34 |
| nac reduction | #34 |
| 11 agematched controls | #34 |
| cytotoxic brain | #34 |
| relation brain | #34 |
| metabolite 5 | #34 |
| encephalopathy hippocampus | #34 |
| nonepileptic controls | #34 |
| severe neurological symptoms | #34 |
| inadequate dietary intake | #34 |
| ammonium tartrate | #34 |
| groups cirrhotic patients | #34 |
| stupor coma | #34 |
| severe neurological dysfunction | #34 |
| astrocytic glutamate | #35 |
| manganese tricarbonyl | #35 |
| overt encephalopathy | #35 |
| fatigue rats | #35 |
| space glutamic | #35 |
| type gaba | #35 |
| effects manganese | #35 |
| fluid ammonia | #35 |
| total thiamine | #35 |
| octadecaneuropeptide | #35 |
| free hepatic | #35 |
| dawley reverse | #35 |
| chronic hepatic encephalopathy | #35 |
| neurotransmitter amino | #35 |
| ammonia concentrations | #35 |
| chapter 29 | #35 |
| severe compromise | #35 |
| neuropsychiatric abnormalities | #35 |
| activation proinflammatory | #35 |
| astrocyte glutamate | #36 |
| synthesis glutamate | #36 |
| detoxification product | #36 |
| uptake glutamate | #36 |
| numerous etiologies | #36 |
| aom treatment | #36 |
| astrocytic glutamine | #36 |
| thioacetamide treatment | #36 |
| electricalfield stimulation | #36 |
| arterial ammonia | #36 |
| cerebral cortical astrocytes | #36 |
| cycle glucose | #36 |
| muscarinic sites | #36 |
| acid brain | #36 |
| brain regions studies | #36 |
| mice ammonia | #37 |
| blood manganese levels | #37 |
| perivenous hepatocytes | #37 |
| 3beta5alpha | #37 |
| csf cisterna magna | #37 |
| mild hypothermia therapy | #37 |
| protein glutamate | #37 |
| alf mice | #37 |
| excitotoxic mechanism | #37 |
| increased blood glucose | #37 |
| increased voluntary | #37 |
| acute receptors | #37 |
| glutamate ammonia | #38 |
| failure male | #38 |
| hypothermia attenuates | #38 |
| brain rats | #38 |
| gfap immunohistochemistry | #38 |
| glutamatergic function | #38 |
| increase glutamine | #38 |
| brain amino acids | #38 |
| ammonium acetate | #38 |
| corneal reflex | #38 |
| astrocytic marker | #38 |
| severe liver dysfunction | #39 |
| loss gene expression | #39 |
| concomitant decreases | #39 |
| benzodiazepine antagonist | #39 |
| findings increased | #39 |
| chronic alcoholism | #39 |
| glutamine formation | #39 |
| brain regional distribution | #39 |
| thiamine administration | #39 |
| hyperammonaemic | #39 |
| pdhc | #39 |
| posterior columns | #39 |
| pca surgery | #39 |
| clive | #39 |
| concentrations catecholamines | #40 |
| argininic acid | #40 |
| quin levels | #40 |
| liver inasl | #40 |
| seizures mental retardation | #40 |
| regiondependent manner | #40 |
| glutamine glycine | #40 |
| neurological alterations | #40 |
| increased density | #40 |
| ammonia homeostasis | #40 |
| regionally selective | #40 |
| concentration areas | #40 |
| arginine uptake | #40 |
| dheas | #40 |
| nitroarginine rats rats | #40 |
| acetylcoa levels | #40 |
| etiology severity | #40 |
| nmdamediated excitotoxicity | #40 |
| deficiency disease | #41 |
| sgc activation | #41 |
| cellcell signalling | #41 |
| thiamine metabolism | #41 |
| regions concentrations | #41 |
| regulation caveolin1 | #41 |
| lateral vestibular nucleus | #41 |
| acid neurotransmitter | #41 |
| increased glutamate release | #41 |
| brain taurine | #41 |
| complications chronic | #41 |
| brain extracts | #41 |
| activation nmda receptor | #41 |
| brain benzodiazepine receptors | #41 |
| detoxification ammonia | #41 |
| vulnerable area | #41 |
| pk11195 binding | #42 |
| cerebral glutamine | #42 |
| trace amines | #42 |
| benzodiazepine sites | #42 |
| thdoc | #42 |
| cerebral alterations | #42 |
| illness terminology topic | #42 |
| complex pdhc | #42 |
| acute ammonia intoxication | #43 |
| nonalcoholic patients | #43 |
| liver assist | #43 |
| metabolism acute | #43 |
| transcarbamylase | #43 |
| carbamoyltransferase deficiency | #43 |
| gabaa tritium | #43 |
| glutamine insulin | #43 |
| increased neuronal | #43 |
| acid glutamine | #44 |
| severe hyperammonemia | #44 |
| toxic liver | #44 |
| ammonia increases | #44 |
| aged portacaval | #44 |
| reduction brain | #44 |
| sarcopenia cirrhosis | #44 |
| behavioral excitation | #44 |
| ohe mhe | #44 |
| mechanisms disorder | #44 |
| cerebral levels | #44 |
| ataxia humans | #44 |
| treament | #44 |
| increased serotonin | #44 |
| western brain dna | #44 |
| cholinergic neuronal | #45 |
| glutamate transporter | #45 |
| model congenital | #45 |
| mild encephalopathy | #45 |
| mice etanercept | #45 |
| welldefined areas | #45 |
| thiamin deficiency | #45 |
| aspartate gaba | #45 |
| isoquinolines kinetics | #45 |
| cortex dose | #45 |
| ventral white matter | #45 |
| small meals | #45 |
| normoglycemic rats | #46 |
| 11cnmethylspiperone | #46 |
| brain gamma | #46 |
| cortex glutamate | #46 |
| fatigue controls | #46 |
| exposed ammonia | #46 |
| brain oxidative metabolism | #46 |
| treatment downregulation | #46 |
| microsomes isolated | #47 |
| benzodiazepine receptors | #47 |
| anaplerotic flux | #47 |
| distinctive pattern | #47 |
| pathophysiologically | #47 |
| brain amino | #47 |
| rtpcr experiments | #47 |
| glutamate removal | #47 |
| neurosteroid | #47 |
| glutamate aspartate | #47 |
| human rat brain | #47 |
| metabolism astrocytes | #47 |
| alcoholic cirrhotics | #47 |
| mitochondrial benzodiazepine | #48 |
| age injection | #48 |
| cerebral dysfunction | #48 |
| maob | #48 |
| allopregnanolone concentrations | #48 |
| amino acid synthesis | #48 |
| tnf brain | #48 |
| neurotoxic agents | #48 |
| hyperammonemia | #48 |
| thalamus pons | #48 |
| 3hmuscimol | #48 |
| 113cglucose | #48 |
| central nervous function | #48 |
| concomitant increases | #48 |
| sites nmda | #48 |
| cerebellum medulla | #48 |
| ammonia detoxification | #49 |
| neurotoxic actions | #49 |
| nmda binding | #49 |
| rcts low risk | #49 |
| central benzodiazepine | #49 |
| cerebellum patients | #49 |
| glycerol phenylbutyrate | #49 |
| brain tryptophan | #49 |
| pallidal | #49 |
| voluntary ethanol | #49 |
| rational explanation | #50 |
| manganese middle | #50 |
| hepatic congestion | #50 |
| alcoholic dementia | #50 |
| tyrosine ammonia | #50 |
| extracellular glycine | #50 |
| expression glt1 | #50 |
| levels brain | #50 |
| effects body temperature | #50 |
| hepatic encephalopathy study | #50 |
| increased extracellular | #50 |
| brain banks | #50 |
| righting | #51 |
| false neurotransmitters | #51 |
| inflamed brain | #51 |
| glutamate receptors nmda | #51 |
| electromyographic evaluation | #51 |
| acids measured | #51 |
| early microglial activation | #51 |
| management hepatic | #51 |
| lcarnitine treatment | #51 |
| neurobehavioral disturbances | #52 |
| 12 rats | #52 |
| altered permeability | #52 |
| alcoholic cirrhotic | #52 |
| synthesis glutamine | #52 |
| pse | #52 |
| vivo microdialysis | #52 |
| mice carnitine | #52 |
| cognitive motor dysfunction | #52 |
| early losses | #52 |
| complex rats | #52 |
| friedreichs ataxia patients | #52 |
| severe stages | #52 |
| brain concentrations | #52 |
| nitroarginine rats | #52 |
| 3hmuscimol binding | #53 |
| pathophysiologic | #53 |
| treatment alf | #53 |
| neurosteroid synthesis | #53 |
| central histaminergic | #53 |
| 3hkainate | #53 |
| neurosteroid pregnenolone | #53 |
| rats portacaval shunt | #53 |
| substitutive therapy | #54 |
| neuropsychiatric syndrome | #54 |
| gene expression liver | #54 |
| mechanisms proposed | #54 |
| ischemic liver | #54 |
| cerebral inflammation | #54 |
| portacaval shunts | #54 |
| portacaval shunt pcs | #54 |
| kidney testis | #54 |
| stroke penumbra | #54 |
| mildest form | #54 |
| activation guanylate cyclase | #54 |
| liver atrophy | #54 |
| subsequent alteration | #54 |
| occludin levels | #55 |
| activation glutamate receptors | #55 |
| concomitant reductions | #55 |
| messenger spraguedawley receptors | #55 |
| human disorder | #55 |
| glutathione plasma | #55 |
| hyperglycemic | #55 |
| heterogenity | #55 |
| neurotransmitter agents | #55 |
| encephalopathy hyperammonemia | #55 |
| ca2dependent release | #56 |
| deficiency decreased | #56 |
| oxidative nitrosative | #56 |
| awaits | #56 |
| delays onset | #56 |
| regions rats | #56 |
| severe cognitive dysfunction | #56 |
| levels allopregnanolone | #56 |
| type mitochondrial | #57 |
| brain glutamate levels | #57 |
| increased intracellular ca2 | #57 |
| resonance signal | #57 |
| h1 receptors | #57 |
| mechanisms implicated | #57 |
| tetrahydroprogesterone | #57 |
| ammonia exposure | #57 |
| current therapeutic options | #57 |
| rats ouabain | #57 |
| failure muscle | #57 |
| coma patients | #57 |
| swelling brain | #58 |
| brain histamine | #58 |
| portacaval shunt | #58 |
| manganese copper | #58 |
| nervous complications | #58 |
| probenecid treatment | #58 |
| activation glutamate | #58 |
| pdhc activity | #58 |
| lowering strategies | #58 |
| dansyl derivatives | #58 |
| levels amino acids | #58 |
| severity encephalopathy | #58 |
| levels ammonia | #58 |
| astrocytes glutamate | #58 |
| saline treated controls | #59 |
| 13c enrichments | #59 |
| uptake arginine | #59 |
| gfap gfap mrna | #59 |
| bilirubin metabolism | #59 |
| acetaminophen toxicity | #59 |
| neuropharmacological studies | #59 |
| patients thiamine | #59 |
| hyperammonaemia | #59 |
| mechanism protective | #59 |
| cirrhotic patients patients | #60 |
| energy metabolites | #60 |
| brain production | #60 |
| alcoholics patients | #60 |
| ammonia intoxication | #60 |
| lazabemide | #60 |
| purposing | #60 |
| ammonia toxicity | #60 |
| alcoholic patients | #60 |
| required cofactor | #60 |
| cirrhosis middle | #60 |
| spontaneous synaptic activity | #60 |
| affinity gaba | #61 |
| maob maoa | #61 |
| bz receptors | #61 |
| stem cerebral | #61 |
| excitotoxic brain injury | #61 |
| subjects free | #61 |
| opioid penicillamine | #61 |
| il1beta mrna expression | #61 |
| 015 mmol | #61 |
| acid distribution | #61 |
| sham operated | #61 |
| threefold increase | #61 |
| ataxia friedreich | #61 |
| comparable magnitude | #61 |
| concentrations glutamate | #61 |
| βendorphin | #62 |
| brain1 | #62 |
| forebrain cholinergic neurons | #62 |
| suggested role | #62 |
| elevated uptake | #62 |
| receptors pathogenesis | #62 |
| taurine synthesis | #62 |
| increased expression mrna | #62 |
| ultimate test | #62 |
| hypertension brain | #62 |
| thiamine | #63 |
| rtpcr gene expression | #63 |
| heavy drinking day | #63 |
| spectroscopy tomography | #63 |
| portocaval | #63 |
| role glutamate | #63 |
| manganese intoxication | #63 |
| focal increases | #63 |
| failure evidence | #63 |
| manganese treatment | #63 |
| metabolism glutamine | #63 |
| regions contrast | #63 |
| subclinical hepatic | #63 |
| gaba glutamic acid | #63 |
| fatigue pbc | #64 |
| disease activities | #64 |
| sodium phenylacetate | #64 |
| neurosteroid allopregnanolone | #64 |
| attenuates oxidative | #64 |
| transketolase activity | #64 |
| thalamus gamma | #64 |
| brain | #64 |
| parietal lobe rats | #64 |
| neurotoxic substances | #64 |
| hypokinesia | #65 |
| methylhistamine | #65 |
| sodium benzoate | #65 |
| symptoms addition | #65 |
| deficiency induced | #65 |
| 2454 | #65 |
| manganese deposits | #65 |
| brain chemistry | #65 |
| frontal parietal cortex | #65 |
| glutamine ammonia | #65 |
| butyrylcholinesterases | #65 |
| female flumazenil | #65 |
| kcl nacl | #65 |
| brain cell death | #65 |
| increases brain | #66 |
| ataxia patients | #66 |
| putative endogenous ligands | #66 |
| mice sodium | #66 |
| uptake cultured | #66 |
| 13cnmr | #66 |
| gaba animals | #66 |
| brain water | #66 |
| isethionic | #66 |
| tyrosine content | #67 |
| brain patients | #67 |
| erythrocyte transketolase | #67 |
| cerebral energy metabolism | #67 |
| lactate increase | #67 |
| brain 24 | #67 |
| αmethylptyrosine | #67 |
| humans korsakoff | #67 |
| ascorbate synthesis | #67 |
| selective reductions | #68 |
| benzodiazepine receptor ligands | #68 |
| glutamate transporter glast | #68 |
| serotonin transport | #68 |
| reduction ammonia | #68 |
| indian national | #68 |
| decreased concentrations | #68 |
| hepatoprotection | #69 |
| processing product | #69 |
| attenuation effects | #69 |
| drug repositioning humans | #69 |
| decreased removal | #69 |
| active removal | #69 |
| unleaded gasoline | #69 |
| substance rats | #69 |
| osmotic effects | #69 |
| rats sham operation | #69 |
| electronic manual searches | #70 |
| m1 sites | #70 |
| bergmann glial | #70 |
| cortex caudate | #70 |
| glutamic acid hippocampus | #70 |
| reduces brain | #70 |
| carbamoyltransferase | #71 |
| alloxan diabetes | #71 |
| animals benzodiazepines | #71 |
| glutamates glutamic | #71 |
| shunting | #71 |
| medium concentrations | #71 |
| failure animals | #71 |
| brain allopregnanolone | #72 |
| hyperammonemia male | #72 |
| common inborn error | #72 |
| organic aciduria | #72 |
| cortex increased | #72 |
| glutamine brain | #72 |
| concentration norepinephrine | #72 |
| agematched control subjects | #72 |
| gabaa tomography | #72 |
| ro15 | #73 |
| cerebroprotective effects | #73 |
| astrocyte swelling | #73 |
| glutamine glutamate | #73 |
| pse patients | #73 |
| thiamine treatment | #73 |
| alterations mitochondrial function | #73 |
| hippocampal ca1 subfield | #73 |
| homologous structures | #73 |
| onset neurological | #73 |
| sites observed | #73 |
| decrease brain | #74 |
| brain content | #74 |
| astrocytes brain | #74 |
| glutamic | #74 |
| cortex chromatography | #74 |
| gaba steroids | #74 |
| bath concentration | #74 |
| mechanisms involving | #74 |
| fully elucidated | #75 |
| expression glial | #75 |
| normal limits | #75 |
| cerebral cortex patients | #75 |
| nature distribution | #75 |
| superfused slices | #75 |
| severe neurological impairment | #75 |
| thiamine transport | #75 |
| acids hepatic | #75 |
| receptors studied | #76 |
| cirrhosis brain | #76 |
| gaba glutamine | #76 |
| larginine uptake | #76 |
| direct toxic effects | #76 |
| glutamate binding | #76 |
| receptors gaba | #76 |
| transporter eaat3 | #76 |
| alcoholic patients cirrhosis | #77 |
| glutamate concentration | #77 |
| brain skeletal muscle | #77 |
| metabolite acetaldehyde | #77 |
| glycine concentrations | #77 |
| millimolar range | #77 |
| muscle acute | #77 |
| function hepatic | #78 |
| brain glucose metabolism | #78 |
| interatomic bonds | #78 |
| benzodiazepines binding | #78 |
| nnos protein | #78 |
| oxide liver | #78 |
| lnitroarginine methyl ester | #78 |
| muscle glutamine | #78 |
| previous reports | #79 |
| l‐carnitine | #79 |
| hepatic energy | #79 |
| metabolism brain | #79 |
| cns function | #79 |
| methylcyclopentadienyl | #79 |
| taming | #79 |
| semiquantitative rtpcr | #79 |
| excited ground states | #79 |
| neuronally | #79 |
| deep coma | #79 |
| thiamine triphosphate | #79 |
| medullapons | #80 |
| encephalopathy treatment | #80 |
| cresyl violet staining | #80 |
| gaba benzodiazepine | #80 |
| maximal binding | #80 |
| pathogenesis animals | #80 |
| neurosteroid biosynthesis | #80 |
| quantitative autoradiographic | #80 |
| expression glutamate | #80 |
| emerging therapeutic target | #80 |
| failure nitric | #80 |
| glutamine astrocytes | #81 |
| 85 mmol | #81 |
| astrocyte morphology | #81 |
| study sections | #81 |
| molecular neurobiology | #81 |
| controls increased | #81 |
| muscle ammonia | #81 |
| agents receptors | #82 |
| shortchain acylcoa dehydrogenase | #82 |
| brain extracellular | #82 |
| glutamate nitric | #82 |
| chaired | #82 |
| receptor regions | #82 |
| lcarnitine administration | #82 |
| ethanol preference | #83 |
| tca cycle flux | #83 |
| 3hro15 | #83 |
| glutamate brain | #83 |
| treatment thiamine | #83 |
| proposed explain | #83 |
| measured brain | #84 |
| 3hflumazenil | #84 |
| pbgd | #84 |
| devascularization | #84 |
| aom induced | #84 |
| elevated ammonia | #84 |
| cerebral cortex striatum | #84 |
| patients decreases | #84 |
| water channel protein | #84 |
| pathophysiologic basis | #84 |
| 3hgammaaminobutyric acid | #85 |
| concomitant decrease | #85 |
| role glutamine | #85 |
| maoa maob | #85 |
| arga | #85 |
| urea cycle enzymes | #85 |
| 5ht turnover | #85 |
| increase brain | #85 |
| ammonia patients | #85 |
| decreased ca2 | #85 |
| glutamate amino | #86 |
| central muscarinic | #86 |
| release synaptic | #86 |
| spraguedawley statistics | #87 |
| wilsonian | #87 |
| rats sacrificed | #87 |
| csf lactate | #88 |
| concomitantly | #88 |
| 52 mmol | #88 |
| benzodiazepines brain | #88 |
| tissue brain | #88 |
| selective vulnerability | #88 |
| brain binding | #88 |
| complication cirrhosis | #88 |
| role human diseases | #89 |
| caudate nuclei | #89 |
| exposure ammonia | #89 |
| undoubtedly | #89 |
| alpha ketoglutarate | #89 |
| edema cerebral | #89 |
| prior onset | #89 |
| brain regions rats | #89 |
| sham operations | #89 |
| olivopontocerebellar atrophy opca | #89 |
| rats species | #90 |
| receptor ligand | #90 |
| lactate increased | #90 |
| encephalopathy ohe | #90 |
| patients alf | #90 |
| glutamatemediated excitotoxicity | #90 |
| bcaa concentrations | #91 |
| gaba modulators | #91 |
| monoamine neurotransmitters | #91 |
| reduced brain | #91 |
| neuroinflammatory response | #92 |
| amino acids brain | #92 |
| altered protein expression | #92 |
| bckdh | #92 |
| enzymopathies | #92 |
| leucine concentrations | #92 |
| congenital deficiencies | #93 |
| induced alf | #93 |
| acid liver | #93 |
| widespread damage | #93 |
| mri intensity | #94 |
| brain compared | #94 |
| brain kidney | #94 |
| increases extracellular | #94 |
| neuronal loss | #94 |
| manganese poisoning | #94 |
| thiamin diphosphate | #94 |
| glutamine synthetase expression | #95 |
| benzodiazepines treatment | #95 |
| inhibitory neurotransmission | #95 |
| induced stereotyped | #95 |
| acetate administration | #95 |
| patients liver failure | #95 |
| ammonia accumulation | #95 |
| discrete areas | #96 |
| skeletal muscle brain | #96 |
| astrocytic function | #96 |
| 16 mmol | #96 |
| ornithine phenylacetate | #96 |
| βlipotropin | #96 |
| ammonia release | #97 |
| covert hepatic encephalopathy | #97 |
| astrocytes neurons | #97 |
| molecules brain | #97 |
| brain vivo | #97 |
| brain cytokine | #97 |
| receptors increased | #98 |
| acrylamides animals | #98 |
| glutamate glutamine | #98 |
| dehydroascorbic acid | #98 |
| glycine transporters | #98 |
| dorsal tegmental nucleus | #98 |
| thiamine diphosphate | #98 |
| hepatocerebral degeneration | #98 |
| carbamoyltransferase ornithine | #98 |
| 3045 | #99 |
| stress ammonia | #99 |
| examination role | #99 |
| walking gait | #99 |
| commonly encountered | #100 |
| symptomatic stage | #100 |
| fatigue impact scale | #100 |
| aspartate levels | #100 |
| animal hypothermia | #101 |
| temporal cortex | #101 |
| proinflammatory | #101 |
| increases levels | #101 |
| inhibitory amino acids | #101 |
| pressure liver | #101 |
| tk activity | #102 |
| synergistic mechanisms | #102 |
| lcarnitine | #102 |
| cerebral cortex cerebellum | #102 |
| microdialysis rats | #102 |
| levels dheas | #102 |
| brain barrier breakdown | #102 |
| treatment complications | #102 |
| neurological symptoms patients | #102 |
| brain levels | #103 |
| removal ammonia | #103 |
| collisional deactivation | #103 |
| brain extracellular space | #103 |
| benzodiazepine receptor | #103 |
| controls cirrhotic patients | #103 |
| regional distribution | #104 |
| thiamine monophosphate | #104 |
| cerebral oxidative metabolism | #104 |
| 90 loss | #104 |
| experimental animal models | #104 |
| label incorporation | #104 |
| methylspiperone | #104 |
| experimental models | #105 |
| loss cholinergic | #105 |
| receptors brain | #105 |
| m3 exposure | #105 |
| transporter glt1 | #105 |
| olivopontocerebellar atrophy | #105 |
| fatigue severity | #105 |
| neurological consequences | #105 |
| complication liver | #106 |
| toxic liver injury | #106 |
| concentrations serotonin | #107 |
| 3h8ohdpat | #107 |
| receptors rats | #107 |
| sham operated controls | #108 |
| characteristic alterations | #108 |
| current theories | #108 |
| monoamines | #108 |
| gaba content | #108 |
| dopaminergic dysfunction | #108 |
| t1weighted magnetic resonance | #109 |
| glutamate plasma | #109 |
| symptomatic animals | #109 |
| disease hepatic | #109 |
| ldeprenyl | #109 |
| azoxymethane aom | #110 |
| 3hnisoxetine | #110 |
| rats hepatic | #110 |
| extrapyramidal symptoms | #110 |
| glutamates humans | #110 |
| deficiency humans | #110 |
| reye syndrome | #111 |
| glt1 glast | #111 |
| enzymes brain | #111 |
| 3alpha5alpha | #112 |
| evidence role | #112 |
| lymphocytes rats | #113 |
| midbrain striatum | #113 |
| activities | #113 |
| metabolic block | #113 |
| expression testis | #113 |
| hypertension liver | #113 |
| brain preparations | #113 |
| ligated rats | #113 |
| glutamate synaptic | #113 |
| nutritional management | #114 |
| radioenzymatic assay | #114 |
| fco | #114 |
| rat astrocytes | #114 |
| 57 reduction | #114 |
| experimental animals | #115 |
| brain dogs | #115 |
| nmda receptor expression | #115 |
| pallidum putamen | #116 |
| mammillary body | #116 |
| 3hmepyramine | #116 |
| gabaa gabaergic | #116 |
| decreased synthesis | #116 |
| friedreich ataxia patients | #117 |
| growing body | #117 |
| cortex alzheimer | #117 |
| cholinergic deficit | #117 |
| opioid brain | #117 |
| tips procedure | #117 |
| controls plasma levels | #117 |
| albumin dialysis | #118 |
| amine levels | #118 |
| brain dopamine | #118 |
| arginine deficiency | #118 |
| allopregnanolone | #118 |
| myelin synthesis | #118 |
| cirrhotic | #118 |
| mechanism ammonia | #118 |
| hydroxylating | #119 |
| patients fatty liver | #119 |
| apapinduced | #119 |
| cerebral energy | #119 |
| site densities | #119 |
| nervous dysfunction | #119 |
| opioid beta | #119 |
| pathologic manifestations | #119 |
| ouabain induced | #120 |
| glutamates | #120 |
| balb cbyj mice | #120 |
| genes coding | #120 |
| frontal cortex | #120 |
| monoamine oxidaseb | #121 |
| mechanisms pathogenesis | #121 |
| pugh score | #121 |
| 3hketanserin | #121 |
| copper manganese | #121 |
| complex activities | #122 |
| brain enzyme | #122 |
| unleaded | #122 |
| rat brain synaptosomes | #122 |
| bergmann glia | #122 |
| nuclear signal | #122 |
| brain evidence | #122 |
| normal human brains | #123 |
| beneficial patients | #123 |
| selective damage | #123 |
| implicated | #123 |
| gene expression brain | #124 |
| modulatory site | #124 |
| asterixis | #124 |
| newborn astrocytes cells | #124 |
| neurological signs | #125 |
| icp cbf | #125 |
| striatum cerebellum | #125 |
| ammonia control | #125 |
| 11cpk11195 | #126 |
| glt1 | #126 |
| ol20 | #126 |
| role ammonia | #126 |
| ornithine aminotransferase | #126 |
| ala2mephe4met0ol | #126 |
| brain male | #126 |
| synthase nitroarginine | #126 |
| high‐affinity | #127 |
| cytokines brain | #128 |
| proteins nitric | #128 |
| taurine uptake | #128 |
| neuronal cell | #128 |
| cox2 immunoreactivity | #129 |
| patients friedreichs ataxia | #129 |
| neurochemical mechanisms | #129 |
| glutamate concentrations | #129 |
| chronic alcoholic patients | #129 |
| agonist action | #130 |
| spontaneous activities | #130 |
| cox2 levels | #130 |
| unanesthetized dogs | #130 |
| blood ethanol levels | #130 |
| ammonia levels | #131 |
| observed brain | #131 |
| llactate dehydrogenase | #131 |
| primary deficit | #131 |
| carnitine administration | #132 |
| blood ammonia | #132 |
| animals azoxymethane | #132 |
| continuous supply | #132 |
| hepatic abnormalities | #132 |
| taurine release | #132 |
| nacetyl cysteine | #133 |
| lipoamide dehydrogenase | #133 |
| ischemia rat | #133 |
| manganese neurotoxicity | #133 |
| friedreich | #133 |
| site human | #133 |
| factor pathogenesis | #133 |
| α ketoglutarate | #133 |
| lactate accumulation | #134 |
| brain glial | #134 |
| models acute | #135 |
| concentrations gaba | #135 |
| exposure manganese | #135 |
| endogenous amino acids | #135 |
| kidney skeletal muscle | #135 |
| impact treatments | #136 |
| function addition | #137 |
| acid ammonia | #137 |
| release glutamate | #137 |
| 3hcitalopram | #137 |
| pregnenolone rats | #137 |
| increased intracranial pressure | #137 |
| manganese toxicity | #137 |
| psychometric testing | #137 |
| neuropsychiatric complications | #138 |
| spinocerebellar degeneration | #138 |
| inherited ataxias | #138 |
| lornithine | #139 |
| tracer doses | #139 |
| disorder animals | #139 |
| glutamine alanine | #139 |
| chatpositive neurons | #139 |
| cycle enzyme | #139 |
| nanomolar affinity | #139 |
| −70°c | #139 |
| cerebral herniation | #139 |
| nutritional recommendations | #140 |
| patients friedreich | #140 |
| nonbenzodiazepine | #141 |
| cortex male | #141 |
| aminobutyric acid | #141 |
| dehydrogenase pdh | #141 |
| concentrations nacl | #141 |
| cerebellar ataxias | #142 |
| humans isoquinolines | #142 |
| alcoholic nonalcoholic | #142 |
| huntingtons chorea | #142 |
| development hepatic | #142 |
| gaba synaptic | #142 |
| cbyj | #142 |
| alternative site | #143 |
| monoamine oxidasea | #143 |
| serotonin precursor | #143 |
| hypothermia induced | #143 |
| diminished activity | #143 |
| brain glucose uptake | #143 |
| lactate alanine | #143 |
| allosteric agonists | #144 |
| selective brain | #144 |
| brain gaba | #144 |
| delayed myelination | #144 |
| insulin hypoglycaemia | #144 |
| ornithine carbamoyltransferase | #144 |
| glutamateglutamine | #144 |
| dopamine metabolism | #144 |
| taurine content | #144 |
| inferior olivary nucleus | #145 |
| cerebral microdialysis | #145 |
| brain tissue | #145 |
| hyperglycemic rats | #145 |
| brain hypothermia | #146 |
| brain peripheral tissues | #146 |
| glucose load | #146 |
| relation degree | #146 |
| receptormediated responses | #146 |
| increase presence | #147 |
| rapid filtration | #147 |
| lateral vestibular | #147 |
| comparable degree | #147 |
| animals brain | #148 |
| energy failure | #148 |
| lactate brain | #148 |
| glutamate neurons | #149 |
| western cells rats | #149 |
| ohe | #149 |
| diazepam binding inhibitor | #149 |
| coa acetyl | #149 |
| acetyllcarnitine | #149 |
| cirrhosis hepatic | #149 |
| neurosteroids | #149 |
| failure studies | #150 |
| probenecid rats | #150 |
| consumption ethanol | #150 |
| metabolic impairments | #150 |
| patient tissue | #151 |
| female friedreich | #151 |
| animals astrocytes | #151 |
| progesterone metabolites | #151 |
| zo2 | #151 |
| fatigue scores | #151 |
| protein tyrosine nitration | #151 |
| patients hepatic encephalopathy | #152 |
| selective neuronal death | #152 |
| beta actin | #152 |
| concentrations amino | #153 |
| testis brain | #153 |
| inhibition binding | #153 |
| increased synthesis | #153 |
| impaired brain | #154 |
| tight junction proteins | #154 |
| transporter protein | #154 |
| alcoholism brain | #154 |
| 15 1788 | #155 |
| increased cerebral | #155 |
| experimental male rats | #156 |
| brain cerebrospinal | #156 |
| ammonia ligase | #156 |
| neuroactive | #157 |
| affinity uptake | #157 |
| 1788 | #157 |
| radioenzymatic | #157 |
| protein acute | #157 |
| korsakoff syndrome | #158 |
| ethanol day | #158 |
| dimethadione | #158 |
| water brain | #159 |
| glt1 expression | #159 |
| gfap expression | #159 |
| increased 5 | #159 |
| prominent increase | #159 |
| nitrosative | #159 |
| brain dysfunction | #160 |
| groups responses | #160 |
| glutamate ampa | #160 |
| astrocytosis | #160 |
| 3methoxytyramine | #160 |
| gfap mrna | #161 |
| expression hepatic | #161 |
| diphosphatase | #161 |
| reaction ammonia | #161 |
| neuropathologically | #161 |
| homogenates | #162 |
| increased stimulation | #162 |
| mercaptans | #162 |
| synaptosomal uptake | #162 |
| perivenous | #162 |
| rats nitric | #163 |
| vicious cycle | #163 |
| neurological evaluation | #163 |
| affinity transport | #163 |
| glutamine production | #164 |
| mice acetaminophen | #164 |
| manganese concentrations | #164 |
| increased degradation | #164 |
| transketolase | #164 |
| human alcoholics | #165 |
| victor | #165 |
| brain energy metabolism | #166 |
| extracellular concentrations | #166 |
| bergmann glial cells | #166 |
| regions levels | #166 |
| glast | #166 |
| severe signs | #167 |
| increased cerebrospinal | #167 |
| increased csf | #167 |
| benzodiazepine | #167 |
| neurotransmitter | #167 |
| aids aidsrelated complex | #167 |
| dansyl chloride | #167 |
| male manganese | #167 |
| surgical models | #168 |
| neurotoxic compounds | #168 |
| deficiency liver | #168 |
| malateaspartate shuttle | #169 |
| precise role | #169 |
| strains spectrometry | #170 |
| monophosphatase | #170 |
| increase pge2 | #171 |
| medial geniculate nucleus | #171 |
| complications liver | #171 |
| elevated activities | #171 |
| acetaminophen acetylcysteine | #171 |
| apap administration | #172 |
| transport brain | #172 |
| terms relationship | #172 |
| expression alpha1 | #172 |
| ketoglutarate | #172 |
| early increases | #172 |
| rats protective | #173 |
| protein gfap | #174 |
| complex pyruvate | #174 |
| stereotyped behavior | #175 |
| chain amino | #175 |
| brain energy | #175 |
| taurine concentrations | #175 |
| binding calcium | #175 |
| dehydroascorbic | #175 |
| synergistic actions | #175 |
| gfap immunoreactivity | #176 |
| guanidino compounds | #177 |
| eaat4 | #178 |
| neurological complications | #178 |
| neurological dysfunction | #178 |
| fine motor function | #179 |
| patients plasma levels | #179 |
| symptoms including | #180 |
| rats csf | #180 |
| brain monoamine | #180 |
| serotonin 5hydroxytryptamine | #180 |
| 3hflunitrazepam | #181 |
| autoradiography binding | #181 |
| brain concentration | #181 |
| experimental hepatic | #181 |
| biochemical consequences | #182 |
| dheas dhea | #182 |
| accumulation brain | #182 |
| dehydroepiandrosterone sulphate | #182 |
| patients mhe | #183 |
| neuropsychiatric | #183 |
| competitive brain | #183 |
| nnos mrna | #184 |
| animals antimetabolites | #184 |
| nutritional consequences | #184 |
| amphetamine apomorphine | #185 |
| branchedchain amino acids | #185 |
| glast glt1 | #185 |
| fluorescence analysis | #185 |
| neurological disorder | #185 |
| mm kcl | #186 |
| sequellae | #187 |
| expression occludin | #187 |
| stress pathogenesis | #187 |
| controls regions | #187 |
| spraguedawley serotonin | #187 |
| alcar | #188 |
| otc | #188 |
| compared sham | #188 |
| dawley serotonin | #188 |
| dehydrogenase complex | #188 |
| cb154 | #188 |
| pcr ratio | #188 |
| vasogenic brain edema | #189 |
| highaffinity uptake | #189 |
| rat cerebellum | #189 |
| aminobutyric | #190 |
| agonist properties | #190 |
| dopamine turnover | #191 |
| aged ammonia | #192 |
| pregnanolone | #192 |
| specific ligand | #192 |
| studies alterations | #193 |
| gilles tourettes syndrome | #194 |
| righting reflex | #194 |
| patient material | #194 |
| pavlov | #194 |
| limited therapeutic | #195 |
| gamma aminobutyric | #195 |
| patients immunohistochemistry | #195 |
| of3h | #195 |
| intracellular receptors | #196 |
| expression tight | #197 |
| mice acute | #197 |
| tissue patients | #197 |
| concomitant loss | #198 |
| unaltered | #198 |
| manganese compounds | #198 |
| mrna protein expression | #198 |
| guanidino | #198 |
| astrocyte function | #198 |
| thalamus hippocampus | #199 |
| etiology patients | #200 |
| noradrenaline transporter | #200 |
| substitutive | #200 |
| glutamatergic synaptic | #200 |
| mitochondria neurons | #200 |
| experimental chronic | #200 |
| 35 degrees | #200 |
| synthetase expression | #201 |
| highest density | #201 |
| brainstem structures | #201 |
| csf concentrations | #201 |
| cerebral glucose utilization | #202 |
| severity liver disease | #202 |
| activation brain | #202 |
| translation clinic | #202 |
| equal | #202 |
| vitro receptor | #203 |
| therapeutic interventions | #203 |
| activities increased | #203 |
| chronic alcohol abuse | #204 |
| benzodiazepine binding | #204 |
| cns dysfunction | #205 |
| ketone oxidoreductases | #205 |
| manganism | #206 |
| poor nutrition | #206 |
| trials low risk | #206 |
| grc | #206 |
| cuznsod | #206 |
| central noradrenergic | #207 |
| ldh1 | #207 |
| ldh5 | #207 |
| astrocytic response | #209 |
| neuropathological studies | #209 |
| laboratory rat | #209 |
| immunohistochemistry messenger receptors | #209 |
| concomitant increase | #210 |
| uptake pattern | #210 |
| overt hepatic | #210 |
| ethanol increased | #210 |
| bergmann | #210 |
| millimolar concentrations | #211 |
| laspartate | #212 |
| isoquinolines male | #212 |
| brain structures | #212 |
| cns gaba | #212 |
| patients liver dysfunction | #212 |
| histopathological studies | #212 |
| cerebellum striatum | #213 |
| patients died | #214 |
| gabaa receptor agonist | #214 |
| address issue | #214 |
| plasma ammonia | #214 |
| 3h8 | #215 |
| role pathogenesis | #215 |
| nitrite nitrate levels | #216 |
| key factor | #216 |
| failure mice | #216 |
| glutamine cycle | #216 |
| animals liver | #216 |
| noradrenergic function | #217 |
| glutamine synthetase activity | #217 |
| bbb breakdown | #217 |
| cultured rat astrocytes | #218 |
| taurine animals | #219 |
| 3hro | #219 |
| thiamine vitamin | #219 |
| inbred strains spectrometry | #220 |
| excitatory neurotransmitters | #221 |
| agonal | #221 |
| new therapeutic opportunities | #221 |
| glutamate exposure | #221 |
| 3 post | #222 |
| level severity | #222 |
| terry | #223 |
| deficient animals | #224 |
| death mechanisms | #224 |
| cyclase sgc | #225 |
| 2 quality | #226 |
| vulnerable period | #226 |
| gaba receptor | #227 |
| exposure inhalation | #228 |
| il1beta mrna | #228 |
| hepatic microcirculation | #228 |
| gaba cns | #228 |
| animals effects | #229 |
| cortical synaptosomes | #229 |
| acute chronic exposure | #229 |
| excitatory transmitter | #229 |
| shunt | #230 |
| muscarinic cholinergic | #230 |
| cholestatic rats | #230 |
| mk801 treatment | #230 |
| opca | #230 |
| previous report | #231 |
| hippocrates | #231 |
| glutamate excitotoxicity | #231 |
| receptor ligands | #231 |
| extracellular glutamate | #232 |
| rats weeks | #233 |
| increasing evidence | #234 |
| increased intracranial | #234 |
| glutamate transport | #234 |
| spraguedawley reference values | #234 |
| phosphate esters | #235 |
| brain deposition | #235 |
| cau | #235 |
| pair fed | #236 |
| liver injury mice | #236 |
| resonance study | #236 |
| serotonin tryptophan | #237 |
| 3hglutamate | #237 |
| glial proliferation | #238 |
| pdh complex | #238 |
| lc3 lipidation | #238 |
| animals rats | #239 |
| encephalopathy mhe | #239 |
| end‐stage liver disease | #240 |
| levels glutamate | #240 |
| binding brain | #240 |
| multiple systematic reviews | #240 |
| reduced glutathione levels | #240 |
| concentrations elevated | #240 |
| caudate putamen | #241 |
| minimal hepatic | #241 |
| nacl kcl | #241 |
| presynaptic neuron | #241 |
| psychoactive medications | #241 |
| 13cacetate | #242 |
| cycle disorders | #242 |
| brain samples | #242 |
| neurobehavioral | #243 |
| treatment central | #243 |
| sgc | #243 |
| glur2 | #243 |
| cerebral cortex hippocampus | #244 |
| neuronal membrane | #244 |
| normal processes | #244 |
| manganese concentration | #244 |
| neuronal localization | #244 |
| alf patients | #244 |
| hypothalamus hypothalamus | #245 |
| aged monoamine | #245 |
| tritium animals | #246 |
| neurologic assessment | #246 |
| glutamine concentration | #246 |
| acids animals | #246 |
| bloodbrain barrier breakdown | #246 |
| unchanged | #246 |
| nonpregnant rats | #247 |
| soluble guanylate | #247 |
| plasma brain | #247 |
| synaptosomal preparations | #247 |
| histaminergic | #248 |
| hippocampal sclerosis | #248 |
| 5 hydroxyindoleacetic | #248 |
| minimal hepatic encephalopathy | #248 |
| neuroactive steroids | #248 |
| allosteric coupling | #249 |
| deficient rats | #249 |
| betaep | #249 |
| glutamate transporter glt1 | #250 |
| increased expression | #250 |
| synaptic transmission | #250 |
| findings activation | #251 |
| reactive nitrogen intermediates | #251 |
| glutamate gaba | #251 |
| gaba uptake | #252 |
| fatigue chronic | #252 |
| reduced cerebral | #253 |
| animals aspartic | #253 |
| symptoms brain | #253 |
| focal loss | #254 |
| rats taurine | #255 |
| rat cerebellar | #256 |
| watersoluble vitamins | #256 |
| brain caudate | #256 |
| therapeutic measures | #257 |
| norepinephrine turnover | #257 |
| soluble guanylate cyclase | #257 |
| 4513 | #257 |
| alterations expression | #257 |
| brain disorder | #257 |
| mhe | #258 |
| animals ataxia | #258 |
| pallidum | #258 |
| transporters amino | #259 |
| ed1 | #259 |
| rats time factors | #259 |
| – brain | #259 |
| choline acetyltransferase | #259 |
| receptor autoradiography | #259 |
| agents rats | #260 |
| precipitating factors | #260 |
| phenylalanine levels | #260 |
| glutamine synthetase | #260 |
| gene expression alterations | #261 |
| liver liver failure | #261 |
| treatment neurological disorders | #262 |
| binding ligands | #262 |
| liver skeletal muscle | #262 |
| endogenous ligands | #262 |
| neurological impairment | #263 |
| acetyl carnitine | #263 |
| spf | #264 |
| muscle rigidity | #264 |
| concentrations brain | #264 |
| liver testis | #264 |
| gamma tumor | #264 |
| alcoholic male | #264 |
| gabaergic neurotransmission | #265 |
| cisterna | #265 |
| rats compared | #265 |
| calleja | #265 |
| cerebellar pathology | #266 |
| dopamine noradrenaline | #267 |
| reactive gliosis | #267 |
| male c57bl6 mice | #267 |
| dopamine spiperone | #267 |
| protein gene expression | #268 |
| isoquinolines | #268 |
| cell volume regulation | #268 |
| electrically stimulated | #268 |
| contributory | #269 |
| expression nitric | #270 |
| female hepatic | #271 |
| hepatic | #271 |
| sleep abnormalities | #271 |
| hydroxyindoleacetic acid | #272 |
| brain human | #272 |
| displaceable | #272 |
| microdialysates | #272 |
| octanoic acid | #272 |
| pharmacological manipulation | #272 |
| brains | #274 |
| neurotransmitter systems | #274 |
| greenwood | #276 |
| expression brain | #277 |
| quin | #277 |
| normal conditions | #277 |
| neuronal cell death | #278 |
| glutamate uptake | #279 |
| neurotoxic action | #280 |
| national association | #280 |
| gamma liver | #280 |
| tryptamine | #280 |
| 14c2 | #281 |
| metal toxicity | #281 |
| striatum cerebral cortex | #281 |
| microassay | #281 |
| guanylate cyclase | #282 |
| intracranial hypertension | #282 |
| gaba levels | #282 |
| maoa | #283 |
| glur3 | #283 |
| cortical astrocytes | #284 |
| severe neurological | #284 |
| behavioural impairment | #284 |
| 3mt | #284 |
| nitrated proteins | #285 |
| ht release | #285 |
| concentrations dopamine | #285 |
| ucds | #285 |
| barrier breakdown | #285 |
| acute hepatic failure | #287 |
| glomerular filtrate | #287 |
| deficiency disorders | #288 |
| acid astrocytes | #289 |
| excitatory amino acids | #289 |
| reduction oxidative stress | #290 |
| adult values | #290 |
| apap hepatotoxicity | #290 |
| azoxymethane | #291 |
| ligands male | #292 |
| brain cerebellum | #292 |
| patients fatigue | #292 |
| mice cerebral | #292 |
| human liver disease | #292 |
| autoradiographic studies | #293 |
| failure rats | #293 |
| glutamine | #293 |
| brain regional | #293 |
| concentrations zinc | #293 |
| reduced capacity | #293 |
| effects hypothermia | #293 |
| blood – | #294 |
| induced swelling | #294 |
| altered expression | #294 |
| odn | #294 |
| substantial increases | #295 |
| synthase expression | #296 |
| rats increased | #297 |
| betaactin | #297 |
| overt hepatic encephalopathy | #300 |
| rats western cells | #300 |
| dawley receptors opioid | #304 |
| actin mrna | #304 |
| groups sham | #304 |
| brain choline | #304 |
| rifamycins rifaximin | #305 |
| cytotoxic mechanism | #306 |
| damaged liver | #306 |
| severe alterations | #306 |
| gamma aminobutyric acid | #306 |
| lnoarg | #306 |
| glutamate | #307 |
| powerful antioxidant | #307 |
| 3hsch | #307 |
| selection model | #307 |
| dihydrolipoamide | #308 |
| bioaccumulation | #308 |
| cerebral function | #308 |
| molecular biological techniques | #310 |
| tight junction protein | #310 |
| serotonin metabolism | #311 |
| brain genes | #312 |
| 4864 | #312 |
| agonists gaba | #312 |
| gaba taurine | #312 |
| treatment rats | #313 |
| rats messenger | #313 |
| male osmolar | #314 |
| secondary biliary cirrhosis | #315 |
| chloride animals | #316 |
| brain serotonin | #316 |
| receptors glutamate | #316 |
| nitrogen metabolism | #318 |
| adjacent sections | #318 |
| mice mutant | #318 |
| mitochondrial proliferation | #319 |
| basal ganglia patients | #319 |
| quantitative autoradiography | #319 |
| humans manganese | #319 |
| cultured hippocampal neurons | #320 |
| cell death mechanisms | #320 |
| rats brain | #320 |
| tailpipe | #321 |
| dehydrogenase activity | #321 |
| 235triphenyltetrazolium chloride | #322 |
| eaat3 | #322 |
| isethionate | #323 |
| aqp4 expression | #324 |
| acid 5 | #325 |
| thalamus | #325 |
| neurochemical studies | #327 |
| nervous function | #327 |
| decreased brain | #327 |
| complications outcome | #327 |
| olivopontocerebellar | #328 |
| 5 hiaa | #328 |
| uptake increased | #329 |
| pathol | #329 |
| cerebellar astrocytes | #330 |
| flumazenil | #330 |
| sites human | #331 |
| β endorphin | #331 |
| aaas | #333 |
| uptake brain | #333 |
| proinflammatory cytokines | #333 |
| locomotor | #333 |
| experimental rat | #334 |
| increased binding | #335 |
| neurotransmitter uptake | #335 |
| 13cglucose | #335 |
| hydroxyindoleacetic | #335 |
| brain accumulation | #336 |
| 8 rats | #336 |
| nitrotyrosine | #337 |
| inhalation exposure | #338 |
| cortex brain | #339 |
| responsible | #339 |
| transport defect | #340 |
| positive synergistic | #340 |
| pdh activity | #341 |
| human hepatic | #341 |
| biological plausibility | #341 |
| cerebral cortical | #342 |
| mutant rats | #342 |
| reyes syndrome | #343 |
| altered mental status | #344 |
| benzodiazepine site | #344 |
| brain 5 | #344 |
| dehydrogenase humans | #345 |
| placebo improvement | #345 |
| dansyl | #346 |
| activation nmda | #346 |
| acid gaba | #347 |
| intraventricularly | #347 |
| control values | #347 |
| vulnerable | #347 |
| bdl rats | #349 |
| marked decreases | #349 |
| pigs groups | #350 |
| increased immunoreactivity | #350 |
| glutamate levels | #350 |
| alanine amino | #351 |
| nonalcoholics | #351 |
| patients dying | #351 |
| cortex cerebellum | #352 |
| consequent increase | #352 |
| manganese | #353 |
| western brain | #354 |
| proinflammatory cytokine release | #354 |
| series studies | #354 |
| consumption rats | #354 |
| apapinduced liver injury | #354 |
| expression increased | #355 |
| brain excitability | #356 |
| thiamine supplementation | #356 |
| complex male | #356 |
| duct ligated | #356 |
| receptor sites | #357 |
| deterioration | #357 |
| wellestablished model | #358 |
| postmortem brain tissue | #358 |
| 5hiaa | #358 |
| proposed role | #359 |
| onset brain | #359 |
| convulsions | #359 |
| glutamate homeostasis | #361 |
| mammalian brain | #361 |
| increase extracellular | #361 |
| autoradiography brain | #362 |
| neuroinflammatory | #363 |
| metabolic events | #363 |
| reduced plasma | #363 |
| histamine h1 | #363 |
| rats cns | #364 |
| 9998 | #365 |
| expression pglycoprotein | #365 |
| acids branched | #366 |
| white matter structures | #366 |
| neuroglia | #367 |
| posttranslational rats rats | #367 |
| folic acid antagonists | #368 |
| methoxytyramine | #369 |
| cerebral oedema | #370 |
| sulfate dheas | #370 |
| 56 mm | #370 |
| sites binding | #371 |
| nacetylcysteine nac | #371 |
| metabolic impairment | #372 |
| glutamate synthesis | #372 |
| perineuronal | #372 |
| acid rats | #373 |
| induction cox2 | #373 |
| encountered | #373 |
| affinities | #373 |
| chemical forms | #373 |
| accompanied | #375 |
| 3hmk801 | #375 |
| astrocytes microglia | #375 |
| anaplerotic | #376 |
| highaffinity | #376 |
| ca1 subfield | #376 |
| nh3 nh4 | #377 |
| antioxidant nacetylcysteine | #377 |
| acetyltransferase chat | #378 |
| cirrhosis alcoholic | #378 |
| ngnitro | #378 |
| novo synthesis | #379 |
| cell swelling | #380 |
| positive allosteric | #380 |
| basal ganglia thalamus | #380 |
| epileptic patients | #382 |
| acute chronic | #382 |
| pons | #382 |
| pregnenolone | #383 |
| overwhelming evidence | #383 |
| densities | #385 |
| exposure brain | #386 |
| dihydrolipoamide dehydrogenase | #386 |
| transporter glut1 | #386 |
| phenylalanine tyrosine | #388 |
| acetylcholine synthesis | #390 |
| cerebral edema | #390 |
| focal cerebral ischemia | #390 |
| hyperglycemic conditions | #390 |
| pbz | #390 |
| effects administration | #390 |
| pet assessment | #392 |
| mice enos | #393 |
| glycine transporter | #394 |
| phthalaldehyde | #394 |
| thioacetamide induced | #394 |
| phenylacetate | #395 |
| scatchard plot | #395 |
| failure induced | #396 |
| model acute | #396 |
| carnitine levels | #397 |
| positive allosteric modulator | #397 |
| omega 3 | #398 |
| methylhistamines | #399 |
| bbb permeability | #399 |
| pathophysiological mechanism | #399 |
| patients platelets | #400 |
| acetyl coa | #400 |
| vestibular nucleus | #400 |
| korsakoff | #400 |
| frontal | #401 |
| insulin metabolism | #401 |
| falls patients | #402 |
| inferior olive | #402 |
| radioligands | #403 |
| rats purpose | #405 |
| liver gut | #407 |
| concerted effort | #407 |
| neuropathologic | #408 |
| methionine sulfoximine | #408 |
| marker enzymes | #408 |
| releasable | #410 |
| adult activities | #412 |
| dopaminergic neurones | #414 |
| shunt surgery | #415 |
| forebrain cholinergic | #416 |
| patients ataxia | #416 |
| ketamine anesthesia | #417 |
| gabaa gammaaminobutyric acid | #418 |
| intellectual function | #419 |
| pk11195 | #419 |
| fibrillary | #421 |
| alcoholic liver | #421 |
| serotonin content | #422 |
| housekeeping gene | #423 |
| asparagine | #423 |
| sham operation | #423 |
| rats animal | #423 |
| regions brain | #423 |
| diazepam binding | #424 |
| hypothermia | #424 |
| tissues brain | #425 |
| salinetreated controls | #425 |
| aidsrelated complex | #426 |
| binding parameters | #426 |
| direct evidence | #426 |
| exsanguination | #427 |
| rats mutant | #428 |
| hepatocyte necrosis | #430 |
| glutamine levels | #431 |
| protein utilization | #431 |
| sacrificed | #432 |
| hippocampus frontal cortex | #434 |
| dawley tissue | #434 |
| onset severe | #434 |
| peripheral benzodiazepine | #434 |
| rats experimental | #435 |
| patients pbc | #437 |
| cytotoxic edema | #437 |
| benzoate | #438 |
| 12 control subjects | #438 |
| addition evidence | #439 |
| isoquinoline | #440 |
| ligand selectivity | #440 |
| central process | #441 |
| attenuates | #441 |
| acids brain | #442 |
| neurological syndrome | #442 |
| 13c enrichment | #443 |
| brain glucose | #443 |
| arginine transport | #443 |
| brain microglia | #443 |
| patients encephalopathy | #443 |
| glyt1 | #444 |
| cultured astrocytes | #444 |
| cultured cerebellar | #445 |
| operated | #445 |
| compounds rats | #446 |
| butterworth | #446 |
| brain water content | #447 |
| agematched controls | #450 |
| topographic distribution | #450 |
| liver skeletal | #450 |
| pyruvate dehydrogenase | #450 |
| acute mice mice | #451 |
| effects liver | #451 |
| brain tissue patients | #451 |
| t1weighted mri | #453 |
| severe liver | #454 |
| s100beta | #455 |
| aged amino | #455 |
| immunohistochemistry liver | #455 |
| central pontine myelinolysis | #455 |
| body evidence | #456 |
| parachlorophenylalanine | #456 |
| brain swelling | #456 |
| h1 receptor | #456 |
| impaired liver function | #457 |
| aspartic | #457 |
| vitro binding assay | #457 |
| brain monoamines | #458 |
| brain alterations | #460 |
| effects brain | #460 |
| neurobiology | #460 |
| increased release | #461 |
| neuropathology | #462 |
| 5ht levels | #463 |
| substantial body | #463 |
| equivocal | #463 |
| neurological | #465 |
| hepatic glutathione | #466 |
| dentate nuclei | #466 |
| neurobehavioural | #467 |
| studies reveal | #468 |
| central cholinergic | #469 |
| glutamic acid | #469 |
| reye | #470 |
| amino acid levels | #471 |
| monoamine metabolism | #471 |
| urea production | #472 |
| patients hippocampal | #473 |
| alcoholic liver disease | #473 |
| putamen patients | #474 |
| gaba glycine | #475 |
| ox42 | #475 |
| liver dysfunction | #475 |
| glutamate transporters | #475 |
| inherited defects | #476 |
| alcohol brain | #477 |
| thiamin | #477 |
| release proinflammatory cytokines | #479 |
| thiamine pyrophosphate | #479 |
| amino acid transporters | #480 |
| acid humans | #480 |
| parkinsons diseases | #481 |
| inferior colliculus | #482 |
| acute male | #482 |
| images brain | #482 |
| brain csf | #484 |
| chronic alcoholics | #484 |
| nitric oxide synthase | #487 |
| manganese levels | #488 |
| concentrations increased | #488 |
| triphosphate amino | #488 |
| acids rats | #490 |
| multinuclear nmr spectroscopy | #491 |
| urea ammonia | #491 |
| glial fibrillary | #492 |
| increased production | #492 |
| role brain | #492 |
| jadad | #492 |
| ischemic cortex | #493 |
| pet ligand | #494 |
| outer mitochondrial membrane | #495 |
| aspartate glutamate | #495 |
| pyruvates | #495 |
| ammonium ion | #495 |
| emitted radiation | #495 |
| schaffer collaterals | #496 |
| rat hippocampal | #496 |
| hexanones | #496 |
| neurons nitric | #499 |
| ataxic | #499 |
| brain diseases | #501 |
| beneficial | #502 |
| brain synaptosomes | #505 |
| 3hd | #505 |
| 5 hydroxytryptophan | #507 |
| ketoacid | #508 |
| acid metabolites | #509 |
| fatal complication | #510 |
| gene therapy treatment | #510 |
| medulla oblongata | #511 |
| increased icp | #511 |
| histamine h1 receptors | #511 |
| discrete brain regions | #511 |
| exposure rats | #515 |
| acids amino | #516 |
| major feature | #517 |
| abnormal metabolism | #517 |
| humans neurons | #518 |
| chain acyl | #518 |
| concentrations 5 | #521 |
| neurochemistry | #523 |
| ltrp | #523 |
| inflammation mediators | #525 |
| toxic agents | #526 |
| brain female | #530 |
| rat hippocampal slices | #530 |
| aom | #531 |
| agents dopamine | #533 |
| receptor complex | #533 |
| dawley receptors | #533 |
| neurotoxins | #534 |
| focal cerebral | #534 |
| ligation bdl | #534 |
| muscle loss | #534 |
| 100 µg | #534 |
| combined actions | #535 |
| cerebellum cerebral | #536 |
| bdz | #537 |
| divalent metals | #538 |
| alcoholic cirrhosis | #539 |
| selective | #539 |
| carroll | #539 |
| severe liver disease | #539 |
| tipss | #540 |
| tyrosine nitration | #541 |
| hydroxymethylbilane | #541 |
| moderate drinking | #542 |
| brain astrocytes | #542 |
| moderate increase | #543 |
| aspartate | #544 |
| pyruvate oxidation | #544 |
| portasystemic | #544 |
| liver enzyme | #545 |
| chronic liver | #545 |
| organic osmolytes | #545 |
| energy metabolism | #546 |
| model hepatic | #547 |
| unanesthetized rats | #548 |
| cumene | #548 |
| dissected | #548 |
| nitrosative stress | #548 |
| alpha1 alpha2 | #549 |
| unconjugated bilirubin | #549 |
| thalamic lesions | #550 |
| taurine levels | #551 |
| brain region | #551 |
| fatigue patients | #553 |
| genes brain | #553 |
| glutamatergic neurotransmission | #554 |
| brain cytokines | #554 |
| increased uptake | #555 |
| water ammonia | #555 |
| nmda receptor antagonist | #556 |
| disease liver | #557 |
| rats bile | #558 |
| failure liver | #558 |
| microdialysate | #563 |
| levels hepatic | #563 |
| gabaergic gaba | #563 |
| cortex female humans | #564 |
| hydroxytryptophan | #564 |
| microglial response | #566 |
| mhe patients | #567 |
| serum bilirubin levels | #567 |
| malnutrition patients | #567 |
| established role | #568 |
| ischemia liver | #568 |
| autoradiographic | #569 |
| transient increase | #569 |
| lhistidine | #569 |
| neurotransmitter glutamate | #571 |
| neurologic signs | #573 |
| pathway brain | #574 |
| gaba | #574 |
| decarboxylase gad | #576 |
| outcome liver | #577 |
| octopamine | #577 |
| expression mrnas | #578 |
| apap induced | #578 |
| il1beta expression | #578 |
| liver pathology | #580 |
| oxobutanoate | #580 |
| biogenic monoamines | #581 |
| octanoic | #582 |
| increases blood | #582 |
| pyridinium compounds | #582 |
| brain metabolism | #583 |
| histological lesions | #583 |
| 5hydroxytryptophan | #584 |
| neurobehavioral effects | #588 |
| bloodbrain barrier | #589 |
| edema formation | #589 |
| monoamine oxidases | #589 |
| human spinal | #590 |
| activity brain | #591 |
| 13c nuclear | #592 |
| accompanying | #593 |
| toxic levels | #593 |
| catalytic sites | #594 |
| pathophysiological mechanisms | #594 |
| endogenous opioid | #594 |
| t1weighted imaging | #597 |
| highenergy phosphates | #598 |
| aminobutyric acid gaba | #599 |
| extracellular fluid | #600 |
| neuronal nitric | #601 |
| leigh disease | #601 |
| include | #601 |
| neuroglial | #601 |
| taurine | #602 |
| 3hcholine | #602 |
| largest increases | #604 |
| male nitric | #606 |
| methyltyrosines | #606 |
| glutamine humans | #607 |
| extracellular compartment | #608 |
| vermis | #608 |
| acetyl | #609 |
| molecular studies | #609 |
| cirrhosis | #609 |
| male metabolism | #610 |
| cortical slices | #610 |
| ammonia concentration | #612 |
| friedreich ataxia | #612 |
| ventricular enlargement | #612 |
| animals autoradiography | #614 |
| spraguedawley receptors | #615 |
| neurovascular unit | #615 |
| axonopathy | #616 |
| selective accumulation | #616 |
| microglial | #616 |
| tricarboxylic | #618 |
| c57bl6 mice | #618 |
| artery ligation | #618 |
| normothermic | #619 |
| increased expression genes | #620 |
| mammillary | #620 |
| acidic protein | #621 |
| controls addition | #624 |
| junction proteins | #624 |
| hippocampal slices | #625 |
| new approaches | #625 |
| oxidase mao | #625 |
| amino acid concentrations | #626 |
| semi quantitative | #626 |
| edema brain | #627 |
| hepatic levels | #628 |
| experimental animal model | #628 |
| nimesulide | #628 |
| clf | #629 |
| dbi | #629 |
| free radical formation | #630 |
| neurobehavior | #631 |
| blood borne | #631 |
| dehydroepiandrosterone sulfate dheas | #633 |
| ataxia | #634 |
| urea synthesis | #635 |
| dopamine striatum | #635 |
| contributory role | #635 |
| allosteric interactions | #635 |
| encephalopathies | #636 |
| neurological damage | #637 |
| astrocyte cultures | #638 |
| harper | #638 |
| levels observed | #638 |
| neuroinflammation | #638 |
| cerebellum | #639 |
| deleterious effects | #640 |
| conduction velocities | #640 |
| rats glucose | #641 |
| acid hippocampus | #643 |
| receptor densities | #644 |
| neuronal excitability | #645 |
| excitatory inhibitory | #645 |
| early role | #646 |
| frontal temporal | #647 |
| nntetraacetic acid | #647 |
| chronic exposure | #647 |
| desoxycorticosterone | #652 |
| matsumoto | #652 |
| excitatory amino | #653 |
| branched chain | #653 |
| cytokines tnf | #654 |
| tricarbonyl | #655 |
| gabaa gaba | #656 |
| mental state | #657 |
| 1400w | #657 |
| enos gene | #659 |
| acid transporter | #659 |
| dawley sodium | #661 |
| potential toxic effects | #662 |
| cerebral cortex | #663 |
| uptake release | #664 |
| 3hspiperone | #665 |
| metabolic basis | #665 |
| fibrillary acidic | #666 |
| cycle enzymes | #668 |
| heterogeneous distribution | #669 |
| cogent | #670 |
| minocycline treatment | #673 |
| inhibitory properties | #673 |
| potassium concentration | #675 |
| metabolism rats | #675 |
| 7ni | #678 |
| 7nitroindazole | #679 |
| evoked release | #682 |
| neuropathological | #683 |
| reduction expression | #683 |
| regional specificity | #684 |
| ornithine | #684 |
| millimolar | #684 |
| excitatory | #684 |
| ammonia treatment | #684 |
| gammaaminobutyric acid | #685 |
| frontal cortex hippocampus | #686 |
| cerebral atrophy | #688 |
| spraguedawley | #688 |
| microg m3 | #688 |
| protein tspo | #691 |
| ca1 pyramidal cells | #695 |
| brain regions | #695 |
| hepatic damage | #695 |
| fulminant | #695 |
| daily administration | #697 |
| acetylcysteine animals | #697 |
| extrapyramidal | #698 |
| synthase nnos | #698 |
| enzyme complex | #699 |
| bcaas | #700 |
| brain disorders | #700 |
| blood‐brain barrier | #701 |
| immunolabeling | #701 |
| ammonia production | #703 |
| normoglycemic | #703 |
| autophagy markers | #704 |
| rats dawley receptors | #705 |
| quinolinic | #706 |
| ethanol ingestion | #706 |
| acetylcysteine nac | #709 |
| cornerstone | #711 |
| glut1 expression | #714 |
| cortex rats | #715 |
| reductions | #719 |
| bmax values | #723 |
| phenylbutyrate | #723 |
| surgical samples | #724 |
| 6 day | #724 |
| nutritional status patients | #725 |
| acute hepatic | #726 |
| ketoglutaric | #729 |
| contribute | #730 |
| serotoninergic | #730 |
| expression isoforms | #736 |
| intensive study | #737 |
| piribedil | #740 |
| fluorimetric detection | #741 |
| mm nacl | #742 |
| ligation liver | #744 |
| dopaminergic function | #745 |
| biochemical alterations | #746 |
| cerebellar granule | #746 |
| methylglucose | #747 |
| tight junction | #748 |
| glucose oxidation | #749 |
| male microdialysis | #749 |
| choline acetyltransferase chat | #752 |
| cytochrome oxidase activity | #753 |
| scatchard analysis | #754 |
| alterations | #754 |
| illness terminology | #756 |
| portasystemic shunt | #757 |
| glutamate glu | #757 |
| delta receptors opioid | #758 |
| alcoholism animals | #760 |
| ergic | #761 |
| varying degrees | #762 |
| ammonium chloride | #763 |
| substantial evidence | #763 |
| tryptamines | #764 |
| opioid delta receptors | #764 |
| neutron activation analysis | #765 |
| levels 5 | #768 |
| excitotoxic | #769 |
| gdh | #769 |
| normal liver function | #769 |
| barrier permeability | #770 |
| control genes | #773 |
| newborn astrocytes | #774 |
| peripheral organs | #775 |
| cellular energy metabolism | #776 |
| ethanol consumption | #777 |
| increased blood | #778 |
| brain gene | #780 |
| species reactive | #783 |
| hepatic dysfunction | #783 |
| receptor function | #784 |
| mnsod | #785 |
| methods principal findings | #785 |
| cortex thalamus | #785 |
| messenger rats | #786 |
| glut1 | #786 |
| nakatpase | #787 |
| globus pallidus | #787 |
| early alterations | #789 |
| brain function | #790 |
| spraguedawley receptors messenger | #791 |
| major route | #791 |
| probenecid | #791 |
| 2 fold | #792 |
| glyceraldehyde3 phosphate | #792 |
| hypothermia treatment | #793 |
| specific ligands | #793 |
| rat cerebral | #795 |
| selective effects | #796 |
| typical cases | #796 |
| plasma clearance | #797 |
| ethanol solution | #797 |
| neuronal integrity | #799 |
| severity liver | #799 |
| nitroarginine | #801 |
| pertinence | #805 |
| hiaa | #806 |
| nh4cl | #807 |
| ultimately | #807 |
| neurotoxic effects | #807 |
| pyruvate metabolism | #808 |
| mrna protein | #809 |
| chat | #811 |
| role astrocytes | #812 |
| predilection | #812 |
| acute brain injury | #812 |
| enos mice | #815 |
| update | #816 |
| coma | #816 |
| glycolytic activity | #819 |
| cerebellar granule cells | #820 |
| nmethyldaspartate | #822 |
| eaat1 | #823 |
| pbc patients | #823 |
| iii groups | #824 |
| complete disappearance | #825 |
| pathogenesis treatment | #825 |
| edema | #826 |
| age matched | #826 |
| alzheimer type | #828 |
| atomic absorption spectrometry | #828 |
| nitrite nitrate | #829 |
| synthesis rates | #829 |
| glial | #830 |
| neurons astrocytes | #831 |
| water homeostasis | #831 |
| alcoholics | #832 |
| diseases alcoholic | #832 |
| eaat2 | #833 |
| monoamine | #834 |
| decreases | #835 |
| manifested | #836 |
| pathophysiological | #837 |
| operated rats | #837 |
| explain | #838 |
| amino3 | #838 |
| animal cell | #839 |
| oligonucleotide primers | #839 |
| treatment improvement | #841 |
| metabolic disorder | #842 |
| expression ho1 | #843 |
| cell loss | #845 |
| hypothermia patients | #846 |
| isotopomer | #846 |
| cfos cjun | #848 |
| pharmacokinetic analyses | #849 |
| oblongata | #849 |
| chronic alcohol consumption | #851 |
| gaba receptors | #852 |
| receptor mediated | #853 |
| nmda receptor | #853 |
| daily injections | #854 |
| matched age | #854 |
| glutamatergic | #856 |
| consequence | #856 |
| compromised | #857 |
| bbb integrity | #858 |
| griess | #861 |
| aromatic amino acids | #861 |
| order role | #862 |
| alcoholic | #862 |
| hepatic disease | #862 |
| antioxidant action | #863 |
| continues | #863 |
| inflammatory mechanisms | #866 |
| thalamic nuclei | #866 |
| cerebellar ataxia | #867 |
| early induction | #867 |
| normalizes | #869 |
| manifest | #870 |
| chronic liver disease | #871 |
| oxide rats | #872 |
| fpc | #874 |
| succimer | #877 |
| low risk bias | #880 |
| nmda receptor antagonists | #881 |
| cisterna magna | #882 |
| excitatory amino acid | #882 |
| barrier bbb | #882 |
| greater susceptibility | #882 |
| stimulated release | #887 |
| dehydrogenase | #890 |
| comatose | #890 |
| western cells | #890 |
| shamoperated animals | #891 |
| multinuclear | #891 |
| cultured hippocampal | #892 |
| nutritional intervention | #893 |
| interfere | #893 |
| mutant mouse | #894 |
| lipoamide | #897 |
| neuropsychiatric symptoms | #898 |
| exp | #899 |
| acetaminophen apap | #900 |
| common death | #901 |
| dizocilpine maleate | #901 |
| sulfoximine | #901 |
| cirrhosis pbc | #902 |
| lowering | #904 |
| neurons rna | #904 |
| experimental animal | #905 |
| quinolinic acid | #905 |
| pcs | #907 |
| autopsy brain | #907 |
| brain activities | #908 |
| factor tumor | #912 |
| acid animals | #912 |
| colliculus | #913 |
| pathophysiology | #913 |
| selective ligands | #913 |
| placebo intervention | #919 |
| publication acidosis | #919 |
| microdialysis study | #920 |
| cerebellar degeneration | #920 |
| rat cortical | #922 |
| liver homogenates | #922 |
| delta receptors | #924 |
| survival mice | #926 |
| urea cycle | #929 |
| striatum hippocampus | #930 |
| pugh | #931 |
| nacetylcysteine | #931 |
| microglial activation | #932 |
| findings evidence | #932 |
| hydroxy2di | #933 |
| activities enzymes | #936 |
| hepatic diseases | #942 |
| developing rat brain | #942 |
| reaction water | #942 |
| tartrates | #942 |
| rats exposed | #943 |
| study liver | #943 |
| agents oxidative | #943 |
| mammalian cns | #943 |
| injured liver | #943 |
| marked | #945 |
| rapid removal | #945 |
| pca | #948 |
| maladies | #949 |
| cirrhosis magnetic | #950 |
| 25mm | #951 |
| concentrations observed | #954 |
| spontaneous release | #957 |
| altered | #962 |
| spraguedawley receptors rats | #963 |
| detailed review | #964 |
| putamen | #967 |
| assay rats | #967 |
| translocator protein | #969 |
| humans hypothermia | #969 |
| moderate hypothermia | #970 |
| cerebral glucose | #971 |
| intermediary metabolism | #971 |
| acid transport | #971 |
| chronic liver diseases | #971 |
| increased glycolysis | #971 |
| nm range | #973 |
| autoradiographic study | #974 |
| kidney heart | #979 |
| aspartic acid | #979 |
| post translational modifications | #980 |
| neurological disease | #983 |
| occludin | #984 |
| oxygenase1 ho1 | #988 |
| pdh | #990 |
| effective measures | #990 |
| 9 mice mice | #990 |
| cirrhosis experimental | #991 |
| aquaporin4 | #991 |
| brain oedema | #992 |
| rats ethanol | #992 |
| spared | #993 |
| increased plasma | #993 |
| propylaminotetralin | #998 |
| damage mechanisms | #999 |
| role oxidative stress | #1006 |
| adaptive mechanisms | #1006 |
| uptake kinetics | #1008 |
| flunitrazepam | #1008 |
| soluble guanylyl | #1008 |
| cerebro | #1009 |
| rifaximin | #1009 |
| metabolic consequences | #1010 |
| rat brain | #1012 |
| neurotoxic | #1013 |
| progressing | #1013 |
| presymptomatic | #1015 |
| modulatory | #1015 |
| fulminant hepatic | #1016 |
| electrified | #1016 |
| publication amino acids | #1017 |
| ligands receptors | #1019 |
| animal models | #1020 |
| unsuspected | #1020 |
| abundant evidence | #1020 |
| acids bcaa | #1023 |
| 1h | #1023 |
| pallidus humans | #1024 |
| antioxidant anti | #1029 |
| astrocyte | #1030 |
| metabolism inborn | #1031 |
| microsomes | #1032 |
| tele | #1032 |
| etanercept treatment | #1034 |
| 7 hours | #1036 |
| muscle expression | #1038 |
| catalepsy | #1039 |
| interleukin1beta | #1041 |
| nutritional assessment | #1043 |
| monoamine oxidase | #1045 |
| pharmacology | #1048 |
| gabaergic | #1050 |
| aqp4 | #1050 |
| acid decarboxylase | #1050 |
| caudate nucleus | #1053 |
| major factor | #1053 |
| endogenous | #1055 |
| aquaporin 4 | #1056 |
| hepatolenticular | #1057 |
| specific antagonist | #1057 |
| synthetase | #1058 |
| involved pathogenesis | #1058 |
| adaptive mechanism | #1060 |
| frontoparietal cortex | #1060 |
| oxygenase1 | #1064 |
| gabaa receptors | #1066 |
| 5ht neurons | #1067 |
| progression liver | #1067 |
| sodium acetate | #1072 |
| efficacy treatment | #1075 |
| rat hepatocytes | #1075 |
| membrane preparations | #1077 |
| reflex | #1077 |
| inflammation infection | #1078 |
| glucose blotting | #1080 |
| accompanies | #1081 |
| gilles | #1083 |
| enzyme activities | #1083 |
| 34dihydroxyphenylacetic acid | #1085 |
| nonneuronal | #1086 |
| content increased | #1090 |
| lactate concentrations | #1092 |
| complex carbohydrates | #1092 |
| major players | #1095 |
| muscle brain | #1097 |
| radioligand assay | #1098 |
| awaiting | #1099 |
| intense staining | #1099 |
| rat primary | #1101 |
| baptaam | #1102 |
| normal physiological conditions | #1106 |
| tpp | #1107 |
| cell culture studies | #1107 |
| junction protein | #1108 |
| medial septum | #1109 |
| 5 mm | #1111 |
| hyperintensity | #1111 |
| assay receptors | #1113 |
| human brain tissue | #1116 |
| inflammation role | #1117 |
| patients alzheimers disease | #1117 |
| cirrhotics | #1118 |
| severe malnutrition | #1122 |
| atrophy brain | #1122 |
| ischemic core | #1127 |
| sprague | #1128 |
| findings role | #1129 |
| cirrhosis male | #1129 |
| astrocytes | #1130 |
| transient elevation | #1131 |
| amino acids | #1134 |
| tetrabenazine | #1135 |
| weight brain | #1137 |
| age controls | #1138 |
| diagonal band | #1139 |
| haloperidol humans | #1142 |
| oxide synthase | #1143 |
| receptors histamine | #1145 |
| hepatobiliary | #1146 |
| pyruvate | #1148 |
| worsens | #1153 |
| nonepileptic | #1153 |
| lactic acidosis | #1153 |
| dehydroepiandrosterone sulfate | #1154 |
| control tissue | #1157 |
| altered brain | #1162 |
| biogenic amines | #1163 |
| cresyl | #1166 |
| portosystemic | #1167 |
| h1 | #1168 |
| benzilate | #1171 |
| combustion products | #1172 |
| emax | #1173 |
| enzymologic | #1174 |
| lactate | #1177 |
| etanercept | #1179 |
| rats subjected | #1180 |
| parkinsonian symptoms | #1181 |
| peripheral tissues | #1182 |
| glutamate dehydrogenase | #1182 |
| nerve conduction | #1183 |
| rats receptors | #1185 |
| nnos | #1185 |
| urine levels | #1186 |
| principally | #1189 |
| mechanisms involved | #1191 |
| cardinal features | #1192 |
| synaptic cleft | #1192 |
| hyperintensities | #1193 |
| delta opioid | #1196 |
| causal factor | #1197 |
| rapid onset | #1198 |
| gabaa receptor | #1199 |
| transcriptase polymerase | #1201 |
| venous blood | #1204 |
| dawley | #1205 |
| dopamine uptake | #1205 |
| death cells | #1207 |
| acetyl cysteine | #1207 |
| hepatolenticular degeneration | #1209 |
| development brain | #1211 |
| increasing body | #1214 |
| direct effects | #1216 |
| stereotypy | #1218 |
| radiometric | #1220 |
| brains mice | #1220 |
| binding inhibitor | #1220 |
| pig model | #1221 |
| 5htp | #1222 |
| nmethyld | #1223 |
| fold increase | #1224 |
| neuropsychological impairment | #1226 |
| skeletal rats rats | #1226 |
| mitochondrial swelling | #1228 |
| transjugular | #1229 |
| deprenyl | #1229 |
| wilson disease | #1229 |
| 100 iu | #1232 |
| cultured rat | #1234 |
| severity assessment | #1234 |
| circadian rhythmicity | #1234 |
| hippocampus vitro | #1236 |
| hyperexcitability | #1239 |
| spraguedawley receptors opioid | #1239 |
| nakatpase activity | #1239 |
| congenitally | #1241 |
| glyceraldehyde3 | #1242 |
| hypermetabolism | #1242 |
| brain axis | #1246 |
| partial recovery | #1251 |
| elucidation | #1252 |
| kinetics male | #1253 |
| receptors neurotransmitter | #1254 |
| sprague dawley | #1255 |
| convincing evidence | #1258 |
| methyl aspartate | #1259 |
| gabaa | #1260 |
| albumen | #1261 |
| 5hydroxyindoleacetic acid | #1261 |
| hippocampus striatum | #1262 |
| clinical entities | #1262 |
| acetylcysteine | #1262 |
| myoinositol | #1264 |
| overactivation | #1270 |
| astroglial | #1271 |
| 1h 13c | #1271 |
| olfactory bulbs | #1273 |
| rats expression | #1276 |
| maleate | #1276 |
| milligram | #1281 |
| congenital | #1281 |
| apoenzyme | #1281 |
| vicious | #1281 |
| variable degree | #1282 |
| glutamate decarboxylase | #1287 |
| patients tle | #1288 |
| loss expression | #1288 |
| induced inhibition | #1289 |
| brain inflammation | #1290 |
| metabolite | #1291 |
| acid male | #1291 |
| acid cycle | #1291 |
| cortex kidney | #1292 |
| quisqualate | #1294 |
| ischemia cerebral | #1295 |
| radioreceptor | #1296 |
| rifamycins | #1296 |
| dawley animals | #1297 |
| deficient | #1297 |
| protective | #1297 |
| zinc concentrations | #1300 |
| permeability blood | #1301 |
| synaptosomes | #1302 |
| potential therapeutic approach | #1305 |
| frontoparietal | #1306 |
| opioid delta | #1308 |
| 7 males | #1308 |
| caveolin1 | #1310 |
| neuronal dysfunction | #1310 |
| 5mm | #1314 |
| liver | #1314 |
| heme oxygenase1 | #1316 |
| greater magnitude | #1317 |
| adrenals | #1318 |
| 35°c | #1319 |
| threefold | #1320 |
| receptors methyl | #1321 |
| invariably | #1324 |
| neurotransmission | #1325 |
| nanomolar | #1328 |
| dopamine serotonin | #1328 |
| guanylyl | #1329 |
| appearance | #1329 |
| animal electrophoresis | #1334 |
| major complication | #1334 |
| signaling mechanisms | #1335 |
| acetyltransferase | #1337 |
| cerebellum hippocampus | #1344 |
| phosphate dehydrogenase | #1344 |
| astrocytes cells | #1346 |
| cgmp pathway | #1349 |
| heavy drinkers | #1350 |
| transporter proteins | #1352 |
| brain effects | #1358 |
| neuronal | #1361 |
| dopamine female | #1361 |
| interleukin1 receptors | #1364 |
| female globus | #1364 |
| shunt tips | #1368 |
| male rats rats | #1369 |
| hypoglycaemic | #1375 |
| small decrease | #1378 |
| fur | #1380 |
| electrolyte balance | #1381 |
| aromatic amino | #1383 |
| bile duct ligation | #1386 |
| chelation therapy | #1387 |
| synergism | #1387 |
| nitrated | #1388 |
| gaba agonists | #1389 |
| ca2independent | #1392 |
| preliminary studies | #1394 |
| neurological sequelae | #1395 |
| transamination | #1396 |
| occipital cortex | #1401 |
| intrauterine growth | #1402 |
| immediateearly genes | #1403 |
| pallidus | #1409 |
| guanylate | #1409 |
| larginine | #1412 |
| selectively | #1416 |
| cerebral | #1417 |
| patients findings | #1425 |
| paper details | #1426 |
| normo | #1427 |
| mutant strains | #1429 |
| acute brain | #1433 |
| motor nerve | #1441 |
| paralleled | #1444 |
| shamoperated | #1445 |
| childpugh score | #1450 |
| common approaches | #1450 |
| mitochondrial membranes | #1451 |
| risk falls | #1451 |
| peripheral | #1452 |
| longer wavelength | #1453 |
| hypoglycaemia | #1455 |
| effective prevention | #1456 |
| intraventricular injections | #1456 |
| benzodiazepinones | #1459 |
| clonazepam | #1460 |
| modulatory effects | #1462 |
| hydroxydopamines | #1465 |
| studies brain | #1471 |
| quinuclidinyl | #1472 |
| swelling | #1477 |
| brain tissues | #1479 |
| patients liver disease | #1481 |
| saturable | #1482 |
| 13c | #1485 |
| 23390 | #1485 |
| deficiency | #1486 |
| characteristic | #1488 |
| excitatory neurotransmission | #1488 |
| gfap | #1491 |
| dopamine agents | #1499 |
| messenger rats rats | #1504 |
| neuroprotective role | #1505 |
| primary concern | #1509 |
| bilirubin levels | #1509 |
| histological studies | #1509 |
| volume regulation | #1512 |
| increases | #1512 |
| cortex striatum | #1513 |
| primary biliary cirrhosis | #1514 |
| receptor subunits | #1515 |
| herniation | #1516 |
| liver disease | #1519 |
| rat cerebral cortex | #1519 |
| 1h magnetic | #1523 |
| glutamic acid decarboxylase | #1525 |
| integrity | #1525 |
| tyrosine residues | #1527 |
| branched | #1530 |
| tk | #1532 |
| temporal profile | #1539 |
| increased capacity | #1541 |
| transport animals | #1546 |
| brain homogenates | #1547 |
| acetylcarnitine | #1548 |
| apomorphine | #1548 |
| cholinergic | #1549 |
| vitamins minerals | #1550 |
| tricarboxylic acid | #1551 |
| wistar receptors rats | #1552 |
| lactulose | #1554 |
| pathological hallmark | #1557 |
| regional differences | #1557 |
| neurochemical | #1559 |
| lactate levels | #1561 |
| cirrhosis liver | #1564 |
| reflexes | #1566 |
| pathological mechanisms | #1567 |
| extracellular | #1568 |
| neurotransmitters | #1572 |
| poor diet | #1575 |
| major forms | #1579 |
| brain cerebral | #1580 |
| biliary cirrhosis | #1584 |
| scad | #1584 |
| light energy | #1584 |
| tryptophan | #1585 |
| epilepsy tle | #1585 |
| brain cell | #1586 |
| patients review | #1589 |
| ependymal cells | #1591 |
| ngnitrolarginine methyl ester | #1592 |
| new findings | #1594 |
| lesser extent | #1595 |
| pyruvate carboxylase | #1596 |
| aspartate nmda | #1598 |
| llysine | #1600 |
| pbc | #1601 |
| rat hippocampus | #1602 |
| mri signal | #1605 |
| brain slices | #1606 |
| specific therapies | #1606 |
| tdp | #1615 |
| ouabain | #1615 |
| travelled | #1618 |
| unanesthetized | #1623 |
| anastomosis | #1626 |
| acute mice | #1627 |
| neuroglia neurons | #1629 |
| deficient diet | #1631 |
| failure mechanisms | #1633 |
| receptor human | #1635 |
| prevents | #1637 |
| zinc copper | #1640 |
| cerebellar | #1641 |
| tritium | #1642 |
| dorsal raphe nucleus | #1646 |
| regulation animals | #1647 |
| male membrane glycoproteins | #1648 |
| died | #1650 |
| animals cerebral | #1651 |
| experimental treatment | #1651 |
| brain endothelial | #1652 |
| neuromodulatory | #1653 |
| synthase nitric | #1653 |
| amino acid transport | #1654 |
| distribution animals | #1657 |
| glutamate receptors | #1657 |
| fourfold | #1658 |
| extracellular space | #1660 |
| excitotoxicity | #1661 |
| bbb disruption | #1664 |
| rapid accumulation | #1664 |
| gapdh | #1667 |
| striking similarities | #1667 |
| supporting cells | #1669 |
| autoradiography | #1673 |
| previous findings | #1674 |
| synthetase activity | #1675 |
| messenger | #1677 |
| veratrum | #1688 |
| brain area | #1691 |
| dehydrogenase deficiency | #1694 |
| diseases metabolic | #1696 |
| glycogen metabolism | #1701 |
| brainstem | #1704 |
| postulated | #1708 |
| midbrain | #1708 |
| thp | #1710 |
| accumulate | #1716 |
| fulminant hepatic failure | #1723 |
| ibotenic | #1723 |
| dizocilpine | #1724 |
| inborn | #1724 |
| polyclonal antibody | #1725 |
| benzodiazepines | #1726 |
| phenomenon | #1726 |
| il1beta | #1733 |
| alternative mechanism | #1734 |
| carnitine | #1735 |
| animals arginine | #1735 |
| cumene hydroperoxide | #1737 |
| noninvasive techniques | #1737 |
| disorders nervous | #1739 |
| decarboxylase | #1750 |
| normalization | #1756 |
| alternative hypothesis | #1757 |
| liver disease patients | #1757 |
| magna | #1759 |
| consequent | #1760 |
| tricarboxylic acid cycle | #1761 |
| shunts | #1762 |
| c57bl6 | #1762 |
| spiperone | #1763 |
| metabolism glucose | #1769 |
| allosteric | #1770 |
| intrahepatic portosystemic | #1770 |
| critical appraisal | #1773 |
| betaamyloid | #1781 |
| granule neurons | #1785 |
| acetaminophen induced | #1788 |
| muscarinic | #1789 |
| cell damage | #1790 |
| brain damage | #1791 |
| rats spraguedawley receptors | #1791 |
| adult rat brain | #1794 |
| normothermia | #1794 |
| body temperature | #1794 |
| glucose utilization | #1797 |
| common complication | #1799 |
| nmr study | #1802 |
| ampa receptors | #1806 |
| superfusion | #1810 |
| preliminary investigation | #1812 |
| primary metabolism | #1813 |
| nutritional supplements | #1815 |
| major organs | #1815 |
| coa dehydrogenase | #1815 |
| endorphin | #1817 |
| pyruvic | #1822 |
| oxazepam | #1822 |
| rat | #1829 |
| hypertension intracranial | #1832 |
| dorsal raphe | #1833 |
| hippocampal ca1 | #1834 |
| hepatic failure | #1835 |
| vmax values | #1836 |
| major roles | #1837 |
| bdl | #1839 |
| mild | #1840 |
| reuptake | #1843 |
| neurological deterioration | #1844 |
| compared controls | #1845 |
| granule cells | #1846 |
| metalloproteinase9 | #1847 |
| γaminobutyric acid | #1849 |
| toxins | #1850 |
| regulatory processes | #1854 |
| capillary gas chromatography | #1856 |
| chronic alcohol | #1857 |
| ammonium compounds | #1857 |
| monoaminergic | #1862 |
| cirrhotic rats | #1863 |
| liver transplantation patients | #1865 |
| body water | #1865 |
| caudate | #1868 |
| cholinergic neurons | #1872 |
| stroke outcome | #1876 |
| immunoreactivities | #1877 |
| lactate production | #1877 |
| platelets patients | #1882 |
| glutamate release | #1886 |
| disorder treatment | #1886 |
| neurotoxicity syndromes | #1886 |
| beta endorphin | #1892 |
| acute | #1900 |
| locomotor activity | #1902 |
| hepatoprotective | #1903 |
| common feature | #1904 |
| induced liver | #1906 |
| atp adp | #1913 |
| induced rats | #1917 |
| cirrhosis biliary | #1919 |
| penicillamine | #1920 |
| stereotyped | #1920 |
| colorimetric assay | #1921 |
| rodent models | #1923 |
| patients cirrhosis | #1923 |
| grossly | #1925 |
| dipeptides | #1930 |
| behavioral abnormalities | #1932 |
| precipitated | #1934 |
| tspo | #1935 |
| nitration | #1937 |
| areas brain | #1941 |
| patients aids | #1944 |
| neurocognitive impairment | #1945 |
| major metabolite | #1952 |
| major site | #1957 |
| synthase | #1958 |
| dpat | #1961 |
| concomitant | #1962 |
| normal dogs | #1965 |
| cerebral metabolism | #1965 |
| acid transporters | #1966 |
| acid synthesis | #1966 |
| spectroscopy male | #1968 |
| manganese superoxide dismutase | #1970 |
| nmethyldaspartate receptors | #1977 |
| druginduced liver injury | #1977 |
| globus | #1977 |
| 5hydroxytryptamine | #1977 |
| 28 weeks | #1981 |
| mice compared | #1981 |
| degeneration humans | #1986 |
| potassium exchanging | #1987 |
| erk1 | #1990 |
| cognitive dysfunction | #1991 |
| neurologic symptoms | #1991 |
| duct ligation | #1991 |
| idazoxan | #1993 |
| ideal model | #1994 |
| oxotremorine | #1994 |
| 5 ht | #1996 |
| recirculating | #1997 |
| primary biliary | #2000 |
| radioligand | #2001 |
| 2fold increase | #2006 |
| mk801 | #2007 |
| ampa receptor | #2015 |
| heterogeneously | #2017 |
| cerebellar cortex | #2019 |
| overactivity | #2020 |
| injury mice | #2022 |
| arterio | #2023 |
| pet imaging | #2028 |
| glucose brain | #2034 |
| sham rats | #2036 |
| aminoacids | #2036 |
| neurologic complications | #2036 |
| microdialysis | #2036 |
| sham | #2040 |
| osmolytes | #2041 |
| peroneal nerve | #2041 |
| exchanging atpase | #2043 |
| resonance nmr | #2043 |
| cyclase | #2046 |
| cerebri | #2046 |
| pathogenetic mechanisms | #2047 |
| passive diffusion | #2050 |
| suggested | #2053 |
| groups iii | #2063 |
| decreased activity | #2064 |
| tracings | #2064 |
| 10 12 | #2068 |
| dawley rats | #2069 |
| convulsants | #2071 |
| stage liver | #2072 |
| vivo brain | #2074 |
| elucidated | #2077 |
| tumor necrosis factoralpha | #2079 |
| penumbra | #2080 |
| biochemical parameters | #2082 |
| deficit | #2084 |
| acetates | #2087 |
| transjugular intrahepatic | #2089 |
| trace amounts | #2090 |
| international society | #2094 |
| autopsy | #2098 |
| ensuing | #2103 |
| zo1 | #2106 |
| solely | #2108 |
| atrophies | #2109 |
| p0018 | #2111 |
| nitric oxide synthesis | #2117 |
| portal pressure | #2117 |
| chp | #2121 |
| parallel | #2121 |
| synthase type | #2125 |
| neurological manifestations | #2141 |
| ligase | #2142 |
| synergistically | #2143 |
| exception | #2143 |
| brain barrier | #2148 |
| subsequent degradation | #2149 |
| indicative | #2150 |
| rats spraguedawley | #2158 |
| bmax | #2158 |
| time onset | #2158 |
| intracranial pressure | #2167 |
| amnestic | #2169 |
| male rat | #2170 |
| muscimol | #2173 |
| acute effects | #2178 |
| human patients | #2179 |
| neural inhibition | #2180 |
| gaa | #2180 |
| reactive nitrogen | #2187 |
| subchronic | #2189 |
| apap | #2194 |
| blood csf | #2194 |
| increasing recognition | #2200 |
| cox2 | #2203 |
| overt | #2205 |
| parkinsonism | #2209 |
| methysergide | #2212 |
| pressure icp | #2217 |
| homovanillic acid | #2217 |
| vitamin supplements | #2220 |
| nitroarginine methyl | #2223 |
| hypothermic | #2223 |
| brain cells | #2225 |
| function brain | #2230 |
| antiparkinson | #2232 |
| liver enzymes | #2238 |
| minocycline | #2242 |
| pss | #2244 |
| chelators | #2245 |
| neurological disorders | #2248 |
| humans liver | #2249 |
| diminution | #2262 |
| liver circulation | #2265 |
| blood brain | #2265 |
| symporters | #2265 |
| doubt | #2267 |
| nutritional deficiencies | #2268 |
| messenger systems | #2271 |
| gliosis | #2279 |
| behavior rats | #2280 |
| additional factors | #2297 |
| synaptic vesicles | #2297 |
| rats liver | #2299 |
| phosphate | #2300 |
| eeg activity | #2302 |
| acrylamides | #2303 |
| patients minimal | #2304 |
| isoxazolepropionic | #2307 |
| immunoreactive neurons | #2308 |
| superoxide dismutase | #2314 |
| tle | #2315 |
| memantine | #2320 |
| multiorgan failure | #2322 |
| cortex hippocampus | #2325 |
| brain expression | #2326 |
| cultured cerebral | #2327 |
| primary cultures | #2328 |
| systemic inflammatory response | #2328 |
| male nerve | #2330 |
| blindly | #2333 |
| hrqol patients | #2334 |
| housekeeping | #2336 |
| relative increase | #2338 |
| acidosis | #2338 |
| convincing | #2340 |
| scatchard | #2349 |
| lactates | #2359 |
| ligands | #2360 |
| binding assays | #2360 |
| olivary | #2362 |
| benzoic | #2364 |
| inbred strains | #2366 |
| patients increased | #2373 |
| endstage liver disease | #2376 |
| voluntary | #2377 |
| synaptic dysfunction | #2377 |
| competitive inhibitor | #2380 |
| clinical condition | #2391 |
| mental fatigue | #2392 |
| deficiencies | #2392 |
| potential adverse effects | #2393 |
| exchanging | #2401 |
| brains patients | #2401 |
| neurotoxin | #2406 |
| homovanillic | #2416 |
| lnmma | #2430 |
| induced brain | #2432 |
| protein mrna | #2433 |
| transporter 2 | #2443 |
| calcium binding | #2449 |
| cerebral metabolic | #2467 |
| extracellular levels | #2471 |
| 01 mm | #2473 |
| histamine receptor | #2483 |
| fluorescence detection | #2489 |
| peripheral inflammation | #2490 |
| adult male rats | #2491 |
| bbb | #2498 |
| receptors ampa | #2502 |
| synaptic function | #2508 |
| pathogenic role | #2509 |
| count cell | #2510 |
| effects alcohol | #2511 |
| pyridinium | #2513 |
| animal model | #2513 |
| activation microglia | #2514 |
| noxious stimuli | #2518 |
| hypotonia | #2524 |
| vmax | #2529 |
| 5ht | #2530 |
| physical conditioning | #2532 |
| dopac | #2534 |
| nuclear magnetic | #2534 |
| metabolic acidosis | #2541 |
| expression endothelial | #2563 |
| alcohol induced | #2566 |
| male matrix | #2571 |
| fmol | #2572 |
| understanding pathophysiology | #2573 |
| humans ligands | #2573 |
| alpha1 | #2577 |
| receptor density | #2577 |
| ataxias | #2577 |
| vessel walls | #2581 |
| postmortem brain | #2588 |
| microglia neurons | #2591 |
| mao | #2594 |
| multiple mechanisms | #2597 |
| acetylcholinesterase | #2598 |
| cerebrospinal | #2601 |
| groups subjects | #2608 |
| il1β il6 | #2619 |
| possibility | #2621 |
| 10 microm | #2621 |
| cognitive motor | #2623 |
| 15–30 | #2625 |
| greater extent | #2626 |
| methylaspartate | #2630 |
| normalisation | #2632 |
| nitrosation | #2635 |
| biochemical evidence | #2639 |
| deteriorating | #2640 |
| circulating concentrations | #2640 |
| day treatment | #2647 |
| activity rats | #2661 |
| transcriptase | #2663 |
| thalamic | #2663 |
| chc | #2665 |
| nitric | #2665 |
| katpase | #2665 |
| binding competitive | #2668 |
| olfactory bulb | #2669 |
| glutathione levels | #2669 |
| osmolar | #2683 |
| patients alcoholic | #2684 |
| guanylyl cyclase | #2685 |
| glial cell | #2686 |
| serotonin 5 | #2689 |
| effects ethanol | #2695 |
| indwelling | #2704 |
| rats control | #2705 |
| nerve terminals | #2705 |
| laboratory findings | #2710 |
| groups animals | #2715 |
| lactic | #2723 |
| situ nickend | #2733 |
| publication animals behavior | #2737 |
| frontal lobe | #2742 |
| hemodiafiltration | #2755 |
| suggests | #2760 |
| glutaminase | #2764 |
| functional integrity | #2767 |
| regions | #2769 |
| 6hydroxydopamine | #2771 |
| neurons animals | #2774 |
| kindred | #2775 |
| turnover rate | #2779 |
| leucine | #2779 |
| 24h | #2786 |
| systemic circulation | #2789 |
| glutamate receptor | #2789 |
| animal rats | #2790 |
| rhythmicity | #2798 |
| amino acid | #2798 |
| severity patients | #2806 |
| osmolar concentration | #2813 |
| inbred strains mice | #2814 |
| pontine | #2817 |
| exposed | #2821 |
| mechanisms | #2824 |
| hydroxy5 | #2826 |
| microglial cells | #2827 |
| p38mapk | #2831 |
| gastrointestinal agents | #2833 |
| regulation enzymologic | #2834 |
| neurological deficit | #2834 |
| minneapolis | #2835 |
| blood brain barrier | #2841 |
| brain calcium | #2847 |
| marked decrease | #2867 |
| bilirubin | #2876 |
| twofold increase | #2877 |
| amino | #2882 |
| alcoholic fatty | #2882 |
| nerve cells | #2883 |
| alanine | #2885 |
| synaptic | #2888 |
| diabetic animals | #2890 |
| ca2dependent | #2893 |
| pet study | #2897 |
| mmt | #2898 |
| trafficking | #2901 |
| kainate | #2903 |
| slices | #2905 |
| rigidity | #2905 |
| standpoint | #2906 |
| ameliorating | #2910 |
| confirming | #2918 |
| clinical syndrome | #2931 |
| cell volume | #2936 |
| normal control | #2938 |
| dying | #2938 |
| normal animals | #2939 |
| subfield | #2943 |
| translocator | #2943 |
| 12 weeks treatment | #2944 |
| receptors opioid | #2962 |
| impaired | #2964 |
| 11c | #2965 |
| assist devices | #2970 |
| astrocytes cell | #2971 |
| brain uptake | #2974 |
| unaffected | #2982 |
| inflammation liver | #2982 |
| pyruvic acid | #3000 |
| excitatory synapses | #3000 |
| intermediary | #3008 |
| normal values | #3015 |
| aquaporin | #3036 |
| uptake | #3039 |
| kainic | #3043 |
| barrier brain | #3047 |
| cox2 expression | #3051 |
| incubation medium | #3051 |
| ca1 pyramidal | #3053 |
| biliary obstruction | #3054 |
| weighted magnetic | #3069 |
| concert | #3073 |
| tmp | #3076 |
| portosystemic shunt | #3078 |
| metabolite concentrations | #3078 |
| harmful effects | #3082 |
| attenuation | #3083 |
| selegiline | #3086 |
| activated microglia | #3088 |
| reserpine | #3093 |
| liver injury | #3095 |
| cd1 | #3099 |
| catecholaminergic | #3109 |
| atp levels | #3111 |
| adult rats | #3113 |
| renal vein | #3115 |
| valine | #3133 |
| short halflife | #3136 |
| toxic effects | #3137 |
| relative roles | #3149 |
| decreased | #3156 |
| myo inositol | #3161 |
| higher doses | #3168 |
| animals binding | #3169 |
| dhea | #3171 |
| nmda | #3172 |
| loss | #3180 |
| carboxamide | #3189 |
| failure | #3192 |
| endorphins | #3192 |
| relation | #3194 |
| abruptly | #3195 |
| radical scavengers | #3198 |
| bcaa | #3199 |
| inhalation | #3199 |
| mental retardation | #3201 |
| enzymologic genes | #3209 |
| clinical presentations | #3210 |
| ketanserin | #3214 |
| liver function | #3214 |
| heavy drinking | #3218 |
| coenzymes | #3220 |
| noradrenaline | #3224 |
| imidodiphosphate | #3226 |
| active transport | #3232 |
| portal | #3235 |
| shortchain fatty acids | #3238 |
| gad | #3238 |
| acidic | #3243 |
| synaptic membranes | #3244 |
| pyrophosphate | #3248 |
| induced hepatic | #3252 |
| treated rats | #3256 |
| nitrogen species | #3267 |
| systemic | #3276 |
| oxidative metabolism | #3281 |
| respects | #3285 |
| induced seizures | #3287 |
| synaptosomal | #3291 |
| drug repositioning | #3296 |
| behavioral symptoms | #3300 |
| water electrolyte | #3306 |
| kcl | #3307 |
| cell death | #3311 |
| metabolic alterations | #3324 |
| anterolateral | #3326 |
| reverse | #3327 |
| metabolized | #3331 |
| nanomolar concentrations | #3335 |
| sedatives | #3342 |
| general circulation | #3344 |
| nac | #3347 |
| dab | #3352 |
| regionally | #3359 |
| rats received | #3359 |
| benzoates | #3360 |
| membrane transport | #3361 |
| dosedependent fashion | #3364 |
| aspartate receptors | #3366 |
| rats inbred | #3368 |
| subsequent studies | #3371 |
| phenylalanine | #3384 |
| opioid | #3388 |
| cerebral ischemia | #3388 |
| inbred strains receptors | #3389 |
| cortex | #3391 |
| robust evidence | #3394 |
| hydroxytryptamine | #3402 |
| tyrphostins | #3403 |
| galactosamine | #3404 |
| brain disease | #3407 |
| brain lesions | #3412 |
| falls | #3421 |
| disturbances | #3421 |
| progressive increase | #3423 |
| histamine | #3423 |
| ldopa | #3426 |
| quaternary ammonium | #3427 |
| morphologic | #3428 |
| transaminases | #3432 |
| gln | #3436 |
| decreased levels | #3437 |
| modulation | #3439 |
| levels liver | #3443 |
| indole3 | #3446 |
| superior colliculus | #3451 |
| epilepsy temporal | #3453 |
| toxic | #3455 |
| strains mice | #3456 |
| biogenic | #3458 |
| accumulates | #3462 |
| timecourse | #3467 |
| phosphocreatine | #3473 |
| rats rats | #3474 |
| indomethacin | #3480 |
| striatum | #3482 |
| developing rat | #3485 |
| upregulation | #3491 |
| glycine | #3492 |
| brain stem | #3495 |
| liver male | #3497 |
| subcortical structures | #3497 |
| electrochemical detection | #3499 |
| new evidence | #3499 |
| basal ganglia | #3500 |
| lobe epilepsy | #3503 |
| rat models | #3503 |
| previous observations | #3507 |
| aids patients | #3511 |
| huntington | #3515 |
| dehydroepiandrosterone | #3537 |
| aging brain | #3542 |
| rats treatment | #3545 |
| neurons oxidative | #3545 |
| kidney liver | #3555 |
| tyramine | #3558 |
| fold | #3563 |
| cytokines disease | #3576 |
| nerve degeneration | #3584 |
| portal vein | #3600 |
| tissue distribution | #3600 |
| inferior vena cava | #3600 |
| brain structure | #3613 |
| antioxidant properties | #3627 |
| truncated 250 | #3627 |
| pathology | #3635 |
| cofactor | #3636 |
| prolonged exposure | #3636 |
| hypertonic saline | #3638 |
| disease states | #3648 |
| implication | #3650 |
| increased activity | #3655 |
| hydroxydopamine | #3657 |
| precipitating | #3664 |
| ache | #3664 |
| fatty liver | #3666 |
| investigator | #3675 |
| circadian rhythms | #3680 |
| scavengers | #3682 |
| lobe | #3694 |
| splanchnic | #3699 |
| regional variation | #3700 |
| arginine | #3718 |
| proinflammatory cytokine | #3722 |
| new model | #3723 |
| medial | #3735 |
| thioacetamide | #3741 |
| cassette transporters | #3742 |
| treated animals | #3746 |
| induced neurotoxicity | #3751 |
| stress rats | #3755 |
| normal mice | #3758 |
| consensus statement | #3765 |
| dopamine d1 | #3773 |
| 4 wk | #3786 |
| 1968 | #3791 |
| parietal lobe | #3793 |
| acetylcholinesterase ache | #3799 |
| dietary protein | #3801 |
| mitochondrion | #3807 |
| finding | #3814 |
| major | #3815 |
| diazepam | #3825 |
| control animals | #3825 |
| neural cell | #3825 |
| resemble | #3833 |
| western blot analyses | #3838 |
| inborn errors | #3846 |
| systemically | #3846 |
| prefrontal | #3857 |
| effects chronic | #3872 |
| nmr spectroscopy | #3879 |
| malabsorption | #3896 |
| type nitric | #3897 |
| dopamine d1 receptors | #3899 |
| dopa | #3907 |
| enhanced production | #3909 |
| metabolic pathway | #3911 |
| elucidate | #3914 |
| levels measured | #3915 |
| new therapeutic approaches | #3919 |
| nitric oxide production | #3919 |
| tone | #3924 |
| pindolol | #3929 |
| peripheral neuropathy | #3937 |
| ascorbate | #3942 |
| reabsorption | #3949 |
| csf | #3949 |
| medulla | #3949 |
| wet weight | #3951 |
| tourette | #3975 |
| neuropsychiatric disorders | #3978 |
| purkinje cells | #3983 |
| antiinflammatory | #3987 |
| fatigue | #3992 |
| complication | #3992 |
| tca cycle | #4003 |
| pseudotumor | #4006 |
| brain activation | #4009 |
| day 5 | #4011 |
| treatment prevention | #4021 |
| transporter | #4026 |
| elevated blood | #4053 |
| nmda receptors | #4053 |
| bz | #4054 |
| strains receptors | #4069 |
| neurotoxicity | #4070 |
| fischer | #4082 |
| cultured neurons | #4097 |
| remove | #4101 |
| gastrointestinal bleeding | #4103 |
| involve | #4104 |
| nonalcoholic | #4111 |
| intracranial | #4134 |
| coa | #4138 |
| visible spectrum | #4140 |
| induced mitochondrial | #4149 |
| exacerbate | #4165 |
| lower affinity | #4172 |
| motor activity | #4178 |
| future clinical trials | #4178 |
| reverse transcriptase | #4185 |
| nitroso | #4190 |
| nuclear magnetic resonance | #4193 |
| oxide production | #4198 |
| ampa | #4204 |
| endothelial nitric | #4205 |
| liver cirrhosis | #4232 |
| steadystate levels | #4244 |
| knockout receptors | #4249 |
| enkephalins | #4276 |
| tips | #4318 |
| isoenzymes | #4321 |
| pathogenetic | #4326 |
| contention | #4326 |
| 3h | #4342 |
| oxidase inhibitors | #4346 |
| female frontal | #4355 |
| alcohol abuse | #4357 |
| matched | #4358 |
| chelator | #4359 |
| vitro model | #4364 |
| groups rats | #4365 |
| chorea | #4373 |
| acids | #4373 |
| geniculate | #4374 |
| prevention | #4375 |
| ratelimiting enzyme | #4382 |
| neocortical | #4398 |
| rtpcr | #4402 |
| mrna expression | #4418 |
| enos | #4425 |
| hepatic artery | #4425 |
| immunohistochemical analysis | #4428 |
| peripherally | #4430 |
| postnatally | #4433 |
| 10 micrograms | #4438 |
| carbon isotopes | #4449 |
| specific activities | #4449 |
| acid amino | #4455 |
| inos | #4460 |
| tetrahydrobiopterin | #4480 |
| diencephalon | #4481 |
| citric | #4487 |
| agents steroidal | #4499 |
| isoleucine | #4507 |
| chemical drug | #4509 |
| incompletely | #4517 |
| hippocampal neurons | #4518 |
| endogenously | #4521 |
| potent inhibitor | #4528 |
| pglycoprotein | #4535 |
| tissue concentrations | #4552 |
| model chronic | #4561 |
| gssg | #4562 |
| animal studies | #4562 |
| mitochondrial dysfunction | #4575 |
| substantia nigra | #4577 |
| neurological function | #4585 |
| explanation | #4600 |
| acetaminophen | #4606 |
| transaminase | #4608 |
| 250 | #4627 |
| small increase | #4629 |
| liver diseases | #4637 |
| mrna | #4639 |
| narcotic | #4643 |
| models neurological | #4666 |
| enzymes | #4671 |
| myo | #4677 |
| dopamine | #4679 |
| choline | #4683 |
| nitrites | #4684 |
| worsening | #4685 |
| tremor | #4694 |
| relate | #4701 |
| ho1 | #4704 |
| diphosphate | #4705 |
| neuronal survival | #4712 |
| develops | #4714 |
| realtime quantitative pcr | #4719 |
| techniques male | #4729 |
| key enzymes | #4730 |
| debilitating | #4732 |
| skeletal muscle | #4736 |
| amines | #4737 |
| receptors tumor | #4740 |
| motor coordination | #4745 |
| neurovascular | #4749 |
| patients liver cirrhosis | #4749 |
| triphosphate | #4752 |
| receptors | #4761 |
| apoptotic cell death | #4774 |
| patients liver | #4775 |
| neuroprotective agents | #4778 |
| mn2 | #4792 |
| male rats | #4793 |
| ulnar | #4795 |
| opioid peptides | #4821 |
| ganglia | #4828 |
| failing | #4835 |
| membrane cells | #4837 |
| liver regeneration | #4853 |
| constellation | #4875 |
| regional cerebral | #4875 |
| nonselective | #4891 |
| opioid receptors | #4901 |
| modulator | #4905 |
| transporters | #4906 |
| tyrosine | #4906 |
| 001 | #4915 |
| animals antioxidants | #4919 |
| injections intraperitoneal | #4921 |
| neurons rats | #4927 |
| glucose humans | #4936 |
| epilepsy humans | #4940 |
| degree | #4943 |
| kainic acid | #4963 |
| evident | #4988 |
| rapid progression | #4996 |
| viral hepatitis | #4998 |
| indazoles | #5000 |
| methyl2 | #5002 |
| clinical conditions | #5004 |
| 25 mm | #5009 |
| ammonium | #5017 |
| acid metabolism | #5018 |
| neurological diseases | #5024 |
| raphe | #5043 |
| consequences | #5048 |
| immunostaining | #5051 |
| weighted mri | #5053 |
| offspring | #5054 |
| tight | #5055 |
| alcoholism | #5063 |
| cyclooxygenase2 | #5066 |
| malnutrition | #5080 |
| metabolism | #5084 |
| suggesting | #5106 |
| endoperoxide | #5129 |
| clinical criteria | #5130 |
| acid | #5133 |
| nitric oxide | #5140 |
| disorder | #5143 |
| sarcopenia | #5163 |
| anticonvulsant | #5164 |
| glial cells | #5213 |
| temporal lobe | #5226 |
| leads | #5232 |
| animals | #5236 |
| portal hypertension | #5238 |
| child pugh | #5266 |
| sustained | #5277 |
| severe | #5277 |
| normal rats | #5278 |
| cerebrum | #5280 |
| organ dysfunction | #5288 |
| cerebrospinal fluid | #5299 |
| animal brain | #5308 |
| restores | #5312 |
| reversal | #5325 |
| methylarginine | #5330 |
| intoxication | #5344 |
| major impact | #5349 |
| 4 groups | #5350 |
| animal humans | #5364 |
| biomarkers brain | #5401 |
| gastroenterology | #5403 |
| experimental model | #5414 |
| superoxide production | #5416 |
| publication animals | #5417 |
| presynaptic | #5426 |
| induced acute | #5434 |
| regional brain | #5435 |
| gastrointestinal diseases | #5444 |
| intracellular levels | #5450 |
| postsynaptic | #5452 |
| concentrations | #5459 |
| food deprivation | #5463 |
| focal | #5466 |
| blotting western | #5466 |
| thioredoxins | #5505 |
| halflife | #5506 |
| aquaporins | #5515 |
| cns | #5517 |
| involving | #5517 |
| effects exposure | #5523 |
| nash | #5525 |
| controls | #5541 |
| catecholamines | #5549 |
| isolated rat | #5552 |
| affinity | #5553 |
| tca | #5564 |
| glucose metabolism | #5569 |
| lack | #5572 |
| higher density | #5575 |
| sleep disturbances | #5580 |
| hyperbilirubinemia | #5586 |
| glucose transport | #5607 |
| n11 | #5608 |
| summarizes | #5611 |
| platelets | #5615 |
| endotoxemia | #5639 |
| major complications | #5645 |
| free radicals | #5647 |
| postnatal development | #5651 |
| magnetic resonance images | #5652 |
| cachexia | #5666 |
| acute ischemic | #5672 |
| drinkers | #5693 |
| antimetabolites | #5699 |
| tnf | #5709 |
| 73 patients | #5711 |
| transport systems | #5712 |
| receptor binding | #5730 |
| 24 hours | #5741 |
| icp | #5768 |
| precipitate | #5790 |
| evidence base | #5790 |
| nonalcoholic steatohepatitis | #5796 |
| dehydrogenases | #5796 |
| p005 | #5800 |
| brain animals | #5810 |
| depolarization | #5812 |
| aspartate receptor | #5824 |
| serotonin | #5840 |
| substances | #5848 |
| prefrontal cortex | #5859 |
| extravasation | #5862 |
| steroidal | #5865 |
| neuroprotective | #5883 |
| levels elevated | #5885 |
| ketone | #5892 |
| western blot analysis | #5897 |
| appropriately | #5900 |
| mounting evidence | #5926 |
| enkephalin | #5928 |
| potentiate | #5945 |
| detoxification | #5949 |
| acrylamide | #5950 |
| disaccharides | #5950 |
| acid antagonists | #5952 |
| 100 microm | #5954 |
| background objectives | #5954 |
| bulb | #5976 |
| metabolites | #5993 |
| muscle mass | #5993 |
| coenzyme | #5994 |
| etiologies | #5997 |
| anterior cingulate cortex | #6016 |
| antagonist | #6019 |
| butyric | #6023 |
| reversible | #6029 |
| aged rats | #6030 |
| sodium potassium | #6068 |
| additional evidence | #6080 |
| transporter 1 | #6103 |
| methyl4 | #6109 |
| zona | #6114 |
| chemistry | #6120 |
| occurs | #6122 |
| barrier | #6138 |
| trh | #6148 |
| postmortem | #6152 |
| cirrhosis patients | #6152 |
| cortical regions | #6162 |
| hippocampus | #6166 |
| hydroperoxide | #6169 |
| deoxyglucose | #6171 |
| risk bias | #6188 |
| inbred | #6199 |
| esters | #6202 |
| proteins rats | #6221 |
| reduction oxidative | #6231 |
| nervous cns | #6235 |
| disruptions | #6250 |
| vascular endothelium | #6265 |
| anti inflammatory | #6284 |
| mitochondrial function | #6287 |
| hematoxylin | #6290 |
| lactate dehydrogenase | #6298 |
| chain | #6315 |
| carboxylase | #6322 |
| alpha2 | #6323 |
| protein expression | #6343 |
| induced increases | #6360 |
| 20 cases | #6371 |
| rna messenger | #6388 |
| dha | #6392 |
| cbf | #6404 |
| gamma | #6412 |
| remained | #6413 |
| chelating agents | #6422 |
| olfactory | #6441 |
| prosencephalon | #6456 |
| snap | #6464 |
| rats animals | #6469 |
| roi | #6470 |
| antagonists | #6475 |
| peripheral nerve | #6478 |
| histidine | #6482 |
| acyltransferases | #6490 |
| patients chronic | #6498 |
| mesencephalon | #6508 |
| notion | #6511 |
| disease brain | #6514 |
| bromocriptine | #6531 |
| ingestion | #6548 |
| ligation | #6552 |
| dopaminergic | #6553 |
| humans kinetics | #6566 |
| control mice | #6572 |
| longterm treatment | #6575 |
| nomenclature | #6576 |
| disease aged | #6579 |
| physiological function | #6586 |
| humans mitochondria | #6594 |
| microg | #6596 |
| oxidase | #6596 |
| led | #6597 |
| accumulation | #6599 |
| fluid csf | #6600 |
| mmol | #6609 |
| animal dose | #6610 |
| glycolytic | #6625 |
| publication analysis | #6642 |
| inducible nitric | #6643 |
| resonance spectroscopy | #6660 |
| glu | #6665 |
| lowers | #6665 |
| animals bile | #6671 |
| slowing | #6682 |
| p001 | #6684 |
| patients placebo | #6688 |
| proceedings | #6700 |
| interferongamma | #6742 |
| differential effects | #6755 |
| poisoning | #6767 |
| granule | #6768 |
| dystonia | #6769 |
| psychometric | #6774 |
| lad | #6783 |
| rats wistar receptors | #6791 |
| biological transport | #6801 |
| specific regions | #6806 |
| transport proteins | #6806 |
| cortices | #6825 |
| nitrates | #6833 |
| inflammatory processes | #6849 |
| n5 | #6849 |
| protects | #6857 |
| receptors dopamine | #6859 |
| tomography emission | #6887 |
| acetaldehyde | #6894 |
| enter | #6908 |
| patients brain | #6909 |
| sleep disorders | #6915 |
| mitochondrial membrane | #6916 |
| nutritional | #6921 |
| hypothalamus | #6930 |
| humans intracranial | #6937 |
| nutrition | #6972 |
| rendered | #6975 |
| cerebral blood flow | #6981 |
| low affinity | #6986 |
| acid levels | #7005 |
| eosin | #7011 |
| vitamins | #7012 |
| ascites | #7020 |
| adenosine triphosphate | #7030 |
| patients alzheimer | #7040 |
| compensatory | #7089 |
| free radical | #7092 |
| rois | #7098 |
| common form | #7109 |
| general agreement | #7117 |
| expression | #7125 |
| prothrombin | #7133 |
| mice treated | #7139 |
| synthases | #7140 |
| 13c nmr | #7146 |
| methyl | #7151 |
| hippocampus male | #7165 |
| methyl ester | #7177 |
| tartrate | #7178 |
| levels blood | #7198 |
| central nervous cns | #7202 |
| protective agents | #7214 |
| catecholamine | #7216 |
| undertaken | #7226 |
| probiotics | #7244 |
| humans inflammation | #7253 |
| systemic inflammation | #7280 |
| antiinflammatory agents | #7284 |
| neurodegeneration | #7290 |
| male sprague | #7307 |
| bile duct | #7311 |
| additional studies | #7322 |
| animal doseresponse relationship | #7334 |
| nh4 | #7336 |
| glucose transporter | #7337 |
| cyclooxygenase 2 | #7344 |
| life hrqol | #7350 |
| administration | #7353 |
| preliminary evidence | #7358 |
| symptomatic | #7371 |
| neuroprotection | #7374 |
| histamine release | #7378 |
| regional | #7382 |
| urea | #7386 |
| hippocampal | #7389 |
| insult | #7392 |
| pyridines | #7404 |
| intravenous infusion | #7420 |
| competitive | #7424 |
| animal | #7433 |
| excitability | #7442 |
| molecular mechanisms | #7448 |
| restored | #7464 |
| spectrophotometric | #7474 |
| osmotic | #7475 |
| biochemical studies | #7481 |
| ht | #7485 |
| excreted | #7507 |
| urease | #7536 |
| organ specificity | #7540 |
| lipid peroxidation | #7550 |
| pathological conditions | #7553 |
| dismutase | #7553 |
| brain ischemia | #7557 |
| implicating | #7564 |
| onset | #7570 |
| cytoprotection | #7580 |
| neuropathic pain | #7583 |
| imaging magnetic | #7585 |
| chromatography mass | #7603 |
| microglia | #7605 |
| matrix metalloproteinase | #7621 |
| mental status | #7630 |
| blood platelets | #7640 |
| characterized | #7659 |
| neuroprotective effects | #7659 |
| deleterious | #7665 |
| neurologic examination | #7672 |
| cortical neurons | #7687 |
| diminished | #7696 |
| specific binding | #7700 |
| guanidines | #7737 |
| perturbations | #7769 |
| alpha tnf | #7777 |
| oxide | #7779 |
| immunoreactivity | #7801 |
| oedema | #7810 |
| il6 levels | #7833 |
| tissue proteins | #7854 |
| tnf α | #7864 |
| animals blotting | #7882 |
| albumins | #7888 |
| m3 | #7897 |
| ca1 | #7899 |
| parietal cortex | #7915 |
| brain development | #7915 |
| freely | #7932 |
| cells brain | #7932 |
| lname | #7950 |
| aspartate aminotransferases | #7961 |
| assayed | #7986 |
| metabolic | #7989 |
| aetiology | #8016 |
| mouse brain | #8023 |
| alzheimer | #8025 |
| liver transplantation | #8033 |
| ka | #8038 |
| constitutes | #8040 |
| computerized | #8040 |
| organometallic compounds | #8052 |
| established | #8056 |
| brain humans | #8073 |
| cerebrovascular circulation | #8079 |
| chelation | #8081 |
| inferior | #8097 |
| reproduces | #8103 |
| modulate | #8143 |
| confirm | #8153 |
| produces | #8156 |
| large variety | #8164 |
| intraperitoneally | #8167 |
| immunohistochemistry male | #8184 |
| maintained | #8185 |
| benzazepines | #8192 |
| organs | #8193 |
| fluorescence intensity | #8201 |
| reduced | #8207 |
| neurologic | #8214 |
| dopamine receptor | #8253 |
| abnormally | #8260 |
| norepinephrine | #8288 |
| inflammatory agents | #8301 |
| neuronal damage | #8302 |
| antioxidant | #8310 |
| condition | #8326 |
| dependent | #8332 |
| therapeutic implications | #8336 |
| epileptic | #8359 |
| chromatography pressure | #8383 |
| turn | #8404 |
| gray matter | #8407 |
| reflect | #8410 |
| and or | #8413 |
| wistar receptors | #8433 |
| receptor expression | #8442 |
| chain reaction | #8446 |
| hyponatremia | #8454 |
| plasma levels | #8470 |
| citalopram | #8472 |
| hyperglycemia | #8472 |
| stereotaxic | #8495 |
| systemic inflammatory | #8499 |
| polymerase chain | #8501 |
| purkinje | #8517 |
| immunocytochemical | #8519 |
| brain imaging | #8538 |
| chloride | #8546 |
| copper | #8549 |
| intracellular ca2 | #8583 |
| restoration | #8595 |
| hepatotoxicity | #8598 |
| ischemia | #8616 |
| activates | #8631 |
| hippocampus humans | #8641 |
| oxide nitric | #8664 |
| levodopa | #8665 |
| n10 | #8672 |
| inflammatory cytokines | #8690 |
| male middle aged | #8715 |
| organometallic | #8716 |
| pyramidal cells | #8724 |
| retardation | #8736 |
| gsh | #8742 |
| oxidative | #8742 |
| 37°c | #8758 |
| emission computed | #8767 |
| parietal | #8790 |
| potassium chloride | #8814 |
| hplc | #8824 |
| nmr | #8871 |
| superoxide | #8875 |
| tonic | #8879 |
| sulfates | #8892 |
| devoid | #8898 |
| egf receptor | #8905 |
| lactic acid | #8906 |
| minimal | #8910 |
| caveolin | #8912 |
| oxo | #8932 |
| biochemical | #8935 |
| consciousness | #8985 |
| reflected | #9011 |
| intravenous injection | #9019 |
| alanine transaminase | #9038 |
| encephalitis | #9077 |
| emission tomography | #9083 |
| methylmercury | #9099 |
| aminotransferases | #9108 |
| acetate | #9111 |
| syndromes | #9112 |
| brain cognition | #9130 |
| aimed | #9163 |
| awake | #9175 |
| 62 patients | #9176 |
| likewise | #9181 |
| treated mice | #9194 |
| normal | #9207 |
| dysfunction | #9218 |
| corpus striatum | #9247 |
| key factors | #9254 |
| elevated | #9263 |
| deprived | #9285 |
| neuropathy | #9344 |
| cerebrospinal fluid csf | #9364 |
| cerebral blood | #9391 |
| pressure liquid | #9396 |
| deoxy | #9420 |
| immunoblotting | #9445 |
| complications patients | #9489 |
| citric acid | #9505 |
| intrahepatic | #9572 |
| oxidative stress | #9585 |
| irreversible | #9607 |
| naloxone | #9609 |
| synthase inos | #9615 |
| absence | #9615 |
| occipital | #9621 |
| neurons | #9627 |
| seizures | #9631 |
| terminals | #9647 |
| nerve tissue | #9655 |
| postoperative day | #9682 |
| compensate | #9687 |
| micromol | #9692 |
| imaging studies | #9718 |
| ameliorated | #9722 |
| bw | #9727 |
| protective effects | #9749 |
| 2 mm | #9756 |
| 064 | #9783 |
| neuro | #9788 |
| tumor necrosis | #9791 |
| middle cerebral | #9809 |
| chelating | #9823 |
| dependently | #9825 |
| patch clamp | #9830 |
| succinate | #9834 |
| diseases liver | #9842 |
| prevented | #9863 |
| severely | #9864 |
| contributes | #9880 |
| receptor agonist | #9912 |
| microm | #9930 |
| necrosis factor | #9933 |
| quantitative | #9943 |
| tight junctions | #9963 |
| liver cells | #9987 |
| neurobiological | #10000 |
| binding cassette | #10002 |
| central nervous | #10003 |
| conflicting | #10023 |
| kinetic parameters | #10033 |
| cycle | #10052 |
| mediated | #10072 |
| cortical | #10128 |
| cava | #10136 |
| dopamine receptors | #10169 |
| liver damage | #10178 |
| negative impact | #10202 |
| minerals | #10211 |
| stores | #10215 |
| ros production | #10235 |
| attenuated | #10240 |
| expression activity | #10242 |
| cgmp | #10262 |
| glutathione gsh | #10266 |
| transport complex | #10286 |
| plasma concentrations | #10292 |
| plasma patients | #10296 |
| urinary excretion | #10301 |
| adversely | #10328 |
| vitamin deficiency | #10328 |
| forebrain | #10337 |
| cassette | #10370 |
| permeable | #10373 |
| specific activity | #10384 |
| steatohepatitis | #10395 |
| electroencephalogram | #10395 |
| areas | #10419 |
| subacute | #10435 |
| biliary | #10436 |
| protein levels | #10453 |
| hrqol | #10455 |
| liver transplant | #10455 |
| nigra | #10479 |
| cerebral artery | #10481 |
| positron emission tomography | #10525 |
| biosynthesis | #10531 |
| substantia | #10550 |
| nervous | #10616 |
| transmitter | #10626 |
| twofold | #10627 |
| management patients | #10657 |
| lipopolysaccharide | #10674 |
| alzheimers disease | #10694 |
| dose dependent | #10699 |
| normal range | #10730 |
| nutritional status | #10752 |
| protein level | #10752 |
| quaternary | #10765 |
| glutathione | #10772 |
| glucose | #10806 |
| water content | #10826 |
| monophosphate | #10827 |
| liver mice | #10852 |
| vena | #10853 |
| nervous diseases | #10861 |
| microgram | #10880 |
| performance liquid | #10883 |
| entity | #10889 |
| eventually | #10941 |
| intraventricular | #10958 |
| occur | #10968 |
| saline | #10968 |
| dietary proteins | #10978 |
| breakdown | #10983 |
| earlier studies | #10997 |
| etiology | #10998 |
| doses | #11003 |
| accumbens | #11004 |
| impair | #11006 |
| rats inbred strains | #11023 |
| radioimmunoassay | #11026 |
| behavior animal | #11026 |
| atrophy | #11041 |
| tnfalpha | #11044 |
| atp binding | #11055 |
| tests male | #11061 |
| western | #11061 |
| peroxidation | #11077 |
| riboflavin | #11140 |
| positron emission | #11153 |
| potentiated | #11172 |
| preparations | #11184 |
| precursor | #11188 |
| adult male | #11195 |
| broad spectrum | #11196 |
| superoxides | #11202 |
| nick | #11227 |
| steroids | #11232 |
| animals anti | #11234 |
| acyl | #11314 |
| enzyme activity | #11342 |
| drug induced | #11347 |
| early identification | #11376 |
| neuropathic | #11380 |
| necrotic | #11392 |
| neurodegenerative disease | #11395 |
| centrally | #11415 |
| depletion | #11434 |
| major component | #11447 |
| clinical signs | #11463 |
| 3 weeks | #11495 |
| receptor antagonist | #11502 |
| animals disease | #11503 |
| complications | #11504 |
| alteration | #11581 |
| il1β | #11649 |
| trp | #11651 |
| prostaglandins | #11656 |
| survival cells | #11657 |
| kd | #11671 |
| gut | #11676 |
| dogs | #11676 |
| alcohol | #11740 |
| wilson | #11741 |
| dentate | #11769 |
| disappearance | #11773 |
| receptor antagonists | #11774 |
| ibuprofen | #11820 |
| neuron | #11824 |
| radiopharmaceuticals | #11825 |
| appears | #11872 |
| pigs | #11917 |
| inherited | #11924 |
| organ size | #11944 |
| mild cognitive impairment | #11954 |
| pyramidal | #12051 |
| corpus callosum | #12054 |
| gasoline | #12095 |
| aged alzheimer | #12101 |
| circulating levels | #12111 |
| carrier proteins | #12112 |
| reactive | #12134 |
| severity | #12227 |
| receptor activation | #12230 |
| blotting | #12274 |
| huntington disease | #12346 |
| infusions | #12347 |
| electrophysiological | #12375 |
| elevation | #12412 |
| aphasia | #12425 |
| emerging evidence | #12434 |
| atpase | #12447 |
| subclinical | #12476 |
| nh3 | #12499 |
| aminotransferase | #12509 |
| peripheral nervous | #12515 |
| absorbed | #12546 |
| cyclooxygenase | #12569 |
| exerts | #12573 |
| scavenger | #12589 |
| bile ducts | #12634 |
| c57bl 6 | #12683 |
| publisher | #12687 |
| chlorides | #12701 |
| reversed | #12782 |
| subcellular fractions | #12790 |
| inositol | #12832 |
| neuronal death | #12840 |
| measured | #12864 |
| intraperitoneal | #12878 |
| disorders | #12899 |
| cultured cells | #12900 |
| tnf alpha | #12912 |
| mediate | #12984 |
| mars | #13100 |
| slowly | #13118 |
| vesicular | #13121 |
| lesser | #13134 |
| pretreatment | #13141 |
| cerebral infarction | #13141 |
| therapeutic strategies | #13143 |
| basal | #13155 |
| 005 | #13194 |
| positron | #13197 |
| tomography pet | #13207 |
| circadian | #13222 |
| md | #13224 |
| caused | #13226 |
| hypotheses | #13238 |
| infused | #13242 |
| ischemic | #13289 |
| subjected | #13291 |
| methionine | #13299 |
| disrupted | #13336 |
| animals biomarkers | #13337 |
| normal controls | #13360 |
| anticonvulsants | #13440 |
| downregulation | #13444 |
| neurodegenerative | #13467 |
| reduction | #13499 |
| 23 patients | #13506 |
| chronic | #13511 |
| histocytochemistry | #13552 |
| psychomotor | #13555 |
| tissue | #13620 |
| sodium | #13631 |
| interleukin1 | #13734 |
| alpha | #13754 |
| cerebrovascular | #13767 |
| agonist | #13768 |
| partially | #13885 |
| oxidant | #13907 |
| postural | #13923 |
| mainstay | #13926 |
| sulfate | #13971 |
| nerve | #14045 |
| necrosis | #14050 |
| improvement | #14081 |
| gray | #14104 |
| hypothesize | #14117 |
| μmol | #14145 |
| skeletal | #14152 |
| exposure | #14214 |
| alcohol drinking | #14214 |
| electroencephalography | #14223 |
| sulfhydryl | #14242 |
| glia | #14250 |
| deficient mice | #14274 |
| blot analysis | #14352 |
| cytokine production | #14379 |
| multifactorial | #14398 |
| p002 | #14416 |
| damage | #14417 |
| enzyme inhibitors | #14422 |
| normalized | #14430 |
| dinoprostone | #14442 |
| permanent | #14471 |
| limbic | #14474 |
| cingulate | #14502 |
| healthrelated quality | #14573 |
| release | #14673 |
| 11 patients | #14695 |
| pge2 | #14705 |
| male | #14712 |
| ethanol | #14751 |
| chronic disease | #14773 |
| alzheimer disease | #14778 |
| cell count | #14785 |
| learning memory | #14831 |
| triphosphate animals | #14839 |
| vivo studies | #14851 |
| understood | #14879 |
| uric | #14905 |
| nmol | #14931 |
| agonists | #14948 |
| subcortical | #14957 |
| imbalance | #14958 |
| weighted | #15064 |
| manifestations | #15066 |
| lactation | #15115 |
| psychiatric | #15192 |
| creatine | #15221 |
| fluid | #15257 |
| cytokines | #15272 |
| triphosphatases | #15273 |
| intake | #15351 |
| protein tyrosine | #15367 |
| tissues | #15409 |
| localized | #15466 |
| ester | #15533 |
| synapses | #15538 |
| intellectual | #15568 |
| 042 | #15583 |
| evoked potentials | #15595 |
| prophylaxis | #15602 |
| clamp | #15646 |
| drinking | #15676 |
| sclerosis | #15727 |
| cholestasis | #15758 |
| nafld | #15783 |
| adenosine | #15804 |
| signs | #15804 |
| hypothesis | #15809 |
| trace | #15853 |
| chromatography | #15875 |
| exert | #15905 |
| appeared | #15927 |
| degeneration | #15939 |
| subcutaneously | #15941 |
| vivo vitro | #16006 |
| magnetic resonance | #16007 |
| reflects | #16036 |
| killed | #16092 |
| released | #16133 |
| parkinsons disease | #16161 |
| plays | #16220 |
| randomized controlled | #16247 |
| therapeutic | #16276 |
| 0001 | #16290 |
| hepatectomy | #16303 |
| muscle skeletal | #16331 |
| 1 week | #16336 |
| dorsal | #16343 |
| symptoms | #16440 |
| cytosolic | #16446 |
| aspect | #16495 |
| hepatitis chronic | #16549 |
| 5 | #16588 |
| transport | #16615 |
| abnormalities | #16625 |
| nucleus accumbens | #16636 |
| induction | #16656 |
| inadequate | #16667 |
| involves | #16686 |
| hepatocyte | #16740 |
| psychometrics | #16793 |
| decreasing | #16803 |
| cd40 | #16918 |
| random allocation | #16959 |
| pet | #17001 |
| mechanism | #17020 |
| spontaneous | #17046 |
| folic | #17100 |
| 10 patients | #17114 |
| organ | #17129 |
| 05 | #17137 |
| administered | #17168 |
| impairment | #17220 |
| transported | #17290 |
| reduces | #17300 |
| prominent | #17312 |
| publication aged aged | #17315 |
| tnfα | #17356 |
| diagnose | #17452 |
| humans | #17580 |
| parkinson | #17599 |
| mitochondrial | #17645 |
| incubation | #17654 |
| evoked | #17725 |
| modulates | #17799 |
| stimulatory | #17860 |
| commonly | #17870 |
| spectroscopy | #18016 |
| alter | #18029 |
| removed | #18045 |
| pharmacological | #18082 |
| 21 patients | #18092 |
| enzyme | #18126 |
| cognition disorders | #18188 |
| adult brain | #18254 |
| hepatocytes | #18338 |
| prevent | #18353 |
| blood samples | #18374 |
| moderately | #18395 |
| putative | #18427 |
| partly | #18450 |
| suffer | #18502 |
| stimulate | #18563 |
| animals biological | #18741 |
| neurodegenerative diseases | #18774 |
| depressed | #18788 |
| metalloproteinase | #18921 |
| vein | #19240 |
| ascorbic | #19380 |
| plasma | #19440 |
| 7 | #19485 |
| blot | #19526 |
| correlated | #19582 |
| membrane potentials | #19625 |
| serves | #19635 |
| depleted | #19648 |
| neuropsychological tests | #19672 |
| traumatic brain injury | #19727 |
| mm | #19825 |
| animals calcium | #19827 |
| soluble | #20005 |
| acetic | #20054 |
| frequently | #20106 |
| tumor necrosis factor | #20133 |
| serine | #20180 |
| dosedependent manner | #20198 |
| vitro techniques | #20371 |
| controversial | #20390 |
| motor | #20407 |
| radical | #20464 |
| ventral | #20527 |
| micrograms | #20674 |
| circulation | #20783 |
| raised | #20843 |
| inducible | #20861 |
| hypothalamic | #20873 |
| oxidation reduction | #20882 |
| counts | #20909 |
| brain mapping | #21000 |
| reactive oxygen | #21049 |
| 16 patients | #21061 |
| underlying mechanisms | #21109 |
| weeks | #21219 |
| labeled | #21292 |
| rodent | #21335 |
| method female | #21700 |
| maximal | #21940 |
| species ros | #22112 |
| vivo | #22128 |
| blood | #22216 |
| response relationship | #22303 |
| inflammation | #22526 |
| 073 | #22553 |
| induced cell | #22589 |
| 13 patients | #22656 |
| activation | #23016 |
| sufficient | #23212 |
| male membrane | #23275 |
| gastrointestinal | #23302 |
| imaging mri | #23302 |
| inflammatory | #23317 |
| intravenously | #23392 |
| infusions intravenous | #23567 |
| releasing | #23665 |
| magnetic resonance imaging | #23801 |
| intracellular | #24009 |
| cellular | #24252 |
| reducing | #24301 |
| c57bl | #24413 |
| correlate | #24434 |
| displayed | #24599 |
| unable | #24707 |
| 096 | #24715 |
| assess | #24780 |
| 12 patients | #24814 |
| activity | #25360 |
| body | #25376 |
| acquired | #25673 |
| modify | #25866 |
| limiting | #25928 |
| inhibit | #26079 |
| inbred c57bl | #26079 |
| modulated | #26122 |
| remain | #26178 |
| immunohistochemical | #26211 |
| cognitive | #26948 |
| represents | #26971 |
| management | #27196 |
| reflecting | #27352 |
| mental | #27490 |
| improves | #27652 |
| preventing | #27673 |
| behavioral | #27813 |
| hydrogen ion | #28292 |
| concluded | #28335 |
| proven | #28570 |
| aims | #28575 |
| evaluate | #28931 |
| proteins mice | #28975 |
| ion concentration | #29194 |
| magnetic | #29339 |
| mechanisms underlying | #29900 |
| subcellular | #29913 |
| mice inbred | #30075 |
| stained | #30210 |
| quantitatively | #30454 |
| arterial | #30516 |
| abnormal | #30579 |
| corrected | #30667 |
| humans hydrogen | #30710 |
| demonstrated | #30993 |
| sensitive | #31344 |
| resonance | #31346 |
| induces | #31608 |
| cultured | #31958 |
| enzyme activation | #32060 |
| markedly | #32813 |
| animals apoptosis | #33677 |
| remains | #34554 |
| unclear | #34875 |
| subsequent | #35401 |
| hypothesized | #36243 |
| treated | #36316 |
| inhibited | #36986 |
| linked | #37013 |
| inbred c57bl mice | #39261 |
| induce | #39552 |
| aged | #56385 |
रिपोर्ट चलाएं | |
Prominent publications by Roger F Butterworth∗
Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients
[ PUBLICATION ]
Modulation of soluble guanylate cyclase (sGC) by nitric oxide (NO) is altered in brain from experimental animals with hyperammonemia with or without liver failure. The aim of this work was to assess the content and modulation of sGC in brain in chronic liver failure in humans. Expression of the alpha-1, alpha-2, and beta-1 subunits of sGC was measured by immunoblotting in autopsied frontal cortex and cerebellum from cirrhotic patients and controls. The contents of alpha-1 and alpha-2 ...
| के लिए जाना जाता है Guanylate Cyclase | Cirrhotic Patients | Modulation Sgc | Nitric Oxide Brain | Cerebellum Activation |
Hypothermia attenuates oxidative/nitrosative stress, encephalopathy and brain edema in acute (ischemic) liver failure
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been suggested that oxidative/nitrosative stress is involved. In the present study we evaluated the role of oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting from hepatic devascularization. We also studied the effect of hypothermia, a ...
| के लिए जाना जाता है Brain Edema | Alf Rats | Nitrosative Stress | Liver Failure | Coma Stages |
KOL-Index: 13463
Acute liver failure (ALF) results in alterations of energy metabolites and of glucose-derived amino acid neurotransmitters in brain. However, the dynamics of changes in glucose metabolism remain unclear. The present study was undertaken using (1)H and (13)C nuclear magnetic resonance (NMR) spectroscopy to determine the rates of incorporation of glucose into amino acids and lactate via cell-specific pathways in relation to the severity of encephalopathy and brain edema in rats with ALF ...
| के लिए जाना जाता है Brain Lactate | Acute Liver | Magnetic Resonance | Coma Stages | Amino Acids |
Effects of hypothermia on brain glucose metabolism in acute liver failure: a 1H/13C-nuclear magnetic resonance study
[ PUBLICATION ]
BACKGROUND & AIMS: Mild hypothermia has a protective effect on brain edema and encephalopathy in both experimental and human acute liver failure. The goals of the present study were to examine the effects of mild hypothermia (35 degrees C) on brain metabolic pathways using combined (1)H and (13)C-Nuclear Magnetic Resonance (NMR) spectroscopy, a technique which allows the study not only of metabolite concentrations but also their de novo synthesis via cell-specific pathways in the ...
| के लिए जाना जाता है Acute Liver | Mild Hypothermia | Brain Glucose Metabolism | Magnetic Resonance | Frontal Cortex |
Neuroactive amino acids and glutamate (NMDA) receptors in frontal cortex of rats with experimental acute liver failure
[ PUBLICATION ]
It has been proposed that alterations of excitatory and inhibitory amino acids play a role in the pathogenesis of hepatic encephalopathy in acute liver failure. To evaluate this possibility, in vivo cerebral microdialysis was used to sample extracellular concentrations of amino acids in the frontal cortex of unanesthetized rats at various times during the progression of encephalopathy resulting from acute liver failure. Liver failure was induced by portacaval anastomosis followed 24 ...
| के लिए जाना जाता है Amino Acids | Frontal Cortex | Acute Liver Failure | Extracellular Concentrations | Hepatic Encephalopathy |
KOL-Index: 12801
Mild hypothermia is effective in the prevention of brain edema associated with cerebral ischemia and traumatic brain injury. Brain edema is also a serious complication of acute liver failure (ALF). To assess the effectiveness of hypothermia in ALF, groups of rats were subjected to hepatic devascularization (portacaval anastomosis, followed 48 hours later by hepatic artery ligation), and body temperatures were maintained at either 35 degrees C (hypothermic) or 37 degrees C (normothermic). ...
| के लिए जाना जाता है Mild Hypothermia | Brain Edema | Acute Liver | Rats Alf | Hepatic Encephalopathy |
Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis
[ PUBLICATION ]
Brain edema, leading to intracranial hypertension and brain herniation, is a major cause of death in fulminant liver failure. Astrocyte swelling is a prominent neuropathological feature in experimental fulminant liver failure. It has been postulated that the osmotic effects of glutamine, generated in astrocytes from ammonia and glutamate in a reaction catalyzed by glutamine synthetase, could mediate brain swelling. Normal rats and rats that received a portacaval anastomosis were infused ...
| के लिए जाना जाता है Intracranial Hypertension | Brain Edema | Portacaval Anastomosis | Ammonium Acetate | Osmotic Effects |
Effect of Portacaval Anastomosis on Glutamine Synthetase Protein and Gene Expression in Brain, Liver and Skeletal Muscle
[ PUBLICATION ]
The effects of chronic liver insufficiency resulting from end-to-side portacaval anastomosis (PCA) on glutamine synthetase (GS) activities, protein and gene expression were studied in brain, liver and skeletal muscle of male adult rats. Four weeks following PCA, activities of GS in cerebral cortex and cerebellum were reduced by 32% and 37% (p<0.05) respectively whereas GS activities in muscle were increased by 52% (p<0.05). GS activities in liver were decreased by up to 90% (p<0.01), a ...
| के लिए जाना जाता है Skeletal Muscle | Portacaval Anastomosis | Gene Expression | Surgical Rna | Pca Rats |
Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: protective effect of minocycline
[ PUBLICATION ]
Encephalopathy and brain edema are serious complications of acute liver failure (ALF). The precise pathophysiologic mechanisms responsible have not been fully elucidated but it has been recently proposed that microglia-derived proinflammatory cytokines are involved. In the present study we evaluated the role of microglial activation and the protective effect of the anti-inflammatory drug minocycline in the pathogenesis of hepatic encephalopathy and brain edema in rats with ALF resulting ...
| के लिए जाना जाता है Brain Edema | Liver Failure | Rats Alf | Microglial Activation | Pathogenesis Hepatic Encephalopathy |
KOL-Index: 11822
There is evidence to suggest that, in acute liver failure (ALF), brain ammonia and proinflammatory cytokines may act synergistically to cause brain edema and its complications (intracranial hypertension, brain herniation). However, the molecular mechanisms involved remain to be established. In order to address this issue, semi-quantitative RT-PCR was used to measure the expression of genes coding for astrocytic proteins with an established role in cell volume regulation in cerebral ...
| के लिए जाना जाता है Brain Edema | Liver Failure | Proinflammatory Cytokines | Astrocytic Proteins | Cultured Astrocytes |
KOL-Index: 11726
Although earlier studies on thiamine deficiency have reported increases in extracellular glutamate concentration in the thalamus, a vulnerable region of the brain in this disorder, the mechanism by which this occurs has remained unresolved. Treatment with pyrithiamine, a central thiamine antagonist, resulted in a 71 and 55% decrease in protein levels of the astrocyte glutamate transporters GLT-1 and GLAST, respectively, by immunoblotting in the medial thalamus of day 14 symptomatic rats ...
| के लिए जाना जाता है Medial Thalamus | Glutamate Transporter | Glt1 Glast | Spraguedawley Statistics | Protein Levels |
KOL-Index: 11620
N-acetylcysteine (NAC) is an effective antidote to treat acetaminophen (APAP)-induced acute liver failure (ALF). NAC is hepatoprotective and prevents the neurological complications of ALF, namely hepatic encephalopathy and brain edema. The protective effect of NAC and its mechanisms of action in ALF due to other toxins, however, are still controversial. In the present study, we investigated the effects of NAC in relation to liver pathology, hepatic and cerebral glutathione, plasma ...
| के लिए जाना जाता है Liver Failure | Nac Alf | Induced Acute | Aom Mice | Brain Edema |
Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats
[ PUBLICATION ]
The pathogenesis of brain edema in acute liver failure is poorly understood. We have previously shown that rats with ischemic acute liver failure (portacaval anastomosis followed by hepatic artery ligation) exhibit brain edema and intracranial hypertension, with swelling of cortical astrocytes as the most prominent neuropathological abnormality. Because ammonia has been shown to induce swelling of astrocytes in vivo and in vitro, we examined the relationship between brain ammonia, amino ...
| के लिए जाना जाता है Amino Acids | Brain Edema | Portacaval Anastomosis | Liver Failure | Glutamine Alanine |
Ammonia induces MK‐801‐sensitive nitration and phosphorylation of protein tyrosine residues in rat astrocytes
[ PUBLICATION ]
Astrocytes play a key role in the pathogenesis of ammonia-induced neurotoxicity and hepatic encephalopathy. As shown here, ammonia induces protein tyrosine nitration in cultured rat astrocytes, which is sensitive to the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801. A similar pattern of nitrated proteins is produced by NMDA. Ammonia-induced tyrosine nitration depends on a rise in [Ca2+]i, IkB degradation, and NO synthase (iNOS) induction, which are prevented by MK-801 and the ...
| के लिए जाना जाता है Rat Astrocytes | Glutamine Synthetase | Protein Tyrosine | Ammonia Induces | Oxide Nitric |
Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: Role of glutamine redefined
[ PUBLICATION ]
Acute liver failure (ALF) is characterized neuropathologically by cytotoxic brain edema and biochemically by increased brain ammonia and its detoxification product, glutamine. The osmotic actions of increased glutamine synthesis in astrocytes are considered to be causally related to brain edema and its complications (intracranial hypertension, brain herniation) in ALF. However studies using multinuclear (1)H- and (13)C-NMR spectroscopy demonstrate that neither brain glutamine ...
| के लिए जाना जाता है Brain Edema | Acute Liver Failure | Hepatic Encephalopathy | Intracranial Hypertension | Glutamine Synthesis |
के लिए प्रमुख लोग Hepatic Encephalopathy
दुनिया में शीर्ष kols
एक खोज वाक्यांश का चयन करें hepatic encephalopathy , hepatic encephalopathy patients , hepatic encephalopathy humans , hepatic encephalopathy 95 , hepatic encephalopathy rats
Roger F Butterworth∗:विशेषज्ञ प्रभाव
जिसके लिए अवधारणाएंRoger F Butterworth∗प्रत्यक्ष प्रभाव है:Hepatic encephalopathy, Acute liver failure, Liver failure, Thiamine deficiency, Cirrhotic patients, Brain edema, Portacaval anastomosis, Mild hypothermia.
Roger F Butterworth∗:कोल इम्पैक्ट
अन्य लेखकों के काम से संबंधित अवधारणाएं जिनके लिएfor which Roger F Butterworth∗ प्रभाव है:Hepatic encephalopathy, Acute liver failure, Thiamine deficiency, Liver cirrhosis, Oxidative stress, Brain edema, Cirrhotic patients.
Tools
क्या यह आपकी प्रोफ़ाइल है? अपनी प्रोफ़ाइल का दावा करें यूआरएल कॉपी करें अपनी प्रोफ़ाइल के लिए लिंक एम्बेड करें |